Cellular reprogramming to reverse aging and promote organ and tissue regeneration

OCT4, SOX2, and KLF4 transcription factors, without c-Myc, are used to rejuvenate cells by reversing age-related epigenetic changes, maintaining cellular identity, and promoting tissue regeneration without teratoma formation.

JP7593639B2Active Publication Date: 2024-12-03PRESIDENT & FELLOWS OF HARVARD COLLEGE
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2021517602
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-07-30
Filing Date
2019-09-27
Publication Date
2024-12-03
Estimated Expiration
2039-09-27

AI Technical Summary

Technical Problem

Existing methods for cellular rejuvenation often result in complete reprogramming, leading to teratomas and other toxicities, and fail to maintain cellular identity, which is crucial for tissue and organ integrity.

Method used

The use of OCT4, SOX2, and KLF4 transcription factors, without c-Myc, for spatially and temporally controlled expression to rejuvenate cells by reversing age-related epigenetic marks, maintaining cellular identity, and promoting a youthful state without full dedifferentiation.

Benefits of technology

This approach effectively rejuvenates cells by restoring youthful epigenetic marks, enhancing cellular function and survival, and preventing teratoma formation, thus promoting tissue and organ regeneration safely in vivo.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007593639000142
    Figure 0007593639000142
  • Figure 0007593639000143
    Figure 0007593639000143
  • Figure 0007593639000144
    Figure 0007593639000144
Patent Text Reader

Abstract

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors such as lentiviral vectors, adenoviral vectors, AAV vectors, herpesvirus vectors, and retroviral vectors) encoding OCT4; KLF4; SOX2; or any combination thereof, which are useful, for example, for inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., the engineered nucleic acids), engineered cells comprising the engineered nucleic acids, recombinant viruses, compositions, engineered cells, engineered proteins, chemical agents capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, engineered proteins selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, antibodies capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating (e.g., an ocular disease), preventing a disease (e.g., an ocular disease), controlling (e.g., inducing, or inducing and then arresting) cellular reprogramming, controlling tissue repair, controlling tissue regeneration, or any combination thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Related Applications This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 62 / 738,922, filed September 28, 2018, U.S. Provisional Application No. 62 / 792,283, filed January 14, 2019, U.S. Provisional Application No. 62 / 865,877, filed June 24, 2019, and U.S. Provisional Application No. 62 / 880,488, filed July 30, 2019, each of which is incorporated herein by reference in its entirety. Government support

[0002] This invention was made with government support under grant numbers R01AG019719 and R01DK100263 awarded by the National Institutes of Health (NIH). The government has certain rights in this invention. [Background technology]

[0003] In many animals, including vertebrates, vital organs have a limited inherent capacity for regeneration and repair. Acute injuries and chronic disorders can damage vital organs and tissues, including the heart, pancreas, brain, kidneys, muscles, skin, and nervous tissue, among others. However, mature somatic cells often cannot survive these injuries, and even if they do, they are unable to self-renew and transdifferentiate to replace damaged cells. Furthermore, cells capable of self-renewal may be limited in number, have limited capacity, and are particularly susceptible to age-related damage. In contrast to somatic cells from adults, cells from individuals closer to conception in chronological age, such as those from embryos and infants, exhibit cellular youthfulness and have a greater ability to resist injury and stress, heal, replicate, and regenerate organs and tissues. Therefore, compositions and methods directed at rejuvenating cells and thereby restoring them from an aged, mature state to a younger, more vigorous state have long been sought for treating certain injuries and diseases, and for generally reversing and preventing aging in the entire organism.

[0004] There are two types of information in the body: digital and analog. DNA is digital information, and the epigenome is analog information. Analog information does not always last as long as digital, nor can it be copied with as much fidelity as digital information. This has consequences for how long an organism lives and develops. Aging was once thought of as a process driven by mutations in a cell's genetic material. This has largely been abandoned as an explanation. The primary cause of aging is now thought to be due to epigenetic changes. These cause cells to transcribe the wrong genes at the wrong time for optimal function, a process that over time becomes more dysfunctional, leading to disease, incurability, and ultimately death. Yamanaka factors (OCT4, SOX2, c-Myc, and KLF4) have been previously shown to induce pluripotency in vitro (Takahashi et al., Cell. 2006 Aug 25;126(4):663-76) and reverse the DNA methylation clock of aging (Horvath, Genome Biol. 2013). Nanog and Lin28 can cooperate with Yamanaka factors to help induce pluripotency. Furthermore, Tet1, NR5A-2, Sall4, and NKX3-1 can substitute for Oct4 (Gao et al., Cell Stem Cell 12, 1-17, April 4, 2013 and Mai et al., Nature Cell Biology 20, 900-908, 2018). However, expression of the original four transcription factors in transgenic mice induces teratomas in vivo, along with other acute toxicities such as intestinal epithelial metaplasia, which can kill the animals within a few days (Abad et al., Nature. 2013 Oct 17;502(7471):340-5). Therefore, a non-toxic and efficient method of cell reprogramming is needed. Summary of the Invention

[0005] It is hypothesized that the cellular aging process is caused by the loss of both genetic and epigenetic information. Previous studies have hypothesized that aging is primarily caused by the loss of genetic information (most commonly in the form of genetic mutations such as substitutions and deletions in an organism's genome), but the compositions and methods of the present disclosure are characterized by the unexpected finding that aging is primarily driven by the loss of specific epigenetic information established closer to fertilization and the terminal differentiation of specific cells. Epigenetic information is sometimes referred to as cellular "analog" information, and typically takes the form of covalent modifications of DNA, such as 5-methylcytosine (5mC), hydroxymethylcytosine (5hmeC), 5-formylcytosine (fC), and 5-carboxylcytosine (caC), and adenine methylation, and of certain proteins, such as lysine acetylation of histone proteins, lysine and arginine methylation, serine and threonine phosphorylation, and lysine ubiquitination and sumoylation. Loss of this analog information can result in the dysregulation of essential cellular processes, such as those that maintain cell identity, causing cells to exhibit traits typically associated with aging, such as senescence.

[0006] The disclosed methods, compositions, and kits rejuvenate cells by preventing and reversing the cellular causes of aging. Without being bound by any particular theory, more specifically, the disclosed methods, compositions, and kits rejuvenate cells by restoring epigenetic information lost due to the aging process, injury, or disease. The disclosed methods, compositions, and kits include the transcription factors OCT4, SOX2, and KLF4. OCT4, SOX2, and KLF4 are three of the four "Yamanaka factors," the fourth being c-Myc. Yamanaka factors have traditionally been used to reprogram cells to a pluripotent state. However, induction of expression of these four transcription factors in transgenic mice resulted in the formation of teratomas in vivo, along with other acute toxicities such as intestinal epithelial metaplasia, which can kill the animals within a few days. Furthermore, the fact that four Yamanaka factors are typically used to fully reprogram cells to a pluripotent state, resulting in cells losing their pre-established cell identity, can be dangerous for in vivo applications where the cell identity of target cells must be maintained for tissue and / or organ integrity. In contrast, in some embodiments, the methods described herein allow for incomplete reprogramming and do not result in global changes in demethylation. In some embodiments, the methods described herein do not require complete dedifferentiation of cells. For example, expression of OCT4, SOX2, and KLF4 promoted regeneration after injury in young and old mice and after vincristine-induced injury in human neurons, but expression of OCT4, SOX2, and KLF4 did not induce a global reduction in DNA methylation (see, e.g., Figures 45B-45C).

[0007] In some embodiments, the results disclosed herein suggest that expression of OCT4, SOX2, and KLF4 may allow diseased cells to revert to a healthier state without inducing complete reprogramming. Without being bound by any particular theory, the results disclosed herein suggest that cells maintain a backup epigenome that can be restored using the methods described herein.

[0008] The disclosed methods, compositions, and kits are characterized in part by the surprising and unexpected discovery that spatially and temporally specific induction of OCT4, SOX2, and KLF4 expression in the absence of induction of c-Myc expression can rejuvenate cells without reprogramming them to a pluripotent state. Using inducible promoters, expression of OCT4, SOX2, and KLF4 can be carefully controlled to reduce and reverse epigenetic marks associated with aging, increase epigenetic marks associated with cellular youthfulness, reduce expression of proteins associated with aging, increase expression of proteins associated with a youthful cellular state, restore the balance between euchromatin and heterochromatin, prevent loss of cellular identity, restore cellular identity, and reverse age-related changes in DNA methylation, thereby rejuvenating cells without reprogramming them to a pluripotent state.

[0009] Thus, in various embodiments, the methods of the present invention rejuvenate cells by restoring the cellular identity of the cell by preventing or reversing the effects of one or more dysregulated developmental pathways. For example, the methods include: (i) increasing the abundance of at least one of histone H2A, histone H2B, histone H3, histone H4, or any combination thereof in a cell; (ii) increasing the abundance of at least one of CHAF1a, CHAF1b, HP1α, NuRD, or any combination thereof in the cells; (iii) increasing at least one heterochromatic mark in the cell, such as, for example, H3K9me3, H3K27me3, or any combination thereof; or decreasing one heterochromatic mark, such as, for example, H4K20me3 or the euchromatic mark H3K4me3; (iv) increasing / decreasing DNA methylation of at least one age-related CpG site in the cells to a young level; (v) increasing the abundance of cellular lamin B1; (vi) increasing cellular histone H3 acetylation at lysine 27 (H3K27ac) or increasing histone H3 acetylation at lysine 56 (H3K56ac), or any combination thereof; (vii) decreasing cellular acetylation of histone H3 at lysine 122 (H3K122Ac) or histone H4 at lysine 16 (H4K16ac), or any combination thereof; (viii) decreasing the abundance of IL6, Cc12, Cc120, Apob, p16, LINE-1 repeats, SatIII repeats, Alu elements, IAPs, or any combination thereof; (ix) restoring the balance between euchromatic epigenetic marks, such as H3K4me3, and heterochromatic epigenetic marks, e.g., H3K9me3 or H3K27me3; (x) induces the formation of euchromatin; (xi) restoring youthful levels of at least one repressive heterochromatin epigenetic mark; and / or (xii) restoring the expression of at least one of the genes listed in Table 5 to youthful levels;

[0010] The present disclosure stems from the unexpected discovery that, in some embodiments, precise expression of OCT4, SOX2, and KLF4 in the absence of exogenous c-Myc expression can be used to promote in vivo reprogramming and tissue regeneration without acute toxicity. The expression vectors provided herein, in certain embodiments, allow for precise control of OCT4, SOX2, and KLF4 (OSK) expression, high viral titers (e.g., 2×10 per preparation), and the production of erythrocytes containing erythrocyte-derived leukocytes (ECs). 12 Particles, 1 x 10 per mL 13 Incorporation into viruses (e.g., adeno-associated viruses (AAV)) in large amounts (more than 10 ...

[0011] As shown in Figure 14, mice with inducible transgene expression of OCT4, SOX2, and KLF4 (OSK) died two days after induction of OSK expression due to generalized cytological and architectural dysplasia in the intestinal epithelium. Similar findings have been reported in mice with OCT4, SOX2, and KLF4 plus c-Myc transgenes (Abad et al., Nature. 2013 Oct 17;502(7471):340-5; Ocampo et al., Cell. 2016 Dec 16;167:1719-33). Surprisingly, in some embodiments, as shown in Figure 14, expression of OCT4, SOX2, and KLF4 did not cause toxicity or cancer in vivo. Continuous expression of OCT4, SOX2, and KLF4 (e.g., induced by doxycycline administration) by AAV9 delivery (TRE-OSK with UBC-rtTA4) did not result in teratoma formation in vivo. When AAV9 viruses encoding these three transcription factors were delivered systemically to mice, no teratomas or weight loss were detected over a 3-month period (Figure 14).

[0012] Thus, in certain embodiments, provided herein are nucleic acids (e.g., engineered nucleic acids) capable of inducing expression of OCT4, KLF4, inducers, and / or SOX2, and / or recombinant viruses (e.g., lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpesvirus, or AAV) comprising the same. The nucleic acid may encode OCT4, KLF4, and / or SOX2. The nucleic acid may encode a transcription factor selected from the group consisting of OCT4; KLF4; SOX2; and any combination thereof. In certain embodiments, the nucleic acid encodes two or more transcription factors selected from the group consisting of OCT4, KLF4, and SOX2. In certain embodiments, the nucleic acid encodes OCT4 and SOX2, or OCT4 and KLF4. In certain embodiments, the nucleic acid encodes SOX2 and KLF4. In certain embodiments, the nucleic acid encodes OCT4, KLF4, and SOX2. In certain embodiments, the nucleic acid encodes four or more transcription factors (e.g., OCT4, SOX2, KLF4, and another transcription factor). In some embodiments, the present disclosure provides a nucleic acid encoding an inducer (e.g., an inducer capable of inducing expression of OCT4, KLF4, SOX2, or a combination thereof). In some embodiments, the nucleic acid encodes a Cas9 fusion protein (CRISPR activator) and a guide RNA sequence that targets a promoter or enhancer at the endogenous locus of OCT4, KLF4, and / or SOX2. In some embodiments, the nucleic acid encodes a Cas9 fusion protein (CRISPR activator) and a guide RNA sequence that targets a promoter or enhancer at the endogenous locus of OCT4, SOX2, KLF4, or any combination thereof.

[0013] Aspects of the present disclosure also provide methods of controlling cellular reprogramming, promoting tissue repair, promoting tissue survival, promoting tissue regeneration, promoting tissue growth, controlling tissue function, promoting organ regeneration, promoting organ survival, controlling organ function, treating and / or preventing disease, or any combination thereof. Controlling can include inducing cellular reprogramming, reversing aging, improving tissue function, improving organ function, tissue repair, tissue survival, tissue regeneration, tissue growth, promoting angiogenesis, reducing scar formation, reducing the appearance of aging, promoting organ regeneration, promoting organ survival, altering the taste and quality of produce derived from animals, treating disease, or any combination thereof, in vivo or in vitro. The method can include administering any of the nucleic acids (e.g., DNA and / or RNA) described herein, any of the engineered proteins encoding KLF4, OCT4, inducers, and / or SOX2, any of the chemical factors that activate (e.g., induce the expression of) OCT4, KLF4, inducers, and / or SOX2, antibodies that activate (e.g., induce the expression of) OCT4, KLF4, inducers, and / or SOX2, and / or any of the recombinant viruses described herein. The method can include administering any of the nucleic acids (e.g., DNA and / or RNA) described herein, any of the engineered proteins encoding KLF4, SOX2, OCT4, or any combination thereof, any of the chemical factors that activate (e.g., induce the expression of) OCT4; KLF4; SOX2; or any combination thereof, antibodies that activate (e.g., induce the expression of) OCT4; KLF4; SOX2; or any combination thereof, and / or any of the recombinant viruses described herein. In certain embodiments, the engineered nucleic acid comprises DNA and / or RNA. The engineered nucleic acid may or may not be an expression vector. For example, the engineered nucleic acid may be mRNA or plasmid DNA.In certain embodiments, the method further comprises administering a nucleic acid (e.g., an engineered nucleic acid) encoding the inducer, an engineered protein encoding the inducer, a chemical agent capable of modulating (e.g., activating or inhibiting) the activity of the inducer, and / or a recombinant virus encoding the inducer. For example, the engineered nucleic acid can be mRNA or plasmid DNA.

[0014] One aspect of the present disclosure provides a vector (e.g., expression vector) comprising a first nucleic acid (e.g., engineered nucleic acid) encoding OCT4, a second nucleic acid (e.g., engineered nucleic acid) encoding SOX2, and a third nucleic acid (e.g., engineered nucleic acid) encoding KLF4, alone or in combination and in the absence of an exogenous nucleic acid (e.g., engineered nucleic acid) capable of expressing c-Myc. In certain embodiments, the vector (e.g., expression vector) comprises a first nucleic acid (e.g., engineered nucleic acid) encoding OCT4, a second nucleic acid (e.g., engineered nucleic acid) encoding SOX2, a third nucleic acid (e.g., engineered nucleic acid) encoding KLF4, or any combination thereof. In certain embodiments, the first, second, and third nucleic acids (e.g., engineered nucleic acids) are present on separate expression vectors. In certain embodiments, two of the first, second, and third nucleic acids (e.g., engineered nucleic acids) are present on the same expression vector. In some embodiments, all three nucleic acids (e.g., engineered nucleic acids) are present on the same expression vector. In certain embodiments, the sequence encoding OCT4 is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 2 or 41. In certain embodiments, the sequence encoding SOX2 is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 4 or 43. In certain embodiments, the sequence encoding KLF4 is at least 70% identical to SEQ ID NO: 6 or 45. In certain embodiments, OCT4, SOX2, KLF4, or any combination thereof, is a human protein. In certain embodiments, OCT4, SOX2, KLF4, or any combination thereof, is a non-human protein (e.g., mammalian (e.g., primate (e.g., cynomolgus monkey, rhesus monkey); commercially relevant mammalian, e.g., cow, pig, horse, sheep, goat, cat, and / or dog) and avian (e.g., commercially relevant bird, e.g., chicken, duck, goose, and / or turkey). When more than one of OCT4, SOX2, and KLF4 is on a single vector, they can be in any order.The words "first," "second," and "third" are not meant to imply any order of genes on the vector.

[0015] The expression vectors of the present disclosure may further comprise an inducible promoter. The expression vector may have only one inducible promoter. In such cases, expression of OCT4, SOX2, and KLF4 is under the control of the same inducible promoter. In some cases, the expression vector comprises more than one inducible promoter. The inducible promoter may be a tetracycline responsive element (TRE) (e.g., TRE3G promoter, TRE2 promoter, or P tight The TRE (e.g., TRE3G) promoter may comprise a nucleic acid (e.g., engineered nucleic acid) sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO:7. By way of example, a TRE (e.g., TRE2) promoter may comprise a nucleic acid (e.g., engineered nucleic acid) sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO:23. By way of example, a TRE (e.g., P tight) promoter can comprise a nucleic acid (e.g., an engineered nucleic acid) sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 24. See, e.g., U.S. Provisional Application No. USSN 62 / 738,894, entitled MUTANT REVERSE TETRACYCLINE TRANSACTIVATORS FOR EXPRESSION OF GENES, filed September 28, 2018, with Attorney Docket No. H0824.70300ETS00, and International Patent Application No. USSN 62 / 738,894, entitled MUTANT REVERSE TETRACYCLINE TRANSACTIVATORS FOR EXPRESSION OF GENES, filed on the same day as this application, with Attorney Docket No. H0824.70300WO00, each of which is incorporated herein by reference in its entirety.

[0016] In certain embodiments, the inducer is capable of inducing expression of a first (e.g., OCT4), second (e.g., SOX2), third (e.g., KLF4) nucleic acid (e.g., an engineered nucleic acid), or any combination thereof, from an inducible promoter in the presence of tetracycline (e.g., doxycycline). In certain embodiments, the inducer is a reverse tetracycline-controlled transactivator (rtTA) (e.g., M2-rtTA, rtTA3, or rtTA4). In certain embodiments, the rtTA is rtTA3 comprising an amino acid sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO:11. In certain embodiments, the rtTA is rtTA4 and comprises a sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 13. In certain embodiments, the rtTA is M2-rtTA and comprises a sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 15.

[0017] In certain embodiments, the inducer is capable of inducing expression of a first nucleic acid (e.g., an engineered nucleic acid) (e.g., OCT4), a second nucleic acid (e.g., an engineered nucleic acid) (e.g., SOX2), a third nucleic acid (e.g., KLF4), or any combination thereof, from an inducible promoter in the absence of tetracycline (e.g., doxycycline). In certain embodiments, the inducer is a tetracycline-controlled transactivator (tTA).

[0018] In certain embodiments, the expression vectors of the present disclosure comprise a constitutive promoter (e.g., CP1, CMV, EF1 alpha, SV40, PGK1, Ubc, human beta-actin, CAG, Ac5, polyhedrin, TEF1, GDS, CaM35S, Ubi, H1, and U6 promoter). The constitutive promoter can be operably linked to a nucleic acid (e.g., engineered nucleic acid) sequence encoding OCT4, KLF4, SOX2, an inducer, or a combination thereof. In some embodiments, the expression vector comprises one constitutive promoter. In some embodiments, the expression vector comprises more than one constitutive promoter.

[0019] In certain embodiments, an expression vector of the present disclosure comprises a terminator sequence derived from SV40. In certain embodiments, the SV40-derived sequence is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO:8.

[0020] In certain embodiments, the expression vectors of the present disclosure include a separator sequence, which can be useful for generating two distinct amino acid sequences from a single transcript. The separator sequence can encode a self-cleaving peptide (e.g., a 2A peptide, including a 2A peptide sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO:9). In certain embodiments, the separator sequence is an internal ribosome entry site (IRES).

[0021] In certain embodiments, the expression vector is a viral vector (e.g., a lentiviral, retroviral, or adeno-associated viral (AAV) vector) (e.g., Figures 2-3). AAV vectors of the present disclosure generally contain inverted terminal repeats (ITRs) flanking a transgene of interest (e.g., a nucleic acid (e.g., an engineered nucleic acid) encoding OCT4, SOX2, KLF4, an inducer, or a combination thereof). In some embodiments, the distance between the two terminal inverted repeats is less than 5.0 kilobases (kb) (e.g., less than 4.9 kb, less than 4.8 kb, less than 4.7 kb, less than 4.6 kb, less than 4.5 kb, less than 4.4 kb, less than 4.3 kb, less than 4.2 kb, less than 4.1 kb, less than 4 kb, less than 3.5 kb, less than 3 kb, less than 2.5 kb, less than 2 kb, less than 1.5 kb, less than 1 kb, or less than 0.5 kb).

[0022] In certain embodiments, expression vectors of the present disclosure (e.g., expression vectors encoding OCT4, KLF4, SOX2, inducers, or combinations thereof) may further comprise a selection agent (e.g., an antibiotic, including blasticidin, geneticin, hygromycin B, mycophenolic acid, puromycin, zeocin, actinomycin D, ampicillin, carbenicillin, kanamycin, and neomycin) and / or a detectable marker (e.g., GFP, RFP, luciferase, CFP, mCherry, DsRed2FP, mKate, biotin, FLAG tag, HA tag, His tag, Myc tag, V5 tag, etc.).

[0023] In some embodiments, an expression vector (e.g., a viral vector) encoding OCT4, KLF4, and SOX2 comprises the sequence provided by SEQ ID NO: 16, SEQ ID NO: 105, or SEQ ID NO: 121. In some embodiments, an expression vector encoding OCT4, KLF4, and SOX2 comprises elements depicted in Figure 2, Figure 3, Figures 4A-4AL, Figures 5A-5D, or a combination thereof. Viral vectors include adeno-associated viral (AAV) vectors, retroviral vectors, lentiviral vectors, and herpes viral vectors.

[0024] In another aspect, the present disclosure provides a recombinant virus (e.g., a lentivirus, adenovirus, retrovirus, herpesvirus, alphavirus, vaccinia virus, or adeno-associated virus (AAV)) comprising any of the expression vectors described herein. In certain embodiments, the recombinant virus encodes a transcription factor selected from OCT4; KFF4; SOX2; and any combination thereof. In certain embodiments, the recombinant virus encodes two or more transcription factors selected from OCT4, KFF4, and SOX2. In certain embodiments, the recombinant virus encodes OCT4 and SOX2, OCT4 and KLF4, OCT4, KLF4, and SOX2, or SOX2 and KLF4. In certain embodiments, the recombinant virus encodes OCT4, KLF4, and SOX2. In certain embodiments, the four or more transcription factors encode four or more transcription factors (e.g., OCT4, SOX2, KLF4, and another transcription factor).

[0025] In yet another aspect, the present disclosure provides a method for controlling (e.g., inducing) cell reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof, comprising administering to a cell a first nucleic acid (e.g., an engineered nucleic acid) encoding OCT4, a second nucleic acid (e.g., an engineered nucleic acid) encoding SOX2, and a third nucleic acid (e.g., an engineered nucleic acid) encoding KLF4 in the absence of an exogenous nucleic acid (e.g., an engineered nucleic acid) capable of expressing c-Myc. In certain embodiments, the first nucleic acid (e.g., an engineered nucleic acid) encoding OCT4, the second nucleic acid (e.g., an engineered nucleic acid) encoding SOX2, and the third nucleic acid (e.g., an engineered nucleic acid) encoding KLF4 are administered to a subject. The subject may be human or non-human. Non-human subjects include, for example, mammals (e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys); commercially relevant mammals such as cows, pigs, horses, sheep, goats, cats, and / or dogs) and birds (e.g., commercially relevant birds such as chickens, ducks, geese, and / or turkeys). In certain embodiments, the three nucleic acids (e.g., engineered nucleic acids) are administered simultaneously. In certain embodiments, the three nucleic acids (e.g., engineered nucleic acids) are administered simultaneously on the same vector.

[0026] In yet another aspect, the present disclosure provides a method of controlling (e.g., inducing) cell reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof, comprising administering to a cell a first nucleic acid (e.g., an engineered nucleic acid) encoding OCT4, a second nucleic acid (e.g., an engineered nucleic acid) encoding SOX2, a third nucleic acid (e.g., an engineered nucleic acid) encoding KLF4, or any combination thereof. In certain embodiments, a first nucleic acid (e.g., an engineered nucleic acid) encoding OCT4, a second nucleic acid (e.g., an engineered nucleic acid) encoding SOX2, a third nucleic acid (e.g., an engineered nucleic acid) encoding KLF4, or any combination thereof is administered to a subject.

[0027] The expression vector comprising one or more of the first, second, and third nucleic acids (e.g., engineered nucleic acids) can be any of the expression vectors described above and herein. In some embodiments, the first nucleic acid, the second nucleic acid, the third nucleic acid, or any combination thereof, are present on separate expression vectors. In certain embodiments, two of the first nucleic acid, the second nucleic acid, the third nucleic acid, or any combination thereof are present on the same expression vector. In certain embodiments, all three nucleic acids (e.g., engineered nucleic acids) are present on the same expression vector. In certain embodiments, at least two of the first, second, or third nucleic acids (e.g., engineered nucleic acids) are operably linked to the same promoter. In certain embodiments, all three of the first, second, and third nucleic acids (e.g., engineered nucleic acids) are operably linked to the same promoter.

[0028] In some embodiments, the expression vector (e.g., a viral expression vector, including lentiviral, retroviral, and adeno-associated viral vectors) comprises an inducible promoter (e.g., a promoter containing a tetracycline responsive element (TRE), such as a TRE3G sequence, a TRE2 sequence, or a P tightIn some embodiments, the method further comprises administering an inducer (e.g., a chemical agent, a nucleic acid (e.g., an engineered nucleic acid) (e.g., a nucleic acid (e.g., an engineered nucleic acid) encoding an inducer), a protein, light, or temperature). In some embodiments, pH is used to induce expression of a nucleic acid operably linked to a promoter. In certain embodiments, the chemical agent capable of modulating the activity of the inducer is tetracycline (e.g., doxycycline). As a non-limiting example, a tetracycline-controlled transactivator (tTA) is an inducer whose activity is inhibited by tetracycline. As a non-limiting example, a reverse tetracycline-controlled transactivator (rtTA) is an inducer whose activity is activated by tetracycline. The inducer (e.g., rtTA or tTA) is encoded by a fourth nucleic acid (e.g., an engineered nucleic acid), which is the administered nucleic acid. In certain embodiments, an inducer (e.g., a chemical agent, a nucleic acid (e.g., an engineered nucleic acid) (e.g., a nucleic acid comprising RNA and / or DNA encoding the inducer), a protein, light, a specific pH, or temperature) is introduced simultaneously with a nucleic acid (e.g., an engineered nucleic acid) encoding OCT4, SOX2, and KLF4. In certain embodiments, an inducer (e.g., a chemical agent, a nucleic acid (e.g., an engineered nucleic acid) (e.g., a nucleic acid comprising RNA and / or DNA encoding the inducer), a protein, light, a specific pH, or temperature) is introduced simultaneously with a nucleic acid (e.g., an engineered nucleic acid) encoding one or more (e.g., two or more, or three or more) transcription factors selected from OCT4; SOX2; KLF4; and any combination thereof. A promoter (e.g., a constitutive promoter including CAG and Ubc, or an inducible promoter) can be operably linked to the nucleic acid (e.g., an engineered nucleic acid) encoding the inducer. In certain embodiments, the promoter operably linked to the nucleic acid (e.g., an engineered nucleic acid) encoding the inducer is a tissue-specific promoter.

[0029] In certain embodiments, the nucleic acid (e.g., engineered nucleic acid) encoding the inducer is present on the same expression vector as at least one of the nucleic acids (e.g., engineered nucleic acids) encoding OCT4, SOX2, KLF4, or a combination thereof. In certain embodiments, the nucleic acid (e.g., engineered nucleic acid) encoding the inducer is present on a separate expression vector from the nucleic acid (e.g., engineered nucleic acid) encoding OCT4, the nucleic acid (e.g., engineered nucleic acid) encoding SOX2, and the nucleic acid (e.g., engineered nucleic acid) encoding KLF4. In certain embodiments, the nucleic acids (e.g., engineered nucleic acids) encoding OCT4, SOX2, and KLF4 are present on a first expression vector, and the fourth nucleic acid (e.g., engineered nucleic acid) is present on a second expression vector.

[0030] In some embodiments, the nucleic acid encoding OCT4, SOX2, KLF4, and / or an inducer is not present on a viral vector. In some embodiments, the nucleic acid encoding one or more (e.g., two or more, or three or more) transcription factors selected from the group consisting of OCT4; SOX2; KLF4; and any combination thereof is not present on a viral vector. In some embodiments, the nucleic acid is delivered without a viral vector. In some embodiments, delivery of a nucleic acid not on a viral vector includes administration of naked nucleic acid, electroporation, the use of nanoparticles, and / or the use of liposomes.

[0031] The expression vector can be a viral vector (e.g., a lentiviral vector, an adenoviral vector, a retroviral vector, a herpesvirus vector, an alphavirus, a vaccinia virus, or an AAV vector). For example, a first expression vector encoding OCT4, SOX2, and KLF4 can comprise the nucleic acid (e.g., engineered nucleic acid) sequence provided by SEQ ID NO: 16. In some embodiments, an expression vector encoding an inducer comprises the sequence provided by SEQ ID NO: 17 (e.g., FIG. 12), SEQ ID NO: 31 (e.g., FIG. 18), or SEQ ID NO: 32 (e.g., FIG. 19).

[0032] In certain embodiments, the fourth nucleic acid (eg, an engineered nucleic acid) encoding the inducer further comprises a terminator sequence derived from SV-40, including a sequence that is at least 70% identical to SEQ ID NO:8.

[0033] In certain embodiments, the inducer is capable of inducing expression from the inducible promoter in the presence of tetracycline (e.g., doxycycline). In certain embodiments, the inducer is rtTA (e.g., rtTA3, including rtTA3 having a sequence at least 70% identical to SEQ ID NO:11, and rtTA4, including rtTA4 having a sequence at least 70% identical to SEQ ID NO:13). In certain embodiments, the method further includes administering tetracycline (e.g., doxycycline) to the cell, tissue, or subject. In certain embodiments, the method includes removing the tetracycline (e.g., doxycycline) from the cell, tissue, or subject.

[0034] In certain embodiments, the inducer is capable of inducing expression from an inducible promoter in the absence of tetracycline (e.g., doxycycline). In certain embodiments, the inducer is a tetracycline transactivator (tTA). Without being bound by any particular theory, tetracycline (e.g., doxycycline) may bind to tTA and prevent tTA from binding to its cognate promoter (e.g., a promoter containing a tetracycline responsive element (TRE)) and driving expression of an operably linked nucleic acid. Without being bound by any particular theory, to reduce the size of the viral vector and improve viral titer, the nucleic acid (e.g., engineered nucleic acid) encoding the inducer may not be in the same vector as any of the nucleic acids (e.g., engineered nucleic acids) encoding OCT4, KLF4, and SOX2.

[0035] In certain embodiments, one or more expression vectors (e.g., AAVs containing expression vectors) are administered to a cell, tissue, or subject in need thereof. The subject may have an injury or condition, be suspected of having a condition or injury, or be at risk for a condition or injury. Without being bound by a particular theory, expression of the transcription factors OCT4, SOX2, and KLF4 induces cellular reprogramming. In some embodiments, when a nucleic acid (e.g., an engineered nucleic acid) encoding OCT4, SOX2, KLF4, or a combination thereof is operably linked to an inducible promoter, an inducer (e.g., a chemical, protein, nucleic acid (e.g., an engineered nucleic acid) (e.g., a nucleic acid (e.g., an engineered nucleic acid) encoding the inducer) is administered under appropriate conditions (e.g., in the presence or absence of tetracycline). of). In certain embodiments, the inducer (e.g., rtTA) is capable of binding to the promoter and driving expression of the operably linked nucleic acid (e.g., engineered nucleic acid) only when the inducer is bound to tetracycline. In certain embodiments, the inducer (e.g., tTA) is unable to bind to the promoter and drive expression of the operably linked nucleic acid (e.g., engineered nucleic acid) when the inducer is bound to tetracycline. The condition can be an ocular disease (e.g., a retinal disease, a corneal disease, or any disease affecting the eye), cancer, aging, an age-related disease, injury, or a neurodegenerative disease. In certain embodiments, the cell or tissue is from the eye, ear, nose, mouth including gums and tooth roots, bone, lung, breast, udder, pancreas, stomach, esophagus, muscle including cardiac muscle, liver, blood vessels, skin including hair, heart, brain, nervous tissue, kidney, testis, prostate, penis, cloaca, fin, ovary, or intestine.

[0036] In certain embodiments, the tissue is damaged (e.g., due to injury, accident, or iatrogenic insult) and / or aged tissue. In certain embodiments, the tissue may be considered healthy but not optimal for performance or survival under current or future conditions (e.g., in agricultural or hazardous conditions involving toxic treatments, sun exposure, or travel outside the Earth's atmosphere).

[0037] In certain embodiments, the method further comprises controlling a biological process. In some embodiments, the methods described herein comprise controlling any biological process, including cell reprogramming, tissue repair, tissue survival, tissue regeneration, tissue growth, tissue function, organ regeneration, organ survival, organ function, or any combination thereof. In some embodiments, the method comprises inducing cell reprogramming, reversing aging, improving tissue function, improving organ function, promoting tissue repair, promoting tissue survival, promoting tissue regeneration, promoting tissue growth, promoting angiogenesis, reducing scar formation, reducing the appearance of aging, including alopecia, hair thinning, hair graying, loose skin, and skin wrinkling, promoting organ regeneration, promoting organ survival, altering the taste and quality of animal-derived produce, treating disease, or any combination thereof, in vivo or in vitro. For example, the method may induce cell reprogramming, cell survival, organ regeneration, tissue regeneration, or a combination thereof. In certain embodiments, the methods include inducing and then arresting cell reprogramming, cell survival, tissue regeneration, organ regeneration, aging, or a combination thereof. In certain embodiments, the methods reverse aging in a cell, tissue, organ, or subject. In some embodiments, the methods do not induce teratoma formation. In some embodiments, the methods do not induce unwanted cell proliferation. In some embodiments, the methods do not induce malignant cell growth. In some embodiments, the methods do not induce cancer. In some embodiments, the methods do not induce tumor growth or tumor formation. In some embodiments, the methods do not induce glaucoma.

[0038] In some embodiments, the methods described herein reverse the epigenetic clock of a cell, tissue, organ, subject, or any combination thereof. In some embodiments, the epigenetic clock is determined using a DNA methylation-based (DNAm) age estimator. In some embodiments, the method alters the expression of one or more genes associated with aging. In some embodiments, the method reduces the expression of one or more genes associated with aging. In some embodiments, the method alters the expression of one or more genes associated with aging. In some embodiments, the one or more genes are one or more sensory genes.

[0039] In some embodiments, the method reduces expression of one or more genes associated with aging, such as 0610040J01Rik, 1700080N15Rik, 2900064F13Rik, 4833417C18Rik, 4921522P10Rik, 4930447C04Rik, 4930488N15Rik, Ace, Ackr1, Acot1O, Acvr1, Adamts17, Adra1b, AI504432, Best3, Boc, Cadm3, Cand2, Cc19, Cd14, Cd36, Cfh, Chrm3, Chrna4, Cntn4, Cracr2b, Cryaa, CT5730 17.2, Cyp26a1, Cyp27a1, D330050G23Rik, D930007P13Rik, Ddo, Dgkg, Dlk2, Dnaja1-ps, Drd2, Dse1, Dytn, Ecscr, Edn1, Ednrb, Efemp1, Elfn2, Ep ha1O, Ephx1, Erbb4, Fam20a, Fbxw21, Ffar4, Flt4, Fmod, Foxp4, Fzd7, Gabrd, Galnt15, Galnt18, Gfra2, Ggt1, Gm10416, Gm14964, Gm17634, Gm206 5, Gm32352, Gm33172, Gm34280, Gm35853, Gm36298, Gm36356, Gm36937, Gm 3898, Gm42303, Gm42484, Gm42537, Gm42743, Gm43151, Gm43843, Gm44545 , Gm44722, Gm45516, Gm45532, Gm47494, Gm47982, Gm47989, Gm48398, Gm4 8495, Gm48593, Gm48958, Gm49089, Gm49326, Gm49331, Gm49760, Gm5796, Gm6374, Gm7276, Gm8237, Gm9796, Gm9954, Gpr75, Gprc5c, Grid2ip, Gsg112, Hapln4, Hcn3, Hcn4, Hhat1, Hs6st2, Htr3a, Illrap, Illrap12, Inka1 , Kbtbd12, Kcnj11, Kcnk4, Kdelc2, Klhl33, Lamc3, Lilra5, Lmanll, Lrfn2, Lrrc38, Lrrn4cl, Ltc4s, Manscl, Mir344c, Msr1, Mycbpap, Myoc, Ngfr,Nipa12, Olfr1372-ps1, Otop3, P2rx5, P2ry12, P4ha2, Pcdha12, Pcdha2, Pcdhac2, Pcdhb18, Pcdhb5, Pcsk2os1, Pcsk6, Perp, Pkp1, Plxna4 , Prickle2, Qsox1, Rapgef4os2, Rbp4, Rcn3, Sec1415, Sel113, Serpinh1, Sgpp2, Shisa6, Siah3, Siglech, Slc12a4, Slc24a2, Slc2a5, Slc4 a4, Slitrk3, Smagp, Smoc2, Speer4b, Spon2, Sstr2, Sstr3, St3ga13, Stc1, Stc2, Syndig1, Syt1O, Thsd7a, Tlr8, Tmem132a, Tmem132d, Tmem200a, Tmem44, Trpc4, Trpv4, Unc5b, Vgf, Vmnlr90, Vwc21, Wfikkn2, Wnt11, Wnt6, Zeb2os, Zfp608, Zfp976, or any combination thereof. In some embodiments, the method reduces the expression of Ace, Kcnk4, Lamc3, Edn1, Syt10, Ngfr, Gprc5c, Cd36, Chrna4, Ednrb, Drd2, or a combination thereof. ,

[0040] In some embodiments, the method increases expression of one or more genes associated with aging. In some embodiments, the method increases expression of one or more genes associated with aging, such as 1700031P21Rik, 1810053B23Rik, 2900045020Rik, 2900060B14Rik, 4921504E06Rik, 4930402F11Rik, 4930453C13Rik, 4930455B14Rik, 4930500H12Rik, 4930549P19Rik, 4930555B11Rik, 4930556J02Rik, 4932442E05Rik, 4933431K23Rik, 4933438K21Rik, 6720475M21Rik, 9 830132P13Rik, A430010J10Rik, A530064D06Rik, A530065N20Rik, Abcb5, Abhd17c, AC116759.2, AC131705.1, AC166779.3, Acotl2, Adig, Akrlc 1, Ankrd1, Asb15, Atp2c2, AU018091, AW822073, Btn11O, C130093G08Rik, C730027H18Rik, Ccdc162, Chi16, Col26a1, Corin, Crls1, Cybrd1, Cyp2 d12, Cyp7a1, D830005E20Rik, Dlx3, Dnah14, Dsc3, Dthd1, Eid2, Eps811, EU599041, Fam90ala, Fancf, Fau-ps2, Fezf1, Gja5, Gm10248, Gm10513, Gm10635, Gm10638, Gm10718, Gm10722, Gm10800, Gm10801, Gm11228, Gm11 251, Gm11264, Gm11337, Gm11368, Gm11485, Gm11693, Gm12793, Gm13050, Gm13066, Gm13323, Gm13339, Gm13346, Gm13857, Gm14387, Gm14770, Gm1 5638, Gm16072, Gm16161, Gm16181, Gm17200, Gm1779l, Gm18025, Gm18757 , Gm18795, Gm18848, Gm19719, Gm20121, Gm20356, Gm2093, Gm2l738, Gm2l 940, Gm22933, Gm24000, Gm24119, Gm25394, Gm26555, Gm27047, Gm28262,Gm28530、Gm29295、Gm29825、Gm29844、Gm3081、Gm32051、Gm32l22、Gm33056、Gm33680、Gm34354、Gm34643、Gm3551、Gm36660、Gm36948、Gm37052、Gm37142、Gm37262、Gm37535、Gm37569、Gm37589、Gm37647、Gm37648、Gm37762、Gm38058、Gm38069、Gm38137、Gm38218、Gm39139、Gm42535、Gm42680、Gm42895、Gm42994、Gm43027、Gm43158、Gm43288、Gm43366、Gm44044、Gm44081、Gm44187、Gm44280、Gm44535、Gm45338、Gm45644、Gm45740、Gm46555、Gm46565、Gm4742、Gm47485、Gm47853、Gm47992、Gm48225、Gm48314、Gm48383、Gm48673、Gm48804、Gm48832、Gm4994、Gm5487、Gm5724、Gm595、Gm6012、Gm6024、Gm7669、Gm7730、Gm8043、Gm8953、Gm9348、Gm9369、Gm9495、H2a12a、Ido2、Igfbp1、Kif7、Klhl31、Lrrc31、Mc5r、Mgam、Msh4、Mucl2、Mug1、Myb12、Myh15、Nek1O、Neurod6、Nr1h5、Olfr1042、Olfr1043、Olfr1082、Olfr1090、Olfr1124、Olfr1167、Olfr1205、Olfr1206、Olfr1223、Olfr1263、Olfr1264、Olfr1269、Olfr127、0lfr1291-ps1、Olfr1406、Olfr1469、Olfr215、Olfr273、Olfr328、Olfr355、Olfr372、Olfr390、Olfr427、Olfr456、Olfr466、Olfr481、Olfr522、Olfr6、Olfr601、Olfr603、Olfr706、Olfr727、Olfr728、Olfr741、Olfr801、Olfr8l2、Olfr8l6、Olfr822、Olfr860、Olfr890、Olfr923、Olfr943、Otog1、Pi15、Pkhd1、increasing the expression of Pkhd111, Platr6, Pou3f4, Prr9, Pvalb, Rhag, Savl, Serpinb9b, Skint1, Skint3, Skint5, Slc10a5, Slc6a4, Smok2a, Tcaf3, Tomm201, Trcgl, Trdn, Ugt1a6a, Usp171a, Vmnlr178, Vmn1r179, Vmn1r33, Vmn1r74, Vmn1r87, Vmn2rl02, Vmn2r113, Vmn2r17, Vmn2r52, Vmn2r66, Vmn2r68, Vmn2r76, Vmn2r78, Wnt16, or any combination thereof. In some embodiments, the method comprises the steps of: Olfr8l6, Olfr8l2, Olfr1264, Olfr727, Olfr923, Olfr1090, Olfr328, Olfr1124, Olfr522, Olfr1082, Olfr1206, Olfr1167, Olfr706, Olfr6, Pou3f4, Olfr603, Olfrl27, Olfr1263, Olfr1269, Olfr1205, Olfr390, Olfr60l, Olfr Increase the expression of r860, Olfr2l5, Olfr74l, Olfr1469, Olfr355, Olfr48l, Olfr456, Olfr042, Olfr728, Olfr372, Olfr80l, Olfr223, Olfr822, Otogl, Olfr943, Olfr406, Olfr273, Olfr466, Olfr043, Olfr427, Olfr890, Rbp4, or any combination thereof.

[0041] A further aspect of the present disclosure relates to a method of reprogramming that includes rejuvenating the epigenetic clock of a cell, tissue, organ, subject, or any combination thereof.

[0042] A further aspect of the present disclosure relates to methods of reprogramming that involve altering the expression of one or more genes associated with aging.

[0043] A further aspect of the present disclosure relates to a method comprising resetting the transcriptional profile of an in vitro aged cell, an aged organ, an aged tissue, and / or any combination thereof.

[0044] A further aspect of the present disclosure relates to a method comprising resetting the transcriptional profile of an in vivo aged cell, an aged organ, an aged tissue, an aged subject, and / or any combination thereof.

[0045] A further aspect of the present disclosure relates to a method for transdifferentiating cells.

[0046] Another aspect of the present disclosure provides engineered cells produced by any of the methods described herein. The methods described herein can be useful for generating any engineered cells, including induced pluripotent stem cells. The engineered cells of the present disclosure can be generated ex vivo, and the method can further include producing an engineered tissue or an engineered organ. In some embodiments, the methods of the present disclosure include administering the engineered cells, engineered tissue, and / or engineered organ of the present disclosure to a subject in need thereof. In some embodiments, the method further includes treating a disease.

[0047] Aspects of the present disclosure also provide compositions comprising, alone or in combination, any of a nucleic acid (e.g., an engineered nucleic acid) (e.g., an expression vector) capable of inducing OCT4, KLF4, inducer, and / or SOX2 expression; any of the engineered proteins described herein; any of a chemical agent that activates (e.g., induces expression of) OCT4, KLF4, inducer, and / or SOX2; any of an antibody that activates (e.g., induces expression of) OCT4, KLF4, inducer, and / or SOX2; and / or any of the recombinant viruses described herein (e.g., lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpesvirus, or AAV). In some embodiments, the pharmaceutical compositions of the present disclosure further comprise a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions further comprise a second engineered nucleic acid (e.g., an engineered nucleic acid) (e.g., an expression vector, including a viral vector) encoding an inducer (e.g., rtTA or tTA).

[0048] Aspects of the present disclosure also provide compositions comprising, alone or in combination, any of the nucleic acids (e.g., engineered nucleic acids) capable of inducing OCT4, KLF4, and / or SOX2 (e.g., expression vectors, including inducible expression vectors), any of the engineered proteins described herein, any of the chemical agents capable of activating (e.g., inducing the expression of) OCT4, KLF4, and / or SOX2, any of the antibodies capable of activating (e.g., inducing the expression of) OCT4, KLF4, and / or SOX2, and / or any of the recombinant viruses described herein (e.g., lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpesvirus, or AAV). In some embodiments, the composition further comprises a nucleic acid (e.g., engineered nucleic acid) encoding an inducer, an engineered protein encoding an inducer, a chemical agent capable of modulating (e.g., activating or inhibiting) the activity of an inducer, and / or a recombinant virus encoding an inducer. In some embodiments, the pharmaceutical compositions of the present disclosure further comprise a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition further comprises a second engineered nucleic acid (e.g., an engineered nucleic acid) (e.g., an expression vector, including a viral vector) encoding an inducer (e.g., rtTA or tTA).

[0049] Aspects of the present disclosure also provide compositions comprising, alone or in combination, any of the nucleic acids (e.g., engineered nucleic acids) (e.g., expression vectors) capable of inducing expression of one or more transcription factors selected from the group consisting of OCT4; SOX2; KLF4; and any combination thereof, any of the engineered proteins described herein, any of the chemical agents that activate (e.g., induce the expression of) one or more transcription factors selected from the group consisting of OCT4; SOX2; KLF4; and any combination thereof, any of the antibodies that activate (e.g., induce the expression of) one or more transcription factors selected from the group consisting of OCT4; SOX2; KLF4; and any combination thereof, and / or any of the recombinant viruses described herein (e.g., lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpes virus, or AAV). In certain embodiments, the composition comprises any of the following, alone or in combination: a nucleic acid (e.g., an engineered nucleic acid) (e.g., an expression vector) capable of inducing expression of two or more transcription factors selected from the group consisting of OCT4, SOX2, KLF4, and any combination thereof; any of the engineered proteins described herein; any of the chemical agents that activate transcription (e.g., induce expression) of two or more transcription factors selected from the group consisting of OCT4, SOX2, KLF4, and any combination thereof; any of the antibodies that activate (e.g., induce expression) of two or more transcription factors selected from the group consisting of OCT4, SOX2, KLF4, and any combination thereof; and / or any of the recombinant viruses described herein (e.g., lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpesvirus, or AAV). The two or more transcription factors may include OCT4 and SOX2, OCT4 and KLF4, OCT4, KLF4, and SOX2, or SOX2 and KLF4.In certain embodiments, the composition comprises any of the nucleic acids (e.g., engineered nucleic acids) (e.g., expression vectors) capable of inducing expression of three or more transcription factors selected from the group consisting of OCT4, SOX2, KLF4, and combinations thereof, any of the engineered proteins described herein, any of the chemical agents that activate transcription (e.g., induce expression) of three or more transcription factors selected from the group consisting of OCT4, SOX2, KLF4, and any combination thereof, any of the antibodies that activate (e.g., induce expression) of three or more transcription factors selected from the group consisting of OCT4, SOX2, KLF4, and any combination thereof, and / or any of the recombinant viruses described herein (e.g., lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpes virus, or AAV), alone or in combination. In certain embodiments, the three or more transcription factors may include OCT4, SOX2, and KLF4. In some embodiments, the pharmaceutical composition further comprises a nucleic acid (e.g., an engineered nucleic acid) (e.g., an expression vector) encoding an inducer (e.g., rtTA or tTA), an engineered protein encoding the inducer, a chemical agent capable of activating (e.g., inducing expression of) the inducer, and / or a recombinant virus encoding the inducer (e.g., a lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpes virus, or AAV). In some embodiments, the pharmaceutical composition of the present disclosure further comprises a pharmaceutically acceptable carrier.

[0050] In yet another aspect, the present disclosure provides kits that include any of the nucleic acids (e.g., engineered nucleic acids) (e.g., expression vectors) that can induce expression of OCT4, KLF4, inducers, and / or SOX2, any of the engineered proteins described herein, any of the chemical agents that activate (e.g., induce expression of) OCT4, KLF4, inducers, and / or SOX2, any of the antibodies that activate (e.g., induce expression of) OCT4, KLF4, inducers, and / or SOX2, and / or any of the recombinant viruses described herein (e.g., lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpes virus, or AAV).

[0051] In yet another aspect, the present disclosure provides kits comprising any of a nucleic acid (e.g., an engineered nucleic acid) capable of inducing expression of OCT4, KLF4, and / or SOX2 (e.g., an expression vector), any of the engineered proteins described herein, any of the chemical agents that activate (e.g., induce expression of) OCT4, KLF4, and / or SOX2, any of the antibodies that activate (e.g., induce expression of) OCT4, KLF4, and / or SOX2, and / or any of the recombinant viruses described herein (e.g., lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpesvirus, or AAV). In some embodiments, the kit further comprises a nucleic acid (e.g., an engineered nucleic acid) encoding the inducer, an engineered protein encoding the inducer, a chemical agent that can modulate (e.g., activate or inhibit) the activity of the inducer, and / or a recombinant virus encoding the inducer.

[0052] In yet another aspect, the present disclosure provides kits comprising any of the nucleic acids (e.g., engineered nucleic acids) (e.g., expression vectors) capable of inducing expression of one or more transcription factors selected from the group consisting of OCT4; SOX2; KLF4; and any combination thereof, any of the engineered proteins described herein, any of the chemical agents that activate (e.g., induce expression of) one or more transcription factors selected from the group consisting of OCT4; SOX2; KLF4; and any combination thereof, any of the antibodies that activate (e.g., induce expression of) OCT4; SOX2; KLF4; and any combination thereof, and / or any of the recombinant viruses described herein (e.g., lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpes virus, or AAV). In certain embodiments, the kit further comprises a nucleic acid (e.g., an engineered nucleic acid) (e.g., an expression vector) encoding the inducer (e.g., rtTA or tTA), an engineered protein encoding the inducer, a chemical agent capable of activating (e.g., inducing the expression of) the inducer, and / or a recombinant virus encoding the inducer (e.g., a lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpes virus, or AAV).

[0053] The details of one or more embodiments of the invention are presented herein. Other features, objects, and advantages of the invention will be apparent from the detailed description, examples, figures, and claims.

[0054] All references cited in this application are hereby incorporated by reference. definition

[0055] Definitions of certain terms are described in more detail below. The present disclosure is not intended to be limited in any way by the exemplary list of substitutions described herein.

[0056] "AAV" or "adeno-associated virus" is a non-enveloped virus that can carry and deliver nucleic acids (e.g., engineered nucleic acids) (e.g., nucleic acids (e.g., engineered nucleic acids) encoding OCT4; KLF4; SOX2; or any combination thereof) and belongs to the genus Dependoparvovirus. In some cases, AAV can deliver nucleic acids encoding inducers. Generally, AAV does not integrate into the genome. The tissue-specific targeting ability of AAV is often determined by the AAV capsid serotype (e.g., see Table 1 below for examples of AAV serotypes and their usefulness in tissue-specific delivery). Non-limiting serotypes of AAV include AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, and variants thereof. In certain embodiments, the AAV serotype is a variant of AAV9 (e.g., AAV PHP.b).

[0057] A "recombinant virus" is a virus (e.g., a lentivirus, adenovirus, retrovirus, herpesvirus, alphavirus, vaccinia virus, or adeno-associated virus (AAV)) that has been isolated from its natural environment (e.g., from a host cell, tissue, or subject) or is artificially produced.

[0058] As used herein, the term "AAV vector" refers to a nucleic acid (e.g., an engineered nucleic acid) that includes AAV inverted terminal repeats (ITRs) flanking an expression cassette (e.g., an expression cassette containing nucleic acids (e.g., engineered nucleic acids) encoding OCT4, KLF4, and SOX2, each alone or in combination, or an expression cassette encoding rtTA or tTA). An AAV vector may further include a promoter sequence.

[0059] As used herein, the terms "administer", "administering", or "administration" refer to any of the compositions described herein, any of the nucleic acids (e.g., engineered nucleic acids) (e.g., expression vectors) that can induce expression of OCT4, KLF4, and / or SOX2, any of the nucleic acids (e.g., engineered nucleic acids) (e.g., expression vectors) that can induce expression of one or more transcription factors selected from the group consisting of OCT4; KLF4; SOX2; and any combination thereof, any of the engineered proteins described herein, any of the chemical factors that activate (e.g., induce expression of) OCT4, KLF4, and / or SOX2, OCT4; KLF4; SOX2; and any combination thereof. "Inducer" refers to the introduction, alone or in combination, of any of the following into a cell, tissue, organ, and / or subject: a chemical agent that activates (e.g., induces the expression of) one or more transcription factors selected from OCT4; KLF4; SOX2; or any combination thereof; an antibody that activates (e.g., induces the expression of) OCT4; KLF4; SOX2; or any combination thereof; and / or any of the recombinant viruses described herein (e.g., lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpesvirus, or AAV). In some embodiments, a nucleic acid (e.g., an engineered nucleic acid) encoding an inducer, an engineered protein encoding an inducer, a chemical agent that can modulate (e.g., activate or inhibit) the activity of an inducer, and / or a recombinant virus encoding an inducer is also administered to a cell, tissue, organ, and / or subject.any nucleic acid (e.g., engineered nucleic acid) (e.g., expression vector) capable of inducing OCT4, KLF4, and / or SOX2 expression; any nucleic acid (e.g., engineered nucleic acid) (e.g., expression vector) capable of inducing expression of one or more transcription factors selected from OCT4; KLF4; SOX2; and any combination thereof; any engineered protein described herein; any chemical factor that activates (e.g., induces expression of) OCT4, KLF4, and / or SOX2; any engineered protein encoding OCT4, SOX2, KLF4, or any combination thereof; any chemical factor that activates (e.g., induces expression of) OCT4; KLF4; SOX2; or any combination thereof; any antibody that activates (e.g., induces expression of) OCT4, KLF4, and / or SOX2; Any of the compositions described herein comprising any of the antibodies, and / or any of the recombinant viruses described herein (e.g., lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpes virus, or AAV), alone or in combination, can be administered intravenously, intradermally, intra-arterially, intralesionally, intratumorally, intracranially, intra-articularly, intraprostatically, intrapleurally, intranasally, intravitreally, intravaginally, intrarectally, topically, intratumorally, intramuscularly, intraperitoneally, subcutaneously, subconjunctivally, intravesicularly, mucosally, intrapericardially, intraumbilically, intraocularly, orally, topically, locally, systemically, by injection, infusion, continuous infusion, localized perfusion bathing directly in target cells, by catheter, by cream, by lipid compositions (e.g., liposomes), or by other methods known to those skilled in the art or by any combination of the foregoing (see, for example, Remington's See Pharmaceutical Sciences (1990).In some embodiments, a composition comprising a nucleic acid (e.g., an engineered nucleic acid) encoding an inducer, an engineered protein encoding an inducer, a chemical agent capable of modulating (e.g., activating or inhibiting) the activity of an inducer, and / or a recombinant virus encoding an inducer is administered to a cell, tissue, organ, and / or subject, and may be administered using any suitable method.

[0060] The terms "epigenome" or "epigenetics" refer to the modifications and structural changes within a cell that control the expression of the cell's nucleic acids (e.g., engineered nucleic acids) or genomic information. Changes in the epigenome occur during and drive embryonic development, disease progression, and the aging process.

[0061] The term "epigenetic clock" can refer to an age estimator or an innate biological process. In some embodiments, rejuvenating or reversing the epigenetic clock refers to reducing the estimated age of a cell, tissue, organ, or subject. The epigenetic clock can be partially or completely reversed or rejuvenated by any of the methods described herein. In some embodiments, the age estimator is an epigenetic age estimator. For example, the epigenetic age estimator can be a set of CpG dinucleotides that, when used in combination with a mathematical algorithm, can be used to estimate the age of a source of DNA, including a cell, organ, or tissue. In some embodiments, the age estimator is a DNA methylation-based (DNAm) age estimator. In some embodiments, the DNAm age estimator is calculated as an age correlation using the Pearson correlation coefficient r between DNA methylation-based (DNam) age (also known as estimated age) and chronological age. In some embodiments, the DNA methylation-based (DNAm) age estimator is a single-tissue DNA methylation-based age estimator. In some embodiments, the DNA methylation-based age estimator is a multi-tissue DNA methylation-based age estimator. In some embodiments, the DNAm age estimator is DNAm PhenoAge. See, e.g., Horvath and Raj, Nat Rev Genet. 2018 Jun;19(6):371-384; Levine et al., Aging (Albany NY). 2018 Apr 18; 10(4):573-591; and examples below.

[0062] As used herein, "epigenetic information" includes covalent modifications of DNA, such as 5-methylcytosine (5mC), hydroxymethylcytosine (5hmeC), 5-formylcytosine (fC), and 5-carboxylcytosine (caC), and of certain proteins, such as lysine acetylation, lysine and arginine methylation, serine and threonine phosphorylation, and lysine ubiquitination and sumoylation of histone proteins, as well as the 3D architecture of cells, including topological domains (TADs) and compartments. Epigenetic information is sometimes referred to as the "analog" information of cells.

[0063] "Restoring expression" of at least one gene in Table 5 to youthful levels is meant to encompass increasing expression of a down-regulated gene or decreasing expression of an up-regulated gene that changes during aging.

[0064] The term "cell" as used herein is not only meant to encompass an individual cell, but also refers to the particular tissue or organ from which it originates.

[0065] The term "cellular senescence" refers to cells that have exited the cell cycle and exhibit epigenetic markers consistent with senescence or express senescent cell markers (e.g., senescence-associated beta-galactosidase or inflammatory cytokines). Cellular senescence can be partial or complete.

[0066] The term "gene expression" refers to the degree to which some or all of a cell's or tissue's genes are transcribed into RNA. In some cases, the RNA is translated into protein by the cell. The epigenome describes gene expression patterns.

[0067] The term "cellular reprogramming" refers to the process of altering a cell's epigenome using reprogramming factors (e.g., by reversing or preventing cellular epigenetic changes that cause dysfunction, weakness, cell death, senescence, or aging). Cellular reprogramming can be complete, resulting in a differentiated cell (e.g., a somatic cell) being reprogrammed into a pluripotent stem cell. Cellular reprogramming can be incomplete, resulting in a differentiated cell (e.g., a somatic cell) retaining its cellular identity (e.g., a lineage-specific stem cell). Cellular reprogramming can be incomplete, for example, no stem cells are produced, resulting in a cell being rejuvenated or taking on more youthful attributes (e.g., increased survival, reduced inflammation, or the ability to divide). Cellular reprogramming can provide additional cellular functions or prevent cellular aging (e.g., transdifferentiation, or transition to cellular senescence). Cellular reprogramming can induce temporary or permanent changes in gene expression. In some embodiments, incomplete cellular reprogramming is indicated by the absence of Nanog expression. In some embodiments, cellular reprogramming prevents senescence from occurring.

[0068] As used herein, the term "rejuvenating cells" is meant to include preventing or reversing the cellular causes of aging without inducing a pluripotent state. Rejuvenated cells as used herein include, for example, retinal ganglion cells that express RBPMS and / or Brn3a.

[0069] As used herein, a "pluripotent state" is meant to encompass a state in which a cell expresses at least one stem cell marker, such as, but not limited to, Esrrb, Nanog, Lin28, TRA-1-60 / TRA-1-81 / TRA-2-54, SSEA1, or SSEA4. Methods for measuring the expression of stem cell markers in a cell are known in the art and include the methods described herein.

[0070] The term "transdifferentiation" refers to the process by which one cell type is transformed into another cell type without entering a pluripotent state.Transdifferentiation can also be referred to as lineage reprogramming or lineage conversion.See, for example, Cieslar-Pobuda et al., Biochim Biophys Acta Mol Cell Res. 2017 July; 1864(7): 1359-1369, the entire contents of which are incorporated herein by reference.

[0071] The terms "condition," "disease," and "disorder" are used interchangeably. Non-limiting examples of conditions, diseases, and disorders include acute injury, neurodegenerative disease, chronic disease, proliferative disease, cardiovascular disease, genetic disease, inflammatory disease, autoimmune disease, neurological disease, hematological disease, painful condition, psychiatric disorder, metabolic disorder, chronic disease, cancer, aging, age-related disease, and diseases affecting any tissue of a subject. For example, age-related conditions include heart failure, stroke, heart disease, atherosclerosis, neurodegenerative disease (e.g., Parkinson's disease and Alzheimer's disease), cognitive decline, memory loss, diabetes, osteoporosis, arthritis, muscle loss, hearing loss (partial or total deafness), eye-related conditions (e.g., blurred vision or retinal disease), glaucoma, premature aging syndromes (e.g., Hutchinson-Gilford progeria syndrome), and cancer. In certain embodiments, the disease is a retinal disease (e.g., macular degeneration). In some embodiments, the age-related condition is senescence. As a non-limiting example, glial cell senescence may be the cause of Alzheimer's disease. See, e.g., Bussian, et al., Nature. 2018 Sep 19. In some cases, the condition is neuronal damage. In some cases, the condition is central nervous system (CNS) damage. In some cases, the neuronal damage is peripheral nerve damage. In some cases, the neuronal damage is neurapraxia, axonotomesis, or neurotomesis.

[0072] In some cases, the condition increases the DNA methylation-based age of the cell, tissue, organ, and / or subject relative to a control. In some cases, the condition increases the DNA methylation-based age of the cell, tissue, organ, and / or subject by at least 1%, at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 200%, at least 300%, at least 400%, at least 500%, at least 600%, at least 700%, at least 800%, at least 900%, or at least 1,000% relative to the control. In some cases, the control is a cell, tissue, organ, and / or subject that does not have the condition. In some cases, the control is the same cell, tissue, organ, and / or subject prior to having the condition. Without being bound by any particular theory, any of the methods described herein may be useful for reducing the DNA methylation-based age of diseased cells, diseased tissues, diseased organs, and / or subjects having, at risk for, or suspected of having a disease. In some cases, the disease increases the DNA methylation-based age of the cells, tissues, organs, and / or subjects. In some cases, the disease is an injury.

[0073] In some cases, the condition is aging. In some cases, aging is driven by epigenetic noise. See, e.g., Oberdoerffer and Sinclair. Nat Rev Mol Cell Biol 8, 692–702, doi: 10.1038 / nrm2238 (2007); Oberdoerffer et al. Cell 135, 907–918, doi:10.1016 / j.cell.2008.10.025 (2008). Without being bound by any particular theory, mammalian cells may retain faithful copies of epigenetic information from early in life. Analogous to Shannon's "observer" system in information theory, this is essentially a backup copy of the original signal to allow its reconstruction at the receiving end if information is lost or noise is introduced during transmission. See, for example, Shannon, The Bell System Technical Journal 27, 379-423 (1948) for a description of the observer system.

[0074] As used herein, "ocular disease" or "eye disease" refers to a disease or condition of the eye. Non-limiting examples of conditions affecting the eye include ectropion, lagophthalmos, blepharochalasis, ptosis, styes, yellow patches, dermatitis, demodex, leishmaniasis, loiasis, onchocerciasis, pediculosis, (herpes simplex), leprosy, molluscum contagiosum, tuberculosis, strawberry disease, shingles, impetigo, dacryoadenitis, lacrimation, exophthalmos, conjunctivitis, scleritis, keratitis, corneal ulcer / abrasion, snow blindness / arc eye, Thygeson's punctate superficial keratitis, corneal neovascularization, Fuchs' dystrophy, keratoconus, keratoconjunctivitis sicca, iritis, iritis, uveitis, and sympathetic ophthalmia. , cataract, lens, chorioretinal inflammation, isolated chorioretinal inflammation, chorioretinitis, choroiditis, retinitis, retinal choroiditis, diffuse chorioretinal inflammation, exudative retinopathy, posterior cyclitis, pars planitis, chorioretinal inflammation, Harada's disease, chorioretinal inflammation, choroid, choroidoretinal scar, macular scar, posterior pole (post-inflammatory) (post-traumatic), solar retinopathy, choroidal degeneration, atrophy, sclerosis, angioid streaks, choroidal dystrophy, choroideremia, choroidal, areolar (para-optic disc), gyriform atrophy, choroid, ornithineemia, choroidal hemorrhage, choroidal detachment, chorioretinal, choroidoretinal Inflammatory, infectious and parasitic diseases, chorioretinitis, syphilis, toxoplasmosis, tuberculosis, chorioretinal, retinal detachment, retina, choroid, astigmatism, retinoschisis, hypertensive retinopathy, diabetic retinopathy, retinopathy, retinopathy of prematurity, age-related macular degeneration, macula, macular degeneration, target maculopathy, preretinal membrane, peripheral retinal degeneration, hereditary retinal dystrophies, retinitis pigmentosa, retinal hemorrhage, retinal layers, central serous retinopathy, retinal detachment, retinal disorders, macular edema, macula, retinal disorders, diabetic retinopathy, glaucoma, optic neuropathy, high intraocular pressure, open-angle glaucoma, angle-closure glaucoma, normal-tension glaucoma The eye diseases include, but are not limited to, open-angle glaucoma, angle-closure glaucoma, floaters, Leber's hereditary optic neuropathy, optic disc drusen, strabismus, ophthalmoplegia, progressive external ophthalmoplegia, esotropia, exotropia, disorders of refraction, accommodation, hyperopia, myopia, astigmatism, anisometropia, presbyopia, ophthalmoplegia, amblyopia, Leber's congenital amaurosis, scotoma, anopsia, color blindness, color blindness / mascanthosis, cone cell, night blindness, blindness, river blindness, microphthalmia / coloboma, optic nerve, brain, spinal cord, ocular redness, Argyll-Robertson pupil, pupil, keratomycosis, xerophthalmia, and aniridia. In some embodiments, the eye disease is an acute or chronic eye injury.

[0075] In some embodiments, the eye condition is a corneal abrasion.

[0076] In some embodiments, the eye disease is glaucoma.

[0077] In some embodiments, the eye disease is a corneal disease (e.g., a disease affecting the cornea or corneal cells). In some embodiments, the eye disease is acanthamoeba keratitis, ectropion, lagophthalmos, anisocoria, astigmatism, Bell's palsy, blepharitis, blurred vision, burning eyes, cataracts, macular degeneration, age-related macular degeneration, diabetic eye disease, glaucoma, dry eye, poor vision (e.g., low vision), astigmatism, blepharitis, cataracts, chalazion, conjunctivitis, diabetic retinopathy, dry eye, glaucoma, keratitis, keratoconus, macular degeneration, high intraocular pressure, pinguecula, pterygium, retinitis pigmentosa, or eye cancer (e.g., retinoblastoma, ocular melanoma, ocular lymphoma, medulloepithelioma, conjunctival squamous cell carcinoma). Examples of corneal diseases include, but are not limited to, corneal neovascularization (NV), corneal dystrophy, corneal inflammation, corneal abrasion, and corneal fibrosis. In some embodiments, the eye disease is keratoconus. In some embodiments, the eye disease is macular degeneration. Additional non-limiting examples of eye diseases can be found in the International Statistical Classification of Diseases and Related Health Problems (e.g., VII diseases of the eye and adnexa).

[0078] The ocular disease can affect any part of the eye and / or adnexa. In some embodiments, the ocular disease is a disorder of the eyelid, lacrimal system, and / or orbit. In some embodiments, the ocular disease is a disorder of the conjunctiva. In some embodiments, the ocular disease is a disorder of the sclera, cornea, iris, and / or ciliary body. In some embodiments, the ocular disease is a disorder of the lens. In some embodiments, the ocular disease is a disorder of the choroid and / or retina. In some embodiments, the ocular disease is glaucoma. In some embodiments, the ocular disease is a disorder of the vitreous body and / or the eyeball. In some embodiments, the ocular disease is a disorder of the optic nerve and / or visual pathway. In some embodiments, the ocular disease is a disorder of the eye muscles, binocular movement, accommodation, and / or refraction. In some embodiments, the ocular disease is a visual disorder and / or blindness. In some embodiments, the ocular disease is age-related, e.g., age-related blindness, age-related visual loss, and / or retinal decline.

[0079] Any suitable method can be used to measure ocular function, non-limiting examples include visual acuity testing, pattern electroretinogram, and pathology.

[0080] The term "genetic disease" refers to a disease caused by one or more abnormalities in a subject's genome, e.g., a disease present from birth. Genetic diseases can be hereditary and can be inherited from parental genes. Genetic diseases can also be caused by mutations or changes in a subject's DNA and / or RNA. In such cases, a genetic disease would be hereditary if it occurs in the germline. Exemplary genetic diseases include Asskog-Scott syndrome, Oze syndrome, achondroplasia, acroostosis dysplasia, addiction, adrenoleukodystrophy, albinism, anephthalmos-macrostomia syndrome, Alagille syndrome, alkaptonuria, alpha-1 antitrypsin deficiency, Alport syndrome, Alzheimer's disease, asthma, autoimmune polyglandular syndrome, androgen insensitivity syndrome, Angelman syndrome, ataxia, ataxia-telangiectasia, atherosclerosis, attention deficit hyperactivity disorder, and the like. Attention-deficit / hyperactivity disorder (ADHD), autism, baldness, Batten disease, Beckwith-Wiedemann syndrome, Best disease, bipolar disorder, brachydactyly), breast cancer, Burkitt's lymphoma, chronic myeloid leukemia, Charcot-Marie-Tooth disease, Crohn's disease, cleft lip, Cockayne syndrome, Coffin-Lowry syndrome, colon cancer, congenital adrenal hyperplasia, Cornelia de Lange syndrome, Costello syndrome, Cowden syndrome, craniofrontonasal dysplasia, Crigler-Najjar syndrome, Creutzfeldt-Jakob syndrome Disease, cystic fibrosis, deafness, depression, diabetes, flexor dysplasia, DiGeorge syndrome, Down syndrome, dyslexia, Duchenne muscular dystrophy, Dubowitz syndrome, ectodermal dysplasia, Ellis-van Creveld syndrome, Ehlers-Danlos syndrome, epidermolysis bullosa, epilepsy, essential tremor, familial hypercholesterolemia, familial Mediterranean fever, fragile X syndrome, Friedreich's ataxia, Gaucher disease, glaucoma, glucose-galactose malabsorption, glutar Aciduria, gyriform atrophy, Goldberg-Shprintzen syndrome (palatocardiofacial syndrome), Gorlin syndrome, Hailey-Hailey disease, hemihypertrophy, hemochromatosis, hemophilia, hereditary motor and sensory neuropathy (HMSN), hereditary nonpolyposis colorectal cancer (HNPCC), Huntington's disease, immunodeficiency with high IgM, early-onset diabetes, Klinefelter syndrome, Kabuki syndrome, Leigh's disease, long QT syndrome, lung cancer, malignant melanoma, bipolar disorder, Marfan syndrome,Menkes syndrome, miscarriage, mucopolysaccharidoses, multiple endocrine neoplasia, multiple sclerosis, muscular dystrophy, amyotrophic lateral sclerosis, myotonic dystrophy, neurofibromatosis, Niemann-Pick disease, Noonan syndrome, obesity, ovarian cancer, pancreatic cancer, Parkinson's disease, paroxysmal nocturnal hemoglobinuria, Pendred syndrome, peroneal muscular atrophy, phenylketonuria (PKU), polycystic kidney disease, Prader-Willi syndrome, primary biliary cirrhosis, prostate cancer, REAR syndrome, Refsum's disease, retinitis pigmentosa, retinoblastoma, Rett syndrome, Sanfilippo syndrome, schizophrenia , severe combined immunodeficiency syndrome, sickle cell anemia, spina bifida, spinal muscular atrophy, spinocerebellar atrophy, sudden adult death syndrome, Tangier disease, Tay-Sachs disease, thrombocytopenic radial deficiency syndrome, Townes-Brocks syndrome, tuberous sclerosis complex, Turner syndrome, Usher syndrome, von Hippel-Lindau syndrome, Waardenburg syndrome, Weaver syndrome, Werner syndrome, Williams syndrome, Wilson disease, xeroderma pigmentosum, progeria syndromes (e.g., Hutchinson-Gilford progeria syndrome), and Zellweger syndrome.

[0081] "Proliferative disease" refers to a disease caused by abnormal growth or progression of cells (Walker, Cambridge Dictionary of Biology, Cambridge University Press: Cambridge, UK, 1990). Proliferative diseases can be associated with: 1) pathological proliferation of normally quiescent cells; 2) pathological migration of cells from their normal location (e.g., neoplastic cell metastasis); 3) pathological expression of proteolytic enzymes such as matrix metalloproteinases (e.g., collagenase, gelatinase, and elastase); or 4) pathological angiogenesis, such as in proliferative retinopathies and tumor metastasis. Exemplary proliferative diseases include cancer (i.e., "malignant neoplasms"), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases.

[0082] The terms "neoplasm" and "tumor" are used interchangeably herein to refer to an abnormal mass of tissue in which the growth of the mass exceeds and is out of step with the growth of normal tissue. Neoplasms or tumors can be "benign" or "malignant" depending on the following characteristics: degree of cellular differentiation (including morphology and functionality), growth rate, local invasion, and metastasis. "Benign neoplasms" are generally well differentiated, characteristically have slower growth rates than malignant neoplasms, and remain localized to the primary site. In addition, benign neoplasms lack the ability to infiltrate, invasive, or metastasize to distant sites. Exemplary benign neoplasms include, but are not limited to, lipomas, chondromas, adenomas, acrochordons, senile hemangiomas, seborrheic keratoses, moles, and sebaceous hyperplasias. In some cases, certain "benign" tumors can later give rise to malignant neoplasms. This can result from additional genetic alterations in a subpopulation of neoplastic cells in the tumor; these tumors are referred to as "premalignant neoplasms." An exemplary premalignant neoplasm is a teratoma. In contrast, "malignant neoplasms" are generally poorly differentiated (anaplastic) and have characteristically rapid growth accompanied by gradual infiltration, invasion, and destruction of surrounding tissue. Furthermore, malignant neoplasms generally have the ability to metastasize to distant sites. The terms "metastasis," "metastatic," or "metastasize" refer to the spread or migration of cancerous cells from a primary or original tumor to another organ or tissue, typically identifiable by the presence of a "secondary tumor" or "secondary cell mass" of the histological type of the primary or original tumor, rather than the organ or tissue in which the secondary (metastatic) tumor is located. For example, prostate cancer that has migrated to bone is said to be metastatic prostate cancer, and includes cancerous prostate cancer cells growing in bone tissue.

[0083] The term "cancer" refers to a class of diseases characterized by the development of abnormal cells that grow uncontrollably and have the ability to invade and destroy normal body tissue. See, e.g., Stedman's Medical Dictionary, 25th ed.; Hensyl ed.; Williams & Wilkins: Philadelphia, 1990. Exemplary cancers include acoustic neuroma; adenocarcinoma; adrenal carcinoma; anal carcinoma; angiosarcoma (e.g., lymphangiosarcoma, lymphangioendothelial sarcoma, angiosarcoma); appendix cancer; benign monoclonal gammopathy; biliary tract cancer (e.g., cholangiocarcinoma); bladder cancer; breast cancer (e.g., adenocarcinoma of the breast, papillary carcinoma of the breast, adenocarcinoma of the breast, medullary carcinoma of the breast); brain tumors (e.g., meningioma, glioblastoma, glioma (e.g., astrocytoma), , oligodendroglioma), medulloblastoma); bronchial carcinoma; carcinoid tumor; cervical cancer (e.g., cervical adenocarcinoma); choriocarcinoma; chordoma; craniopharyngioma; colorectal cancer (e.g., colon cancer, rectal cancer, colorectal adenocarcinoma); connective tissue carcinoma; epithelial carcinoma; ependymoma; endothelial sarcoma (e.g., Kaposi's sarcoma, multiple idiopathic hemorrhagic sarcoma); endometrial cancer (e.g., uterine carcinoma, uterine sarcoma); esophageal cancer (e.g., esophageal adenocarcinoma, Barrett's adenocarcinoma); Ewing's sarcoma; eye cancer (e.g., intraocular melanoma, retinoblastoma); familial eosinophilia; gallbladder cancer; gastric cancer (e.g., gastric adenocarcinoma); gastrointestinal stromal tumor (GIST); germ cell carcinoma; head and neck cancer (e.g., head and neck squamous cell carcinoma, oral cancer (e.g., oral squamous cell carcinoma), throat cancer (e.g., laryngeal cancer, pharyngeal cancer, nasopharyngeal carcinoma, oropharyngeal carcinoma); hematopoietic cancer (e.g., leukemia, such as acute lymphocytic leukemia (ALL) (e.g., B-cell ALL, T-cell ALL), acute myeloid leukemia (AML) (e.g., B-cell AML, T-cell AML), chronic myeloid leukemia (CML) (e.g., B-cell CML, T-cell CML), and chronic lymphocytic leukemia (CLL) (e.g., B-cell CLL, T-cell CLL));Lymphomas, such as Hodgkin's lymphoma (HL) (e.g., B-cell HL, T-cell HL) and non-Hodgkin's lymphoma (NHL) (e.g., B-cell NHL, such as diffuse large cell lymphoma (DLCL) (e.g., diffuse large B-cell lymphoma), follicular lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), mantle cell lymphoma (MCL), marginal zone B-cell lymphoma (e.g., mucosa-associated lymphoid tissue (MALT) lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt's lymphoma, lymphoid plasma lymphoma, cell lymphomas (i.e., Waldenstrom's macroglobulinemia), hairy cell leukemia (HCL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, and primary central nervous system (CNS) lymphoma; and T-cell NHL, such as precursor T-lymphoblastic lymphoma / leukemia, peripheral T-cell lymphomas (PTCL) (e.g., cutaneous T-cell lymphoma (CTCL) (e.g., mycosis fungoides, Sézary syndrome), angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma, enteropathic T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, and anaplastic large cell lymphoma (ANCL)). cell lymphomas); mixtures of one or more of the leukemias / lymphomas listed above; and multiple myeloma (MM), heavy chain diseases (e.g., alpha chain diseases, gamma chain diseases, mu chain diseases); hemangioblastoma; hypopharyngeal carcinoma; inflammatory myofibroblastic tumors; immune cell amyloidosis; kidney cancer (e.g., nephroblastoma, also known as Wilms' tumor, renal cell carcinoma); liver cancer (e.g., hepatocellular carcinoma (HCC), malignant hepatoma); lung cancer (e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung); leiomyosarcoma (LMS); mastocytosis (e.g., generalized obesity) myelodysplastic syndromes (MDS); mesothelioma; myeloproliferative disorders (MPDs) (e.g., polycythemia vera (PV), essential thrombocythemia (ET), idiopathic myeloid metaplasia (AMM), also known as myelofibrosis (MF), chronic idiopathic myelofibrosis, chronic myelogenous leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES)); neuroblastoma; neurofibromas (e.g., neurofibromatosis (NF) type 1 or 2, schwannomatosis); neuroendocrine carcinomas (e.g., gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs), carcinoid tumors); osteosarcomas (e.g., bone cancer);Ovarian cancer (e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma); papillary adenocarcinoma; pancreatic cancer (e.g., pancreatic adenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), pancreatic islet cell tumor); penile cancer (e.g., Paget's disease of the penis and scrotum); pinealoma; primitive neuroectodermal tumor (PNT); plasma cell neoplasm; paraneoplastic syndrome; intraepithelial neoplasia; prostate cancer (e.g., prostatic adenocarcinoma); rectal cancer; rhabdomyosarcoma; salivary gland cancer; skin cancer (e.g., squamous cell carcinoma (SCC), keratoacanthoma (KA), melanoma, basal cancers, including, but not limited to, bladder cancer, small intestine cancer (e.g., appendix cancer); soft tissue sarcomas (e.g., malignant fibrous histiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath tumor (MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma); sebaceous gland carcinoma; small intestine cancer; sweat gland carcinoma; synovium; testicular cancer (e.g., seminoma, testicular embryonal carcinoma); thyroid cancer (e.g., papillary carcinoma of the thyroid, papillary thyroid carcinoma (PTC), medullary thyroid carcinoma); urethral cancer; vaginal cancer; and vulvar cancer (e.g., Paget's disease of the vulva);

[0084] The term "inflammatory disease" refers to a disease caused by, resulting from, or resulting in inflammation. The term "inflammatory disease" can also refer to a dysregulated inflammatory response that causes an excessive response by macrophages, granulocytes, and / or T lymphocytes, leading to abnormal tissue damage and / or cell death. Inflammatory diseases can be either acute or chronic inflammatory conditions and can result from infectious or non-infectious causes.Inflammatory diseases include, without limitation, atherosclerosis, arteriosclerosis, autoimmune disorders, multiple sclerosis, systemic lupus erythematosus, polymyalgia rheumatica (PMR), gouty arthritis, osteoarthritis, tendonitis, bursitis, psoriasis, cystic fibrosis, osteoarthritis, rheumatoid arthritis, inflammatory arthritis, Sjogren's syndrome, giant cell arteritis, progressive systemic sclerosis (scleroderma), ankylosing spondylitis, polymyositis, dermatomyositis, pemphigus, pemphigoid, diabetes (e.g., type 1), myasthenia gravis, Hashimoto's thyroiditis, Graves' disease, Goodpa's disease, and rheumatoid arthritis. Schuer's disease, mixed connective tissue disease, sclerosing cholangitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, pernicious anemia, inflammatory dermatoses, usual interstitial pneumonitis (UIP), asbestosis, silicosis, bronchiectasis, beryllium pneumonia, talc pneumonia, pneumoconiosis, sarcoidosis, desquamative interstitial pneumonia, lymphocytic interstitial pneumonia, giant cell interstitial pneumonia, cellular interstitial pneumonia, extrinsic allergic alveolitis, Wegener's granulomatosis and related forms of vasculitis (temporal arteritis and polyarteritis nodosa), inflammatory dermatoses, hepatitis, delayed hypersensitivity reactions ( For example, poison ivy dermatitis), pneumonia, airway inflammation, adult respiratory distress syndrome (ARDS), encephalitis, immediate hypersensitivity reaction, asthma, hay fever, allergy, acute anaphylaxis, rheumatic fever, glomerulonephritis, pyelonephritis, cellulitis, cystitis, chronic cholecystitis, ischemia (ischemic injury), reperfusion injury, allograft rejection, host-versus-graft rejection, appendicitis, arteritis, blepharitis, bronchiolitis, bronchitis, cervicitis, cholangitis, chorioamnionitis, conjunctivitis, dacryoadenitis, dermatomyositis, endocarditis, endometritis, enteritis, small intestine colitis, epicondylitis Inflammatory eye diseases include, but are not limited to, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, gingivitis, ileitis, iritis, laryngitis, myelitis, myocarditis, nephritis, omphalitis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, pharyngitis, pleuritis, phlebitis, pneumonitis, proctitis, prostatitis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, orchitis, tonsillitis, urethritis, cystitis, uveitis, vaginitis, vasculitis, vulvitis, vulvovaginitis, vasculitis, chronic bronchitis, osteomyelitis, optic neuritis, temporal arteritis, transverse myelitis, necrotizing fasciitis, and necrotizing enterocolitis. In some embodiments, the inflammatory disease is inflammatory (e.g., inflammation that is a side effect of aging).

[0085] "Autoimmune disease" refers to a disease that results from an inappropriate immune response by a subject's body against substances and tissues that are normally present in the body. In other words, the immune system mistakes some part of the body for a pathogen and attacks its own cells. This may be limited to certain organs (e.g., autoimmune thyroiditis) or may involve specific tissues in different locations (e.g., Goodpasture's disease, which can affect the basement membrane of both the lungs and kidneys). Treatment of autoimmune diseases is typically immunosuppressive, e.g., by drugs that reduce the immune response. Exemplary autoimmune diseases include, but are not limited to, glomerulonephritis, Goodpasture's syndrome, necrotizing vasculitis, lymphadenitis, periarteritis nodosa, systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, psoriasis, ulcerative colitis, systemic sclerosis, dermatomyositis / polymyositis, antiphospholipid syndrome, scleroderma, pemphigus vulgaris, ANCA-associated vasculitis (e.g., Wegener's granulomatosis, microscopic polyangiitis), uveitis, Sjogren's syndrome, Crohn's disease, Reiter's syndrome, ankylosing spondylitis, Lyme disease, Guillain-Barré syndrome, Hashimoto's thyroiditis, and cardiomyopathy.

[0086] The term "liver disease" or "liver disorder" refers to damage or disease of the liver. Non-limiting examples of liver disorders include intrahepatic cholestasis (e.g., Alagille syndrome, biliary cirrhosis), fatty liver (e.g., alcoholic fatty liver, Reye's syndrome), hepatic vein thrombosis, hepatolenticular degeneration (i.e., Wilson's disease), hepatomegaly, liver abscess (e.g., amebic liver abscess), cirrhosis (e.g., alcoholic, biliary, and experimental cirrhosis), alcoholic liver disease (e.g., fatty liver, hepatitis, cirrhosis), parasitic liver disease (e.g., hepatic echinococcosis), and the like. , fascioliasis, amoebic liver abscess), jaundice (e.g., hemolytic, hepatocellular, cholestatic jaundice), cholestasis, portal hypertension, hepatomegaly, ascites, hepatitis (e.g., alcoholic hepatitis, animal hepatitis), chronic hepatitis (e.g., autoimmune, hepatitis B, C, D, drug-induced chronic hepatitis), toxic hepatitis, viral human hepatitis (e.g., hepatitis A, B, C, D, E), granulomatous hepatitis, secondary biliary cirrhosis, hepatic encephalopathy, varices, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular adenoma, hemangioma, gallstones, liver failure (e.g., hepatic encephalopathy, acute liver failure), angiomyolipoma, calcified liver metastases, cystic liver metastases, fibrolamellar hepatocellular carcinoma, hepatic adenoma, hepatoma, liver cysts (e.g., simple cyst, polycystic liver disease, intrahepatic bile duct cystadenoma, choledochal cyst), mesenchymal tumors (mesenchymal hamartoma, infantile hemangioendothelioma, hemangioma, peliosis hepatis, lipoma, inflammatory pseudotumor), epithelial tumors (e.g., bile duct hamartoma, bile duct adenoma) , focal nodular hyperplasia, nodular regenerative hyperplasia, hepatoblastoma, hepatocellular carcinoma, cholangiocarcinoma, cystadenocarcinoma, vascular tumors, angiosarcoma, Kaposi's sarcoma, hemangioendothelioma, embryonal sarcoma, fibrosarcoma, leiomyosarcoma, rhabdomyosarcoma, carcinosarcoma, teratoma, carcinoid, squamous cell carcinoma, primary lymphoma, peliosis hepatis, erythropoietic porphyrias, hepatic porphyrias (e.g., acute intermittent porphyria, porphyria cutanea tarda), and Zellweger syndrome.

[0087] The term "spleen disease" refers to diseases of the spleen. Examples of spleen diseases include, but are not limited to, splenomegaly, splenic cancer, asplenia, splenic injury, idiopathic purpura, Felty's syndrome, Hodgkin's disease, and immune-mediated destruction of the spleen.

[0088] The terms "lung disease" or "pulmonary disease" refer to diseases of the lungs. Examples of pulmonary diseases include, but are not limited to, bronchiectasis, bronchitis, bronchopulmonary dysplasia, interstitial lung disease, occupational lung disease, emphysema, cystic fibrosis, acute respiratory distress syndrome (ARDS), severe acute respiratory syndrome (SARS), asthma (e.g., intermittent asthma, mild persistent asthma, moderate persistent asthma, severe persistent asthma), chronic bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, interstitial lung disease, sarcoidosis, asbestosis, aspergilloma, aspergillosis, pneumonia (e.g., lobar pneumonia, multilobar pneumonia, bronchopneumonia, interstitial pneumonia), pulmonary fibrosis, pulmonary tuberculosis, rheumatic lung disease, pulmonary embolism, and lung cancer (e.g., non-small cell lung carcinoma (e.g., adenocarcinoma, squamous cell lung carcinoma, large cell lung carcinoma), small cell lung carcinoma).

[0089] "Hematological disorders" include disorders affecting hematopoietic cells or tissues. Hematological disorders include disorders associated with abnormal hematological content and / or function. Examples of hematological disorders include disorders resulting from bone marrow irradiation or chemotherapy treatment for cancer, disorders such as pernicious anemia, hemorrhagic anemia, hemolytic anemia, aplastic anemia, sickle cell anemia, sideroblastic anemia, anemia associated with chronic infections such as malaria, trypanosomiasis, HTV, hepatitis virus, or other viruses, myelophthisic anemia caused by bone marrow failure, renal failure resulting from anemia, anemia, polycythemia, infectious mononucleosis (EVI), acute nonlymphocytic leukemia (ANLL), acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), acute osteoporosis (OA), and osteoporosis. These include myelomonocytic leukemia (AMMoL), polycythemia vera, lymphoma, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia, Wilms' tumor, Ewing's sarcoma, retinoblastoma, hemophilia, disorders associated with an increased risk of thrombosis, herpes, thalassemia, antibody-mediated disorders such as transfusion reactions and erythroblastosis, mechanical trauma to red blood cells such as microangiopathic hemolytic anemia, thrombotic thrombocytopenic purpura and disseminated intravascular coagulation, infection with parasites such as Plasmodium, chemical injury from, for example, lead poisoning, and hypersplenism.

[0090] The term "neurological disease" refers to any disorder of the nervous system, including diseases and injuries involving the central nervous system (brain, brainstem, and cerebellum), peripheral nervous system (including cranial nerves), and autonomic nervous system (parts of which are located in both the central and peripheral nervous systems). Neurodegenerative diseases refer to a type of neurological disease marked by loss of nerve cells, including, but not limited to, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, tauopathies (including frontotemporal dementia), and Huntington's disease. Examples of neurological diseases include, but are not limited to, vascular dementia, stroke, headache, stupor and coma, dementia, seizures, sleep disorders, trauma, infection, neoplasms, neuro-ophthalmology, movement disorders, demyelinating diseases, spinal cord disorders, and disorders of the peripheral nerves, muscles, and neuromuscular junction. Addiction and psychosis, including, but not limited to, bipolar disorder and schizophrenia, are also included in the definition of neurological disease. Further examples of neurological disorders include acquired epileptic aphasia; acute disseminated encephalomyelitis; adrenoleukodystrophy; agenesis of the corpus callosum; agnosia; Aicardi syndrome; Alexander disease; Alpers disease; alternating hemiplegia; Alzheimer's disease; amyotrophic lateral sclerosis; anencephaly; Angelman syndrome; angiomatosis; anoxia; aphasia; apraxia; arachnoid cysts; arachnoiditis; Arnold-Chiari malformation; cerebral arteriovenous malformations; Asperger's syndrome; ataxia-telangiectasia; attention-deficit hyperactivity disorder; autism; autonomic dysfunction; back pain; Batten disease; Behçet's disease; Bell's palsy; benign essential blepharospasm; benign focal muscular atrophy; benign intracranial hypertension; Binswanger's disease; blepharospasm; Bloch-Sulzberger syndrome; Brachial plexus injury; brain abscess; brain injury; brain tumor (including glioblastoma multiforme); spinal cord tumor; Brown-Séquard syndrome; Canavan disease; carpal tunnel syndrome (CTS); causalgia; central pain syndrome; central pontine myelinolysis; craniopathy; cerebral aneurysm; cerebral arteriosclerosis; cerebral atrophy; cerebral gigantism; cerebral palsy; Charcot-Marie-Tooth disease; chemotherapy-induced neuropathy and neuropathic pain; Chiari malformation; chorea; chronic inflammatory demyelinating polyneuropathy (CIDP); chronic pain; chronic regional pain syndrome; Coffin-Lowry syndrome; coma including persistent vegetative state; congenital bilateral facial palsy; corticobasal degeneration; cranial arteritis; craniosynostosis; Creutzfeldt-Jakob disease; cumulative trauma disorder;Cushing's syndrome; cytomegalic inclusion body disease (CIBD); cytomegalovirus infection; dancing eye, dancing foot syndrome; Dandy-Walker syndrome; Dawson's disease; Domorsia syndrome; Dejerine-Klumpke palsy; dementia; dermatomyositis; diabetic neuropathy; diffuse sclerosis; autonomic neuropathy; dysgraphia; dyslexia; dystonia; early infantile epileptic encephalopathy; empty sella syndrome; encephalitis; encephalocele; trigeminal region angiomatosis; epilepsy; Erb's palsy; essential tremor; Fabry disease; Fahr's syndrome; fainting vertigo; familial spastic paraparesis ;Febrile convulsions;Fisher syndrome;Friedreich's ataxia;Frontotemporal dementia and other "tauopathies";Gaucher's disease;Gerstmann's syndrome;Giant cell arteritis;Giant cell inclusion disease;Globoid cell leukodystrophy;Guillain-Barré syndrome;HTFV-1-associated myelopathy;Hallervorden-Spatz disease;Head injury;Hemifacial spasm;Hereditary spastic paraplegia;Hereditary polyneuropathic ataxia;Herpes zoster oticus;Hirayama syndrome;HIV-associated dementia and neuropathy (see also Neurological Manifestations of AIDS);Holoprosencephaly;Huntington's disease and and other polyglutamine repeat disorders; hydroanencephaly; hydrocephalus; hypercortisolism; hypoxia; immune-mediated encephalomyelitis; inclusion body myositis; incontinentia pigmenti; infantile form; phytanic acid storage disease; infantile Refsum disease; infantile spasms; inflammatory myopathy; intracranial cysts; intracranial hypertension; Joubert syndrome; Kearns-Sayre syndrome; Kennedy disease; Kinsborn syndrome; Klippel-Feil syndrome; Krabbe disease; Kugelberg-Welander disease; kuru; Lafora disease; Lambert-Eaton myasthenic syndrome; Landau-Kleffner syndrome; lateral medulla (Wallenberg) Gehrig's syndrome; learning disabilities; Leigh's disease; Lennox-Gastaut syndrome; Lesch-Nyhan syndrome; leukodystrophy; dementia with Lewy bodies; lissencephaly; locked-in syndrome; Lou Gehrig's disease (also known as motor neuron disease or amyotrophic lateral sclerosis); lumbar disc disease; neurological sequelae of Lyme disease; Machado-Joseph disease; megacephaly; megalencephaly; Melkerson-Rosenthal syndrome; Meniere's disease; meningitis; Menkes disease; metachromatic leukodystrophy; microcephaly; migraine; Miller-Fisher syndrome; petit mal seizures; mitochondrial myopathy; Moebius syndrome;Unilateral muscular atrophy; Motor neuron disease; Moyamoya disease; Mucopolysaccharidosis; Multi-infarct dementia; Multifocal motor neuropathy; Multiple sclerosis and other demyelinating disorders; Multiple system atrophy with orthostatic hypotension; Muscular dystrophy; Myasthenia gravis; Myelinating diffuse sclerosis; Myoclonic encephalopathy of infants; Myoclonus; Myopathy; Congenital myotonia; Narcolepsy; Neurofibromatosis; Neuroleptic malignant syndrome; Neurological manifestations of AIDS; Neurological sequelae of lupus; Neuromyotonia; Neuronal ceroid lipofuscinosis; Neuronal migration disorders; Niemann-Pick disease; O'Sullivan-Mac Lord's syndrome; occipital neuralgia; latent spinal insufficiency sequence; Ohtahara syndrome; olivopontocerebellar atrophy; opsoclonus-myoclonus; optic neuritis; orthostatic hypotension; overuse syndrome; paresthesias; Parkinson's disease; congenital paramyotonia; paraneoplastic disorders; seizures; Parry-Romberg syndrome; Pelizaeus-Merzbach disease; periodic paralysis; peripheral neuropathy; painful neuropathy and neuropathic pain; persistent vegetative state; pervasive developmental disorder; photophobic sneeze reflex; phytanic acid storage disease; Pick's disease; pinch nerve; pituitary tumor; polymyositis; porencephaly; Pos Topolio syndrome; postherpetic neuralgia (PHN); postinfectious encephalomyelitis; orthostatic hypotension; Prader-Willi syndrome; primary lateral sclerosis; prion disease; progressive; facial hemifacial atrophy; progressive multifocal leukoencephalopathy; progressive sclerosing poliodystrophy; progressive supranuclear palsy; pseudotumor cerebri; Ramsay-Hunt syndrome (types I and II); Rasmussen encephalitis; reflex sympathetic dystrophy syndrome; Refsum's disease; repetitive movement disorder; repetitive stress injury; restless legs syndrome; retrovirus-associated myelopathy; Rett's syndrome; Reye's syndrome; Saint Vitus chorea; Sandhoff's disease; Schilder's disease ;schizencephaly;septo-optic dysplasia;shaken baby syndrome;herpes zoster;Shy-Drager syndrome;Sjögren's syndrome;sleep apnea;Sotos syndrome;spasticity;spina bifida;spinal cord injury;spinal tumor;spinal muscular atrophy;stiff-person syndrome;stroke;Sturge-Weber syndrome;subacute sclerosing panencephalitis;subarachnoid hemorrhage;subcortical arteriosclerotic encephalopathy;Sydenham chorea;syncope;syringomyelia;tardive dyskinesia;Tay-Sachs disease;temporal arteritis;tethered cord syndrome;Thomsen's disease;thoracic outlet syndrome;trigeminal neuralgia;Todd's palsy;Tourette's syndrome;transient ischemic attack;Transmissible spongiform encephalopathies; transverse myelitis; traumatic brain injury; tremor; trigeminal neuralgia; tropical spastic paraparesis; tuberous sclerosis; vascular dementia (multi-infarct dementia); vasculitis, including temporal arteritis; von Hippel-Lindau disease (VHL); Wallenberg syndrome; Werdnig-Hoffmann disease; West syndrome; whiplash; Williams syndrome; Wilson's disease; and Zellweger syndrome.

[0091] The term "musculoskeletal disease" or "MSD" refers to injury and / or pain in the joints, ligaments, muscles, nerves, tendons, and structures that support the limbs, neck, and back of a subject. In certain embodiments, MSD is a degenerative disease. In certain embodiments, MSD includes inflammatory conditions. Parts of a subject's body that may be associated with MSD include the back and waist, neck, shoulders, and extremities (arms, legs, feet, and hands). In certain embodiments, the MSD is a bone disease, e.g., achondroplasia, acromegaly, bony callus, bone demineralization, bone fracture, bone marrow disease, myeloid neoplasm, dyskeratosis congenita, leukemia (e.g., hairy cell leukemia, lymphocytic leukemia, myeloid leukemia, Philadelphia chromosome positive leukemia, plasma cell leukemia, stem cell leukemia), systemic mastocytosis, myelodysplastic syndrome, paroxysmal nocturnal hemoglobinuria, myeloid sarcoma, myeloproliferative disorders, multiple myeloma, polycythemia vera, Pearson myelopancreatic syndrome, bone neoplasm, myeloid neoplasm, Ewing's sarcoma, osteochondroma, osteoclastoma, osteosarcoma, brachydactyly, Kamurati-Engelman syndrome, craniosynostosis, Crouzon craniofacial dysostosis, dwarfism, achondroplasia, Bloom's syndrome, Cockayne's syndrome, Ellis-van Creveld syndrome, Zehnder's syndrome, Kell syndrome, spondyloepiphyseal dysplasia, congenital spondyloepiphyseal dysplasia, Werner syndrome, hyperostosis, osteophytes, Klippel-Trenaunay-Weber syndrome, Marfan syndrome, McCune-Albright syndrome, osteitis, osteoarthritis, osteochondritis, osteochondrodysplasia, Kashin-Beck disease, Leri-Weill osteochondrodysplasia, osteochondrosis, osteodystrophy, osteogenesis imperfecta, osteolysis, Gorham-Stout syndrome, osteomalacia, osteomyelitis, osteonecrosis, osteopenia, osteopetrosis, osteoporosis, osteosclerosis, otospondylomegaly epiphyseal dysplasia, hypertrophic dermoperiostosis, Paget's disease of bone, polydactyly, Meckel syndrome, rickets, Rothmund-Thomson syndrome, Sotos syndrome, spondyloepiphyseal dysplasia, congenital spondyloepiphyseal dysplasia, syndactyly, Apert syndrome, syndactyly type II, or Werner syndrome. In certain embodiments, the MSD is a cartilage disease, such as a cartilage neoplasia, osteochondritis, osteochondrodysplasia, Kashin-Beck disease, or Leri-Weill osteochondrodysplasia. In certain embodiments, the MSD is a herniation, such as a herniated intervertebral disc.In certain embodiments, the MSD is a joint disease, such as joint pain, arthritis (e.g., gout (e.g., Kelly-Seegmiller syndrome, Lesch-Nyhan syndrome), Lyme disease, osteoarthritis, psoriatic arthritis, reactive arthritis, rheumatic fever, rheumatoid arthritis, Felty syndrome, synovitis, Blau syndrome, Nail-Patera syndrome, spondyloarthropathy, reactive arthritis, Stickler syndrome, synovial disease, synovitis, or Blau syndrome. In certain embodiments, the MSD is Langer-Gideon syndrome. In certain embodiments, MSDs include muscle diseases such as Barth syndrome, mitochondrial encephalomyopathy, MELAS syndrome, MERRF syndrome, MNGIE syndrome, mitochondrial myopathy, Kearns-Sayre syndrome, myalgia, fibromyalgia, polymyalgia rheumatica, myomas, myositis, dermatomyositis, neuromuscular diseases, Kearns-Sayre syndrome, muscular dystrophy, myasthenia, congenital myasthenic syndrome, Lambert-Eaton myasthenic syndrome, myasthenia gravis, myotonia, congenital myotonia, spinal muscular atrophy, tetany, ophthalmoplegia, or rhabdomyolysis. In certain embodiments, the MSD is Proteus syndrome. In certain embodiments, the MSD is a rheumatic disease, such as arthritis (e.g., gout (e.g., Kelly-Seegmiller syndrome, Lesch-Nyhan Lyme disease)), osteoarthritis, psoriatic arthritis, reactive arthritis, rheumatic fever, rheumatoid arthritis, Felty syndrome, synovitis, Blau syndrome, gout (e.g., Kelly-Seegmiller syndrome, Lesch-Nyhan syndrome), polymyalgia rheumatica, rheumatic fever, rheumatic heart disease, or Sjogren's syndrome. In certain embodiments, the MSD is Schwartz-Jampel syndrome. In certain embodiments, the MSD is a skeletal disease, such as Leri-Weill osteochondrodysplasia, skeletal malformation, Melnick-Needles syndrome, hypertrophic dermatoperiostosis, Rieger syndrome, spinal column disease, herniated disc, scoliosis, spina bifida, spondylitis, ankylosing spondylitis, spondyloarthropathy, reactive arthritis, spondyloepiphyseal dysplasia, congenital spondyloepiphyseal dysplasia, or spondylosis. In some embodiments, the disease is a musculoskeletal disease.

[0092] "Painful conditions" include neuropathic pain (e.g., peripheral neuropathic pain), central pain, deafferentation pain, chronic pain (e.g., chronic nociceptive pain and other forms of chronic pain, such as post-operative pain, e.g., pain occurring after hip, knee, or other replacement surgery), pre-operative pain, stimulation of nociceptors (nociceptive pain), acute pain (e.g., phantom and transient acute pain), non-inflammatory pain, inflammatory pain, cancer-related pain, wound pain, burn pain, post-operative pain, pain associated with a medical procedure, pain resulting from pruritus, bladder pain Pain conditions contemplated herein include, but are not limited to, pain associated with premenstrual syndrome, premenstrual dysphoric disorder and / or premenstrual syndrome, pain associated with chronic fatigue syndrome, pain associated with preterm labor, pain associated with withdrawal from drug addiction, arthralgia, arthritic pain (e.g., pain associated with crystalline arthritis, osteoarthritis, psoriatic arthritis, gouty arthritis, reactive arthritis, rheumatoid arthritis, or Reiter's arthritis), lumbosacral pain, musculoskeletal pain, headache, migraine, myalgia, lower back pain, neck pain, dental pain, dental / maxillofacial pain, visceral pain, and the like. One or more of the painful conditions contemplated herein may comprise a mixture of various types of pain (e.g., nociceptive pain, inflammatory pain, neuropathic pain, etc.) provided above and herein. In some embodiments, a particular type of pain may predominate. In other embodiments, the painful condition comprises two or more types of pain, without one type predominating. A skilled clinician can determine the dosage to achieve a therapeutically effective amount for a particular subject based on the painful condition.

[0093] The term "mental disorder" refers to a disease of the mind and includes diseases and disorders listed in the Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV), American Psychiatric Association, Washington, DC (1994). Mental disorders include anxiety disorders (e.g., acute stress disorder, agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, separation anxiety disorder, social phobia, and specific phobia), childhood disorders (e.g., attention-deficit / hyperactivity disorder, conduct disorder, and oppositional defiant disorder), eating disorders (e.g., anorexia nervosa and bulimia nervosa), mood disorders (e.g., depression, bipolar disorder, cyclothymic disorder, dysthymic disorder, and major depressive disorder), personality disorders (e.g., antisocial personality disorder, avoidant personality disorder, borderline personality disorder, dependent personality disorder, histrionic personality disorder, narcissistic personality disorder, obsessive-compulsive disorder, and dysphoric personality disorder). These disorders include, but are not limited to, personality disorders (e.g., brief psychotic disorder, delusional disorder, schizoaffective disorder, schizophreniform disorder, schizophrenia, and shared psychotic disorder), substance-related disorders (e.g., alcohol dependence, amphetamine dependence, cannabis dependence, cocaine dependence, hallucinogen dependence, inhalant dependence, nicotine dependence, opioid dependence, phencyclidine dependence, and sedative dependence), adjustment disorder, autism, delirium, dementia, multi-infarct dementia, learning and memory disorders (e.g., amnesia and age-related memory loss), and Tourette's syndrome.

[0094] The term "metabolic disorder" refers to any disorder involving an alteration in the normal metabolism of carbohydrates, lipids, proteins, nucleic acids, or a combination thereof. Metabolic disorders are associated with either a deficiency or excess in a metabolic pathway, resulting in an imbalance in the metabolism of nucleic acids, proteins, lipids, and / or carbohydrates. Factors that affect metabolism include, but are not limited to, endocrine (hormonal) control systems (e.g., insulin pathway, enteroendocrine hormones, including GLP-1, PYY, or the like), neural control systems (e.g., GLP-1 in the brain), or the like. Examples of metabolic disorders include, but are not limited to, diabetes (e.g., type 1 diabetes, type 2 diabetes, gestational diabetes), hyperglycemia, hyperinsulinemia, insulin resistance, and obesity.

[0095] In some embodiments, the disease is characterized by cellular dysfunction. For example, the disease can be a mitochondrial disease. Non-limiting mitochondrial diseases include Friedreich's ataxia, Alper's disease, Barth syndrome, beta-oxidation disorder, carnitine deficiency, CPT1 deficiency, and mitochondrial DNA depletion. The cellular dysfunction can include mitochondrial dysfunction, RNA replication dysfunction, DNA replication dysfunction, translation dysfunction, and / or protein folding dysfunction.

[0096] In some embodiments, the disease or condition is due to scarring during a wound, bleeding, injury (e.g., fracture, gunshot wound, incision, surgery (e.g., Cesarean section)).

[0097] In some embodiments, the disease is an infectious disease (e.g., a disease caused by a pathogen and / or virus). Non-limiting examples of infectious diseases include tuberculosis, HIV / AIDS, rabies, plague, cholera, dengue fever, measles, malaria, meningitis, whooping cough, Lyme disease, influenza, hepatitis C, typhoid, and polio.

[0098] As used herein, "cellular causes of aging" encompasses the loss or alteration of epigenetic information.

[0099] The term "c-Myc" or "Myc" refers to a nuclear phosphoprotein associated with cell cycle progression. c-Myc can form heterodimers with the transcription factor MAX, and the heterodimer can bind to an E-box consensus sequence on a nucleic acid (e.g., an engineered nucleic acid) to regulate transcription of a target gene. In certain embodiments, a nucleotide sequence encoding c-Myc comprises a sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to a sequence set forth in the NCBI RefSeq database under accession number NM_001354870.1 or NM_002467.5. In certain embodiments, the amino acid sequence encoding c-Myc comprises a sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to NP_002458.2 or NP_001341799.1. In certain embodiments, the method comprises inducing expression of OCT4; KLF4; SOX2; or any combination thereof, in the absence of inducing c-Myc expression or in the absence of activating c-Myc. The absence of inducing c-Myc expression may refer to the absence of substantial induction of c-Myc expression above endogenous levels of c-Myc expression in a cell, tissue, subject, or any combination thereof. Absence of substantial induction of c-Myc expression relative to the endogenous level of c-Myc expression in a cell, tissue, subject, or any combination thereof can refer to increasing c-Myc expression by less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, or any value therebetween, relative to the endogenous level of c-Myc expression in a cell, tissue, subject, or any combination thereof. Absence of activating c-Myc expression can refer to absence of substantial activation of c-Myc (e.g., activity) above endogenous c-Myc activity in a cell, tissue, subject, or any combination thereof.The absence of substantial induction of c-Myc activity compared to endogenous c-Myc activity in a cell, tissue, subject, or any combination thereof may refer to an increase in c-Myc activity by less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, or any value therebetween, compared to endogenous c-Myc activity in a cell, tissue, subject, or any combination thereof.

[0100] As used herein, the terms "effective amount" and "therapeutically effective amount" refer to an amount or concentration of a compound of the present invention that, when administered to a subject, is effective to at least partially treat a condition from which the subject suffers.

[0101] As used herein, a protein that is "functional" or "active" is one that retains its biological activity (e.g., can act as a transcription factor or as an inducer). Conversely, a protein that is non-functional or inactive is one that is unable to perform one or more of its wild-type functions.

[0102] The term "gene" refers to a nucleic acid (e.g., an engineered nucleic acid) fragment that expresses a protein and includes regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. A "native gene" refers to a gene found in nature with its own regulatory sequences. A "chimeric gene" or "chimeric construct" refers to any gene or construct that is not a native gene and contains regulatory and coding sequences that are not found together in nature. Thus, a chimeric gene or chimeric construct can contain regulatory and coding sequences from different sources, or regulatory and coding sequences from the same source but arranged in a manner different from that found in nature. An "endogenous gene" refers to a native gene in its natural location on the genome of an organism. A "foreign" gene refers to a gene not normally found in a host organism but that is introduced into a host organism by gene transfer. A foreign gene can include a native gene inserted into a non-native organism or a chimeric gene. A "transgene" is a gene that has been introduced into the genome by a transformation procedure.

[0103] "Homolog" or "homologous" refers to a sequence (e.g., a nucleic acid (e.g., an engineered nucleic acid) or amino acid sequence) that shares a certain percent identity (e.g., at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, (At least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% percent identity). Homologous sequences include, but are not limited to, paralogous or orthologous sequences. Paralogous sequences arise from gene duplication within the genome of a species, while orthologous sequences diverge after a speciation event. Functional homologs retain one or more biological activities of the wild-type protein. In certain embodiments, a functional homolog of OCT4, KLF4, or SOX2 retains at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 100% of the biological activity (e.g., transcription factor activity) of its wild-type counterpart.

[0104] "KLF4," which may also be referred to as Kruppel-like factor 4, EZF, or GKLF, is a zinc finger transcription factor. KLF4 has been implicated in the regulation of differentiation and proliferation and can interact with coactivators, including members of the p300-CBP coactivator family. The KLF4 transcription factor, its homologs (e.g., functional homologs), or variants used herein can be derived from any species, including humans. In certain embodiments, a nucleic acid (e.g., an engineered nucleic acid) encoding human KLF4 comprises a sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to a nucleic acid (e.g., an engineered nucleic acid) listed in the NCBI RefSeq database under accession number NM_004235.5 or NM_001314052.1. Non-limiting examples of KLF4 variants include Krueppel-like factor 4 transcript variant 1 and Krueppel-like factor 4 transcript variant 2. In certain embodiments, KLF4 comprises a nucleic acid (e.g., an engineered nucleic acid) sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 5 or SEQ ID NO: 44. SEQ ID NO: 5 is a non-limiting example of a nucleotide sequence encoding KLF4 from Mus musculus. SEQ ID NO: 44 is a non-limiting example of a nucleotide sequence encoding human KLF4. In certain embodiments, KLF4 comprises an amino acid sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to NP_001300981.1 or NP_004226.3. In certain embodiments, KLF4 comprises an amino acid sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 6. In certain embodiments, KLF4 comprises an amino acid sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 45. SEQ ID NO: 6 is a non-limiting example of an amino acid sequence encoding KLF4 from Mus musculus.SEQ ID NO: 45 is a non-limiting example of an amino acid sequence encoding human KLF4.

[0105] "Inverted terminal repeats" or "ITRs" are nucleic acid (e.g., engineered nucleic acid) sequences that are reverse complements of each other. Generally, in AAV vectors, ITRs are found on both sides of the cassette (e.g., expression cassettes containing nucleic acids (e.g., engineered nucleic acids) encoding OCT4; KLF4; SOX2; or any combination thereof). In some cases, the cassette encodes an inducer. AAV ITRs include ITRs from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, and their AAV variants.

[0106] The terms "nucleic acid," "polynucleotide," "nucleotide sequence," "nucleic acid (e.g., engineered nucleic acid) molecule," "nucleic acid (e.g., engineered nucleic acid) sequence," and "oligonucleotide" refer to a series of nucleotide bases (also called "nucleotides") on DNA and RNA, and refer to any chain of two or more nucleotides. The terms "nucleic acid" or "nucleic acid (e.g., engineered nucleic acid) sequence," "nucleic acid (e.g., engineered nucleic acid) molecule," "nucleic acid (e.g., engineered nucleic acid) fragment," or "polynucleotide" can be used interchangeably with "gene," "mRNA encoded by a gene," and "cDNA."

[0107] Nucleic acids (e.g., engineered nucleic acids) can be single-stranded or double-stranded, chimeric mixtures, or derivatives or modified versions thereof. Oligonucleotides can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve the molecule's stability, its hybridization parameters, etc. Typically, the nucleotide sequence carries genetic information, including information used by cellular machinery to make proteins and enzymes. These terms encompass double- or single-stranded genomic and cDNA, RNA, either synthetic or engineered polynucleotides, and both sense and antisense polynucleotides. This encompasses single- and double-stranded molecules, i.e., DNA-DNA, DNA-RNA, and RNA-RNA hybrids, as well as "protein nucleic acids (e.g., engineered nucleic acids)" (PNAs) formed by conjugating bases to an amino acid backbone. This also encompasses nucleic acids (e.g., engineered nucleic acids) containing carbohydrates or lipids. Exemplary DNA includes single-stranded DNA (ssDNA), double-stranded DNA (dsDNA), plasmid DNA (pDNA), genomic DNA (gDNA), complementary DNA (cDNA), antisense DNA, chloroplast DNA (ctDNA or cpDNA), microsatellite DNA, mitochondrial DNA (mtDNA or mDNA), kinetoplast DNA (kDNA), provirus, lysogen, repetitive DNA, satellite DNA, and viral DNA.Exemplary RNAs include single-stranded RNA (ssRNA), double-stranded RNA (dsRNA), short interfering RNA (siRNA), messenger RNA (mRNA), precursor messenger RNA (pre-mRNA), short hairpin RNA or short hairpin RNA (shRNA), microRNA (miRNA), guide RNA (gRNA), transfer RNA (tRNA), antisense RNA (asRNA), heterogeneous nuclear RNA (hnRNA), coding RNA, non-coding RNA (ncRNA), long non-coding RNA (long ncRNA or lncRNA), satellite RNA, viral satellite RNA, signal recognition particle RNA, small cytoplasmic RNA, small nuclear RNA (snRNA), ribosomal RNA (rRNA), Piwi-interacting RNA (piRNA), polyinosinic acid, ribozymes, flexizymes, small nucleolar RNA (snoRNA), splice leader RNA, viral RNA, and viral satellite RNA.

[0108] The nucleic acids (e.g., engineered nucleic acids) described herein can be synthesized by standard methods known in the art, for example, by using an automated DNA synthesizer (e.g., commercially available from Biosearch, Applied Biosystems, etc.). For example, phosphorothioate oligonucleotides can be synthesized by the method of Stein et al., Nucl. Acids Res., 16, 3209, (1988), and methylphosphonate oligonucleotides can be synthesized using controlled-pore glass polymer supports (Sarin et al., Proc. Natl. Acad. Sci. USA 85, 7448-7451, (1988)). Several methods have been developed for delivering antisense DNA or RNA to cells. For example, antisense molecules can be directly injected into tissue sites, or modified antisense molecules designed to target desired cells (antisense linked to peptides or antibodies that specifically bind to receptors or antigens expressed on the surface of target cells) can be administered systemically. Alternatively, RNA molecules can be produced by in vitro and in vivo transcription of DNA sequences encoding antisense RNA molecules. Such DNA sequences can be incorporated into a wide variety of vectors incorporating suitable RNA polymerase promoters, such as the T7 or SP6 polymerase promoter. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly, depending on the promoter used, can be stably introduced into cell lines. However, in many cases, it is difficult to achieve intracellular concentrations of antisense sufficient to suppress the translation of endogenous mRNA. Therefore, a preferred approach utilizes recombinant DNA constructs in which antisense oligonucleotides are placed under the control of a strong promoter. Use of such constructs to transfect patient target cells will result in the transcription of sufficient amounts of single-stranded RNA that will form complementary base pairs with endogenous target gene transcripts, thereby preventing translation of the target gene mRNA.For example, a vector can be introduced in vivo so that it can be taken up by cells and direct the transcription of antisense RNA. As long as it can be transcribed to produce the desired antisense RNA, such a vector can remain episomal or be integrated into a chromosome. Such a vector can be constructed by standard recombinant DNA technology methods in the art. The vector can be a plasmid, viral, or other vector known in the art that can be used for replication and expression in mammalian cells. The expression of the sequence encoding the antisense RNA can be driven by any promoter known in the art to function in mammalian, preferably human, cells. Such promoters can be inducible or constitutive. Any type of plasmid, cosmid, yeast artificial chromosome, or viral vector can be used to prepare a recombinant DNA construct that can be directly introduced into a tissue site.

[0109] Nucleic acids (e.g., engineered nucleic acids) can be flanked by natural regulatory (expression control) sequences or can be associated with heterologous sequences, including promoters, internal ribosome entry sites (IRES) and other ribosome binding site sequences, enhancers, response elements, suppressors, signal sequences, polyadenylation sequences, introns, 5' and 3' non-coding regions, and the like. Nucleic acids (e.g., engineered nucleic acids) can also be modified by many means known in the art. Non-limiting examples of such modifications include methylation, "caps," substitution of one or more of the naturally occurring nucleotides with analogs, and internucleotide modifications, such as, for example, with uncharged linkages (e.g., methylphosphonates, phosphotriesters, phosphoramidates, carbamates, etc.) and with charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.). Polynucleotides may contain one or more additional covalently linked moieties, such as proteins (e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.), intercalating agents (e.g., acridine, psoralen, etc.), chelating agents (e.g., metals, radioactive metals, iron, oxidizing metals, etc.), and alkylating agents. Polynucleotides may be derivatized by forming methyl or ethyl phosphotriester or alkyl phosphoramidate linkages. Furthermore, the polynucleotides of the present application may also be modified with a label capable of providing a detectable signal, either directly or indirectly. Exemplary labels include radioisotopes, fluorescent molecules, epitope tags, isotopes (e.g., radioisotopes), biotin, and the like.

[0110] A "recombinant nucleic acid (e.g., engineered nucleic acid) molecule" or "engineered nucleic acid" is a nucleic acid (e.g., engineered nucleic acid) molecule that has undergone molecular biological manipulation, i.e., a non-naturally occurring nucleic acid (e.g., engineered nucleic acid) molecule or a genetically engineered nucleic acid (e.g., engineered nucleic acid) molecule. Furthermore, the term "recombinant DNA molecule" or "engineered nucleic acid" refers to a nucleic acid (e.g., engineered nucleic acid) sequence that does not occur in nature or that can be made by the artificial combination of two otherwise separate segments of nucleic acid (e.g., engineered nucleic acid) sequence, i.e., by ligating together pieces of DNA that are not normally contiguous. By "recombinantly produced" is meant an artificial combination, often accomplished either by chemical synthesis means or by the artificial manipulation of isolated segments of nucleic acid (e.g., engineered nucleic acid). For example, by genetic engineering techniques using restriction enzymes, ligases, and similar recombinant techniques described, for example, by Sambrook et al., Molecular Cloning, second edition, Cold Spring Harbor Laboratory, Plainview, NY; (1989), or Ausubel et al., Current Protocols in Molecular Biology, Current Protocols (1989), and DNA Cloning: A Practical Approach, Volumes I and II (ed. D.N. Glover), IREL Press, Oxford, (1985); each of which is incorporated herein by reference.

[0111] Such manipulations can typically be performed to introduce or remove sequence recognition sites, replacing codons with redundant codons or conservative amino acids that encode them. Alternatively, they can be performed to join together nucleic acid (e.g., engineered nucleic acid) segments of desired functions to create a single gene entity containing a desired combination of functions not found in nature. In many cases, restriction enzyme recognition sites are the target of such artificial manipulations, but other site-specific targets, such as promoters, DNA replication sites, regulatory sequences, control sequences, open reading frames, or other useful features, can be incorporated by design.

[0112] "OCT4," which may also be referred to as octamer-binding transcription factor 4, OCT3, OCT3 / 4, POU5F1, or POU class 5 homeobox 1, is a transcription factor implicated in embryonic development and cell fate determination. Similar to other OCT transcription factors, OCT4 is characterized by a bipartite DNA-binding domain called the POU domain. The OCT4 transcription factor, its homologs, or variants used herein may be derived from any species, including humans. In certain embodiments, a nucleic acid (e.g., an engineered nucleic acid) encoding human OCT4 is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to a nucleic acid (e.g., an engineered nucleic acid) set forth in NCBI RefSeq under accession numbers NM_002701, NM_203289, NM_001173531, NM_001285986, or NM_001285987. In certain embodiments, a nucleic acid (e.g., an engineered nucleic acid) encoding OCT4 comprises a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to the nucleic acid (e.g., engineered nucleic acid) sequence provided by SEQ ID NO: 1. SEQ ID NO: 1 is a non-limiting example of a nucleotide sequence encoding OCT4 from Mus musculus. In certain embodiments, a nucleic acid (e.g., an engineered nucleic acid) encoding human OCT4 comprises a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to the nucleic acid (e.g., engineered nucleic acid) sequence provided as SEQ ID NO: 40. SEQ ID NO: 40 is a non-limiting example of a nucleotide sequence encoding human OCT4. Non-limiting examples of OCT4 variants encompassed herein include POU5F1 transcript variant 1, POU5F1 transcript variant 2, POU5F1 transcript variant 3, POU5F1 transcript variant 4, and POU5F1 transcript variant 5.In certain embodiments, the amino acid sequence encoding human OCT4 is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to a nucleic acid (e.g., an engineered nucleic acid) set forth in NCBI RefSeq under accession numbers NP001167002.1, NP_001272915.1, NP_001272916.1, NP_002692.2, or NP_976034.4. In certain embodiments, OCT4 comprises an amino acid sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 2. SEQ ID NO: 2 is a non-limiting example of an amino acid sequence encoding OCT4 from Mus musculus. In certain embodiments, OCT4 comprises an amino acid sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 41. SEQ ID NO: 41 is a non-limiting example of an amino acid sequence encoding human OCT4. Other OCT4 transcription factors (e.g., from other species) are known, and nucleic acids (e.g., engineered nucleic acids) encoding OCT4 transcription factors can be found in publicly available databases, including GenBank.

[0113] The term "promoter" refers to a control region of a nucleic acid (e.g., an engineered nucleic acid) sequence at which the initiation and rate of transcription of the remainder of the nucleic acid (e.g., an engineered nucleic acid) sequence are controlled. A promoter may also contain subregions to which regulatory proteins and molecules, such as RNA polymerase and other transcription factors, can bind. Promoters can be constitutive, inducible, activatable, repressible, tissue-specific, or any combination thereof. A promoter drives the expression or drives the transcription of a nucleic acid (e.g., an engineered nucleic acid) sequence that it controls. As used herein, a promoter is considered "operably linked" when it is in the correct functional location and orientation relative to the nucleic acid (e.g., an engineered nucleic acid) sequence that it controls to control ("drive") the initiation of transcription of that sequence, the expression of that sequence, or a combination thereof.

[0114] A promoter can promote ubiquitous or tissue-specific expression of an operably linked nucleic acid (e.g., engineered nucleic acid) sequence from any species, including humans. In some embodiments, the promoter is a eukaryotic promoter. Non-limiting examples of eukaryotic promoters include TDH3, PGK1, PKC1, TDH2, PYK1, TPI1, AT1, CMV, EF1 alpha, SV40, PGK1 (human or mouse), Ubc, human beta actin, CAG, TRE, UAS, Ac5, polyhedrin, CaMKIIa, GAL1, GAL10, TEF1, GDS, ADH1, CaMV35S, Ubi, H1, and U6, which will be known to those of skill in the art (see, e.g., the Addgene website: blog.addgene.org / plasmids-101-the-promoter-region).

[0115] Non-limiting examples of ubiquitous promoters include tetracycline-responsive promoters (under appropriate conditions), CMV (e.g., SEQ ID NO: 48), EF1 alpha, SV40 promoter, PGK1, Ubc, CAG, human beta-actin gene promoter, RSV promoter (e.g., SEQ ID NO: 47), EFS promoter (e.g., SEQ ID NO: 49), and promoters containing an upstream activating sequence (UAS). In certain embodiments, the promoter is a mammalian promoter.

[0116] Non-limiting examples of tissue-specific promoters include brain-specific, liver-specific, muscle-specific, neuron-specific, lung-specific, heart-specific, bone-specific, intestine-specific, skin-specific promoters, brain-specific promoters, and eye-specific promoters. For example, a muscle-specific promoter is the desmin promoter (e.g., a sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 29). Non-limiting examples of eye-specific promoters include the human GRK1 (rhodopsin kinase) promoter (e.g., SEQ ID NO: 50), the human CRX (cone-rod homeobox transcription factor) promoter (e.g., SEQ ID NO: 51), and the human NRL promoter (neural retina leucine zipper transcription factor enhancer upstream of the human TK terminal promoter).

[0117] In some embodiments, the promoter is specific to senescent cells. For example, the promoter can specifically induce the expression of an operably linked nucleic acid in senescent cells but not in non-senescent cells. As a non-limiting example, the p16 promoter can be used to promote the expression of an operably linked nucleic acid in senescent cells.

[0118] In some embodiments, the promoters of the present disclosure are suitable for use in AAV vectors, see, e.g., US Patent Application Publication No. 2018 / 0155789, which is incorporated herein by reference in its entirety for this purpose.

[0119] Non-limiting examples of constitutive promoters include CP1, CMV, EF1 alpha, SV40, PGK1, Ubc, human beta-actin, beta-tubulin, CAG, Ac5, Rosa26 promoter, COL1A1 promoter, polyhedrin, TEF1, GDS, CaM35S, Ubi, H1, U6, red opsin promoter (red promoter), rhodopsin promoter (rho promoter), cone arrestin promoter (car promoter), and rhodopsin kinase promoter (rk promoter). The Ubc promoter may comprise a sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 18. In some cases, the constitutive promoter is the Rosa26 promoter. In some cases, the constitutive promoter is the COL1A1 promoter. The red opsin promoter may comprise a sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 101. The rho promoter may comprise a sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 102. The cone arrestin promoter may comprise a sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 103. The rhodopsin kinase promoter may comprise a sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 104. Tissue-specific promoters can be used to drive expression of engineered nucleic acids, including, for example, nucleic acids encoding rtTA, tTA, OCT4, KLF4, SOX2, or any combination thereof. In some embodiments, tissue-specific promoters are used to drive expression of rtTA or rTA. In some embodiments, tissue-specific promoters are used to drive expression of OCT4, KLF4, and SOX2.In some embodiments, the tissue-specific promoter is selected from the group consisting of SEQ ID NOs: 101-104. In some embodiments, the hRK promoter is used to drive expression of OCT4, KLF4, and SOX2.

[0120] An "inducible promoter" is one that is characterized by initiating or enhancing transcriptional activity when in the presence of, affected by, or contacted by an inducer. The inducer can be endogenous or can be a normally exogenous condition, compound, agent, or protein that contacts an engineered nucleic acid (e.g., an engineered nucleic acid) in such a way that it is active in inducing transcriptional activity from the inducible promoter. In certain embodiments, the inducer is a tetracycline-sensitive protein (e.g., tTA or rtTA, TetR family regulators).

[0121] Inducible promoters for use in accordance with the present disclosure include any inducible promoter described herein or known to one of skill in the art. Examples of inducible promoters include, without limitation, chemically / biochemically regulated and physically regulated promoters, such as alcohol-regulated promoters, tetracycline-regulated promoters (e.g., anhydrotetracycline (aTc)-responsive promoters), and other tetracycline-responsive promoter systems. These include tetracycline repressor protein (TetR, e.g., SEQ ID NO: 26, or TetRKRAB, e.g., SEQ ID NO: 27), tetracycline operator sequence (tetO) and tetracycline transactivator fusion protein (tTA), and tetracycline operator sequence (tetO) and reverse tetracycline transactivator fusion protein (tTA). These include promoters such as activator fusion proteins (rtTA), steroid-regulated promoters (e.g., promoters based on the rat glucocorticoid receptor, human estrogen receptor, moth ecdysone receptor, and promoters from the steroid / retinoid / thyroid 25 receptor superfamily), metal-regulated promoters (e.g., promoters derived from metallothionein (a protein that binds and sequesters metal ions) genes from yeast, mouse, and human), pathogenesis-regulated promoters (e.g., induced by salicylic acid, ethylene, or benzothiadiazole (BTH)), temperature / heat-inducible promoters (e.g., heat shock promoters), pH-regulated promoters, and light-regulated promoters. Non-limiting examples of inducible systems using light-regulated promoters are provided by Wang et al., Nat. Methods. 2012 Feb 12;9(3):266-9.

[0122] In certain embodiments, the inducible promoter comprises a tetracycline (Tet) responsive element. For example, the inducible promoter can be a TRE3G promoter (e.g., a TRE3G promoter comprising a sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO:7). By way of example, a TRE (e.g., TRE2) promoter can comprise a nucleic acid (e.g., engineered nucleic acid) sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO:23. By way of example, a TRE (e.g., P tight ) The promoter can comprise a nucleic acid (e.g., an engineered nucleic acid) sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO:24.

[0123] Additional non-limiting examples of inducible promoters include mifepristone-responsive promoters (e.g., the GAL4-E1b promoter) and coumermycin-responsive promoters. See, e.g., Zhao et al., Hum Gene Ther. 2003 Nov 20;14(17):1619-29.

[0124] As used herein, a "reverse tetracycline transactivator" ("rtTA") is a transactivator that activates a TRE promoter (e.g., TRE3G, TRE2 promoter, or P) in the presence of tetracycline (e.g., doxycycline). tightAn rtTA is an inducer capable of binding to a TRE promoter (e.g., a TRE promoter) and driving expression of a transgene operably linked to the TRE promoter. rtTAs generally comprise a mutant tetracycline repressor DNA-binding protein (TetR) and a transactivation domain (see, e.g., Gossen et al., Science. 1995 Jun 23;268(5218):1766-9, and any of the transactivation domains listed therein). When bound to tetracycline, the mutant TetR domain can bind to the TRE promoter. See, e.g., U.S. Provisional Application No. 62 / 738,894, entitled "MUTANT REVERSE TETRACYCLINE TRANSACTIVATORS FOR EXPRESSION OF GENES," filed September 28, 2018, attorney docket number H0824.70300US00, and incorporated herein by reference in its entirety.

[0125] "SRY box 2" or "SOX2" is a member of the SRY-related HMG box (SOX) family of transcription factors. SOX2 has been implicated in promoting embryonic development. Members of the SOX (SRY-related HMG box) family of transcription factors are characterized by a high mobility group 5 (HMG) box DNA sequence. This HMG box is a DNA-binding domain that is highly conserved among eukaryotic species. The SOX2 transcription factor, its homolog, or variant used herein can be derived from any species, including humans. In certain embodiments, a nucleic acid (e.g., an engineered nucleic acid) encoding SOX2 comprises a sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to a nucleic acid (e.g., an engineered nucleic acid) set forth in NCBI RefSeq under accession number NM_011443.4. In certain embodiments, a nucleic acid (e.g., an engineered nucleic acid) encoding human SOX2 comprises a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to a nucleic acid (e.g., an engineered nucleic acid) set forth in NCBI RefSeq under accession number NM_003106.4. In certain embodiments, SOX2 comprises a nucleic acid (e.g., an engineered nucleic acid) sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO:3 or SEQ ID NO:42. SEQ ID NO:3 is a non-limiting example of a nucleotide sequence encoding SOX2 from Mus musculus. SEQ ID NO:42 is a non-limiting example of a nucleotide sequence encoding human SOX2. In certain embodiments, a nucleic acid (e.g., an engineered nucleic acid) encoding human SOX2 comprises a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to the amino acid sequence set forth in NCBI RefSeq under accession number NP_003097.1. In some cases, SOX2 comprises an amino acid sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO:4.In some cases, SOX2 comprises an amino acid sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 43. SEQ ID NO: 4 is a non-limiting example of an amino acid sequence encoding SOX2 from Mus musculus. SEQ ID NO: 43 is a non-limiting example of an amino acid sequence encoding human SOX2.

[0126] A "multicistronic vector" is a vector encoding more than one amino acid sequence (e.g., a vector encoding OCT4 and KLF4, OCT4 and SOX2, KLF4 and SOX2, or OCT4, SOX2, and KL4 (OSK)). Multicistronic vectors allow for the expression of multiple amino acid sequences from a nucleic acid (e.g., engineered nucleic acid) sequence. The nucleic acid (e.g., engineered nucleic acid) sequences encoding each transcription factor (e.g., OCT4, KLF4, or SOX2) can be connected or separated to produce an unconnected protein. For example, an internal ribosome entry site (IRES) or polypeptide cleavage signal can be placed between the nucleic acid (e.g., engineered nucleic acid) sequences encoding each transcription factor on the vector. Exemplary polypeptide cleavage signals include 2A peptides (e.g., T2A, P2A, E2A, and F2A). The 2A peptide can comprise a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 9. In some embodiments, the expression vector of the present disclosure is a multicistronic expression vector.

[0127] As used herein, "reversing aging" or "reversing ageing" refers to modifying the physical characteristics associated with aging. All animals typically go through a period of growth and maturation, followed by a period of gradual and irreversible physiological decline, culminating in death. The length of time from birth to death is known as an organism's lifespan, and each organism has a characteristic average lifespan. Aging is the physical manifestation of changes underlying the passage of time, measured by a percentage of the average lifespan.

[0128] "Subjects" to which administration is contemplated include, but are not limited to, humans (i.e., male or female of any age group, e.g., pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle-aged adults, or older adults)) and / or other non-human animals, such as mammals (e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys); commercially relevant mammals such as cows, pigs, horses, sheep, goats, cats, and / or dogs) and birds (e.g., commercially relevant birds such as chickens, ducks, geese, and / or turkeys). In certain embodiments, the animal is a mammal. The animal can be male or female, and at any stage of development. The non-human animal can be a transgenic animal.

[0129] Those skilled in the art will recognize that the biological age of a pediatric or adult subject may vary depending on the type of animal. As a non-limiting example, an adult mouse may be 1 year old, while an adult human may be more than 21 years old. In some embodiments, a pediatric subject is less than 21 years old, less than 20 years old, less than 15 years old, less than 10 years old, less than 9 years old, less than 8 years old, less than 7 years old, less than 6 years old, less than 5 years old, less than 4 years old, less than 3 years old, less than 2 years old, less than 1 year old, less than 10 months old, less than 9 months old, less than 8 months old, less than 7 months old, less than 6 months old, less than 5 months old, less than 4 months old, less than 2 months old, or less than 1 month old. In some embodiments, the adult subject is at least 3 weeks old, 1 month old, at least 2 months old, at least 3 months old, at least 4 months old, at least 5 months old, at least 6 months old, at least 7 months old, at least 8 months old, at least 9 months old, at least 10 months old, at least 11 months old, at least 1 year old, at least 2 years old, at least 3 years old, at least 5 years old, at least 10 years old, at least 15 years old, at least 20 years old, at least 25 years old, at least 30 years old, at least 40 years old, at least 50 years old, at least 55 years old, at least 60 years old, at least 65 years old, at least 70 years old, at least 75 years old, at least 80 years old, at least 90 years old, or at least 100 years old. In some embodiments, the middle-aged adult subject is between 1 and 6 months old, between 6 and 12 months old, between 1 and 5 years old, between 5 and 10 years old, between 10 and 20 years old, between 20 and 30 years old, between 30 and 50 years old, between 50 and 60 years old, between 40 and 60 years old, between 40 and 50 years old, or between 45 and 65 years old.In some embodiments, an older adult subject is at least 1 month old, at least 2 months old, at least 3 months old, at least 4 months old, at least 5 months old, at least 6 months old, at least 7 months old, at least 8 months old, at least 9 months old, at least 10 months old, at least 11 months old, at least 1 year old, at least 2 years old, at least 3 years old, at least 5 years old, at least 10 years old, at least 15 years old, at least 20 years old, at least 25 years old, at least 30 years old, at least 40 years old, at least 50 years old, at least 55 years old, at least 60 years old, at least 65 years old, at least 70 years old, at least 75 years old, at least 80 years old, at least 90 years old, or at least 100 years old.

[0130] As used herein, a "terminator" or "terminator sequence" is a nucleic acid (e.g., engineered nucleic acid) sequence that causes transcription to stop. A terminator can be unidirectional or bidirectional. It is composed of a DNA sequence involved in the specific termination of an RNA transcript by an RNA polymerase. A terminator sequence prevents transcriptional activation of a downstream nucleic acid (e.g., engineered nucleic acid) sequence by an upstream promoter. Thus, in certain embodiments, a terminator that ends the production of an RNA transcript is contemplated.

[0131] The most commonly used type of terminator is a forward terminator. Normally, when placed downstream of a nucleic acid (e.g., an engineered nucleic acid) sequence to be transcribed, a forward transcription terminator will cause transcription to cease. In some embodiments, a bidirectional transcription terminator can be used, which normally causes transcription to terminate on both the forward and reverse strands. In some embodiments, a reverse transcription terminator can be used, which normally terminates transcription of only the reverse strand.

[0132] Non-limiting examples of mammalian terminator sequences include the bovine growth hormone terminator, and viral termination sequences, such as the SV40 terminator, spy, yejM, secG-leuU, thrLABC, rrnB T1, hisLGDCBHAFI, metZWV, rrnC, xapR, aspA, and arcA terminators. In certain embodiments, the terminator sequence is SV40 and comprises a sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO:8.

[0133] As used herein, a "Tet-Off system" is a type of inducible system that can suppress expression of a particular transgene in the presence of tetracycline (e.g., doxycycline (DOX)). Conversely, a Tet-Off system can induce expression of a particular transgene in the absence of tetracycline (e.g., doxycycline DOX). In certain embodiments, a Tet-Off system comprises a tetracycline-responsive promoter and a tetracycline-controlled transactivator (tTA) operably linked to a transgene (e.g., encoding OCT4; KLF4; SOX2; or any combination thereof). The tetracycline-responsive promoter (e.g., TRE3G, P tight The transgene (having TRE1 or TRE2) and the tetracycline-controlled transactivator can be encoded on the same vector or on separate vectors. See, e.g., U.S. Provisional Application No. 62 / 738,894, entitled MUTANT REVERSE TETRACYCLINE TRANSACTIVATORS FOR EXPRESSION OF GENES, filed September 28, 2018, attorney docket number H0824.70300US00, which is incorporated herein by reference in its entirety.

[0134] As used herein, a "Tet-On" system is a type of inducible system that can induce expression of a particular transgene in the presence of tetracycline (e.g., doxycycline (DOX)). In certain embodiments, the Tet-On system comprises a tetracycline-responsive promoter operably linked to a transgene (e.g., encoding OCT4; KLF4; SOX2; or any combination thereof) and a reverse tetracycline-controlled transactivator (rtTA). For example, rtTA can be rtTA3, rtTA4, or a variant thereof. In certain embodiments, a nucleic acid (e.g., an engineered nucleic acid) encoding rtTA3 comprises a sequence at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100%) identical to SEQ ID NO: 10. In certain embodiments, the amino acid sequence encoding rtTA3 comprises a sequence that is at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 100%) identical to (SEQ ID NO: 11). In certain embodiments, the nucleic acid (e.g., an engineered nucleic acid) encoding rtTA4 comprises a sequence that is at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 100%) identical to SEQ ID NO: 12. In certain embodiments, the amino acid sequence encoding rtTA4 comprises a sequence that is at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 100%) identical to (SEQ ID NO: 13). Tetracycline-responsive promoters (e.g., TRE3G, P tightThe expression cassette encoding the reverse tetracycline-controlled transactivator (a promoter containing a TRE, including TRE2, and a promoter containing a TRE) and the reverse tetracycline-controlled transactivator can be encoded on the same vector or on separate vectors. See, e.g., U.S. Provisional Application No. 62 / 738,894, entitled MUTANT REVERSE TETRACYCLINE TRANSACTIVATORS FOR EXPRESSION OF GENES, filed September 28, 2018, attorney docket number H0824.70300US00, which is incorporated herein by reference in its entirety.

[0135] The term "tissue" refers to any biological tissue (including a group of cells, a body part, or an organ) or portion thereof of a subject, including blood vessels and / or lymphatic vessels, which are the targets for delivery of the compounds, particles, and / or compositions of the present invention. The tissue may be abnormal, damaged, or unhealthy tissue, which may require treatment. The tissue may also be normal or healthy tissue that is at higher than normal risk of becoming abnormal or unhealthy, which may require prevention. In certain embodiments, the tissue is considered healthy but not optimal for performance or survival under current or future conditions. For example, in agricultural practices, environmental conditions (e.g., nutrition), including weather and growing conditions, may be benefited by any of the methods described herein. In certain embodiments, the tissue is the central nervous system. In certain embodiments, the tissue refers to an empty tissue. In certain embodiments, the cells or tissues are from the eye, ear, nose, mouth including gums and tooth roots, bone, lung, breast, pancreas, stomach, esophagus, muscle including cardiac muscle, liver, blood vessels, skin including hair, heart, brain, nervous tissue, kidney, testis, prostate, penis, cloaca, fin, ovary, or intestine. In certain embodiments, the tissue is damaged (e.g., due to a congenital defect, injury, accident, or iatrogenic injury) and / or aged tissue. In certain embodiments, the tissue is a deep tissue accessible by a fiber optic probe.

[0136] The term "tetracycline repressor" or "TetR" refers to a protein that can bind to a Tet-O sequence (e.g., a Tet-O sequence of a TRE, e.g., the Tet-O sequence can comprise SEQ ID NO: 19) in the absence of tetracycline (e.g., doxycycline) and prevents the binding of rtTA (e.g., rtTA3, rtTA4, or a variant thereof) in the absence of tetracycline (e.g., doxycycline). TetR prevents gene expression from a promoter containing a TRE in the absence of tetracycline (e.g., doxycycline). In the presence of tetracycline, TetR cannot bind to a promoter containing a TRE and TetR cannot prevent transcription. Non-limiting examples of TetR include tetR (e.g., SEQ ID NO: 26), tetRKRAB (e.g., SEQ ID NO: 28). In some embodiments, the TetR is a TetR fusion (e.g., TRSID, which can be created by fusing TetR to the mSIN30-interacting domain (SID) of Mad1). See, e.g., Zhang et al., J Biol Chem. 2001 Nov 30;276(48):45168-74.

[0137] As used herein, a "TRE promoter" refers to a promoter containing a tetracycline responsive element (TRE). A TRE, as used herein, contains at least one (e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) Tet-O sequence. A non-limiting example of a Tet-O sequence is a sequence that is at least 70% (e.g., 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 19. In some embodiments, the TRE promoter further contains a minimal promoter located downstream of the tet-0 sequence. A minimal promoter is a promoter that contains the minimum elements of a promoter (e.g., a TATA box and a transcription start site) but is inactive in the absence of an upstream enhancer (e.g., a sequence containing Tet-O). By way of example, a minimal promoter can be a minimal CMV promoter comprising a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO:20. For example, the TRE promoter can be a TRE3G promoter (e.g., a TRE3G promoter comprising a sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO:7. In some embodiments, the TRE promoter is a TRE2 promoter comprising a sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO:23. In some embodiments, the TRE promoter is a TRE2 promoter comprising a sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO:24. tight He is a promoter.

[0138] The term "tissue repair" in the context of damaged tissue refers to the restoration of tissue architecture, function, or a combination thereof following tissue damage. Tissue repair encompasses tissue regeneration, cell growth, tissue replacement, and / or rewiring (reprogramming) of existing tissue.

[0139] The term "tissue regeneration" refers to the generation of new tissue or cells within a tissue that are of the same type as the desired tissue (e.g., the same type as the damaged tissue or cells). In some embodiments, the methods provided herein promote organ regeneration.

[0140] The term "tissue replacement" refers to the production of a different type of tissue compared to the target tissue (eg, connective tissue to replace damaged tissue).

[0141] As used herein, the terms "treatment," "treat," and "treating" refer to reversing, alleviating, delaying the onset of, or inhibiting the progression of a disease or disorder described herein, or one or more symptoms thereof. In certain embodiments, treatment may be administered after one or more symptoms have occurred. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms, or may be treated with another damaging agent (e.g., in light of a history of symptoms, genetic or other predisposition, disease therapy, or any combination thereof). Treatment may also be continued after symptoms have resolved, for example, to prevent or delay their recurrence.

[0142] The term "variant" refers to a sequence that contains modifications relative to the wild-type sequence. Non-limiting modifications of amino acid sequences include insertions, deletions, and point mutations. Non-limiting modifications of nucleic acid (e.g., engineered nucleic acid) sequences include frameshift mutations, nucleotide insertions, and nucleotide deletions.

[0143] The term "WPRE" refers to the woodchuck hepatitis virus (WHP) post-transcriptional regulatory element (WPRE). The WPRE can create tertiary structure in a nucleic acid (e.g., an expression vector) and enhance transgene expression (e.g., from a viral vector). In certain embodiments, the WPRE sequence is at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 100%) identical to SEQ ID NO:21.

[0144] These and other exemplary substitutes are described in more detail in the detailed description, examples, and claims. The present invention is not intended to be limited in any way to the above exemplary list of substitutes. [Brief explanation of the drawings]

[0145] [Figure 1] Figure 1 is a linear schematic diagram of expression vectors encoding OCT4, SOX2, and KLF4, with TRE3G shown as an exemplary inducible promoter and SV40 shown as an exemplary terminator sequence.

[0146] [Figure 2] Figure 2 shows the vector map of the OSK-encoding AAV vector, TRE3G-OSK-SV40pA. Features including the OCT4, SOX2, and KLF4 coding sequences and the location of the inverted terminal repeats (ITRs) are indicated.

[0147] [Figure 3] FIG. 3 is a vector map showing the locations of restriction enzyme digestion sites on TRE3G-OSK-SV40pA.

[0148] [Figure 4] Figures 4A-4AL include a series of schematic diagrams mapping the features shown in Figures 2 and 3 onto the nucleic acid (eg, engineered nucleic acid) sequence of TRE3G-OSK-SV40pA.

[0149] [Figure 5] Figures 5A-5D show the nucleotide positions and lengths of the nucleic acid (eg, engineered nucleic acid) sequences of the features shown in Figures 4A-4AL.

[0150] [Figure 6] Figures 6A-6C contain Western blot data showing that different serotypes of AAV encoding OSK (TRE3G-OSK-SV40pA, SEQ ID NO: 16) were successfully used in a doxycycline (DOX)-inducible system to control OSK expression in 293T cells. Expression of OCT4, KLF4, and H3 was detected by antibodies. H3 refers to histone 3 and serves as a loading control. Figure 6A shows the effect of doxycycline on protein expression in cells infected with AAV9 viruses carrying the TRE3G-OSK-SV40pA vector and AAV9 viruses carrying a vector encoding rtTA3 (tetracycline (Tet)-on system). Figure 6B shows the effect of DOX on protein expression in cells infected with AAV2 viruses carrying the TRE3G-OSK-SV40pA vector and AAV2 viruses carrying a vector encoding tTA (Tet-off system). Figure 6C shows the effect of DOX treatment and DOX withdrawal on protein expression in cells infected with AAV.PHP.b virus carrying the TRE3G-OSK-SV40pA vector and AAV.PHP.b virus carrying a vector encoding rtTA3 (Tet-On system). The length of DOX treatment (+DOX) or DOX withdrawal (-DOX) is indicated in parentheses.

[0151] [Figure 7]Figures 7A-7F contain data showing that AAV encoding OSK induced partial reprogramming and promoted optic nerve regeneration after nerve crush in an inducible manner. Figure 7A contains a series of photographs showing that injection of TRE-OSK-SV40 AAV virus and CAG-tTA AAV virus into mouse retinas resulted in expression of KLF4 in mouse retinal ganglion cells (RGCs). RBPMS (RGC marker) and KLF4 staining of optical coherence tomography (OCT) sections from mouse retinas are shown. Figure 7B contains a series of photographs showing that injection of TRE-OSK-SV40 AAV virus and CAG-tTA AAV virus resulted in inducible expression of KLF4 and OCT4 in mouse retinas. OCT4 and KLF4 staining of retinal whole mounts in the absence of doxycycline treatment (top two photographs) and after 4 days of DOX treatment (bottom two photographs) are shown. Figure 7C shows the experimental timeline for determining the effect of TRE-OSK-SV40 AAV virus alone or in combination with CAG-tTA AAV virus on optic nerve regeneration after optic nerve crush injury. CTB stands for cholera toxin β subunit, allowing fluorescent imaging of axons. Figure 7D shows colocalized staining of OCT4 and KLF4 from whole-mount retinas injected with TRE-OSK-SV40 AAV virus in combination with CAG-tTA. RBPMS specifically stains retinal ganglion cells. Figure 7E shows fluorescent imaging of CTB-labeled axons in the optic nerve after crush injury in mouse retinas injected with TRE-OSK-SV40 AAV virus alone (left) or TRE-OSK-SV40 AAV in combination with CAG-tTA AAV (right). The asterisk indicates the site of injury. Figure 7F shows additional fluorescent images of optic nerves treated as in Figure 7E with the indicated viruses.

[0152] [Figure 8]Figures 8A-8G show that administration of a virus encoding OSK improved RGC axon regeneration after nerve crush injury. Figure 8A shows the effects of a virus encoding TRE-OSK-SV40 in the absence of DOX (circles, n = 9), a virus encoding TRE-OSK-SV40 in the presence of DOX (triangles, n = 5), or a virus encoding tTA in combination with a virus encoding d2EGFP (squares, control, n = 5) on RGC axon regeneration. The estimated number of axons per nerve is shown as a function of distance (μm) from the injury site. Figure 8B shows a timeline of an experiment to determine the effect of d2EGFP expression on RGC axon regeneration. Figure 8C shows a series of images showing CTB-labeled axons from the experiment outlined in Figure 8B. Figure 8D shows a timeline of an experiment to determine the effect of uninduced OSK expression on axon regeneration. Figure 8E shows a series of images showing CTB-labeled axons from the experiment outlined in Figure 4D. Figure 8F is a timeline of an experiment to determine the effect of induced OSK expression on axon regeneration. Figure 8G is a series of images showing CTB-labeled axons from the experiment outlined in Figure 8F. The asterisk indicates the site of injury.

[0153] [Figure 9]Figures 9A-9D show that OSK-infected RGCs have a higher survival rate after nerve crush injury compared to cells not infected with OSK virus. Figure 9A shows staining for RBPMS and GFP in uncrushed RGCs (top left) and crushed RGCs (top right) infected with GFP AAV, and staining for RBPMS and KLF4 in uncrushed RGCs (bottom left) and crushed RGCs (bottom right) infected with OSK AAV. Figure 9B shows the ratio of RBPMS (an RNA-binding protein with multiple splicing)-positive cells for uncrushed and crushed RGCs infected with a destabilized form of GFP (d2EGFP) virus or OSK virus. GFP-infected RGCs have the same survival rate as uninfected RGCs. Thus, the GFP+RBPMS+% remains the same after crush injury. OSK-infected RGCs have a threefold higher survival rate compared to uninfected RGCs, and thus, the KLF4+RBPMS+% increased after crush injury. Figure 9C shows surviving RGCs under uncrushed (left) and crushed (right) conditions following OSK virus infection, and Figure 9D shows the survival of RGCs (RBPMS+) under uncrushed and crushed conditions when they were infected with d2EGFP virus or OSK virus.

[0154] [Figure 10] Figures 10A-10B show that OSK-mediated regeneration and protection are independent of mTOR activation. Figure 10A is a series of images showing RBPMS and pS6 staining of uncrushed or crushed control and OSK-infected RGCs. Figure 10B is a graph quantifying the percentage of pS6-positive cells from a series of images like Figure 10A.

[0155] [Figure 11]Figures 11A-11D show that the AAV Tet-On system containing the CMV-rtTA vector (SEQ ID NO: 31) induces faster gene expression in retinal cells after nerve crush injury compared to the AAV Tet-Off system. Figure 11A shows a timeline of an experiment to test the effect of doxycycline withdrawal on GFP expression in the AAV Tet-Off system. Lines indicate the length of DOX treatment. The indicated treatments A-D correspond to photographs 1-4 in Figure 7B, respectively. Figure 11B is a series of photographs showing the results of the experiment outlined in Figure 11A. GFP-positive cells from mouse retinas infected with a virus encoding tTA and a virus encoding TRE-d2EGFP are shown at the indicated days after DOX withdrawal. Figure 11C shows a timeline of an experiment to test the effect of doxycycline treatment on GFP expression in the AAV Tet-On system containing the CMV-rtTA vector (SEQ ID NO: 31). Lines indicate the length of DOX treatment. The indicated treatments A-C correspond to photographs 1-3, respectively, in Figure 11D. Figure 11D is a series of photographs showing the results of the experiment outlined in Figure 11C. Shown are GFP-positive cells from mouse retinas infected with viruses encoding rtTA and TRE-d2EGFP at the indicated days of DOX treatment.

[0156] [Figure 12] 12 is a vector map showing features on an adeno-associated virus (AAV) vector encoding reverse tetracycline transactivator 4 (rtTA4). Ubc is a constitutive promoter that is operably linked to a nucleic acid (e.g., an engineered nucleic acid) encoding rtTA4. SV40pA is a terminator sequence derived from SV40. The sequence of this vector is provided by SEQ ID NO: 17.

[0157] [Figure 13]Figures 13A-13C contain data showing that the Tet-On system containing rtTA4 (SEQ ID NO: 13) has low leakage in mouse liver. Figure 13A is a series of immunofluorescence images showing KLF4 expression in the liver of mice administered AAV carrying the nucleic acid (e.g., engineered nucleic acid) shown in Figure 13B in the absence (without DOX) and presence (with DOX) of doxycycline. DAPI is a nuclear stain used to visualize cells. Figure 13B is a schematic diagram illustrating two nucleic acids (e.g., engineered nucleic acids) administered to mice by AAV9 virus. Figure 13C is a Western blot of liver samples from mice that received the construct shown in Figure 13B and were treated without or with doxycycline. OCT4, KFF4, and SOX2 levels were detected using antibodies as indicated. Actin is shown as a loading control.

[0158] [Figure 14] Figure 14 is a graph comparing the weight of mice with the various treatments indicated. WT indicates wild-type mice without exogenous OSK expression. All died indicates that all OSK transgenic mice treated with doxycycline died.

[0159] [Figure 15] Figures 15A-15B contain data showing that induction of OCT4, KFF4, and SOX2 expression reversed aging in mouse ear fibroblasts as dictated by the expression of histone and Chaf (chromatin assembly factor) genes, but did not induce Nanog expression. The asterisk (*) indicates endogenous KFF4 expression from the 293T cell line.

[0160] [Figure 16]Figure 16 is a Western blot showing that AAV vectors containing nucleic acid (e.g., engineered nucleic acid) sequences greater than 4.7 kb between the two ITRs on the vector have low viral titers and produce non-functional AAV when integrated into AAV. The TRE2-OSK vector is provided as SEQ ID NO: 33. Expression of OCT4, KLF4, and H3 was detected using antibodies. H3 is shown as a loading control. The asterisk (*) indicates endogenous Klf4 from the 293T cell line.

[0161] [Figure 17] Figure 17 is a Western blot showing that administration of modified mRNA encoding OCT4, SOX2, and KLF4 induced expression of KLF4 and OCT4 in mouse cells. Antibodies against KLF4, OCT4, GAPDH, and H3 were used to detect the indicated proteins.

[0162] [Figure 18] Figure 18 is a vector map of pAAV2_CMV_rtTA(VP16) (SEQ ID NO: 31). This vector is a non-limiting example of a vector encoding rtTA.

[0163] [Figure 19] 19 shows the vector map of pAAV-MCS-tTA2 (or CAG-tTA) (SEQ ID NO: 32). This vector is a non-limiting example of a vector encoding tTA under the CAG promoter.

[0164] [Figure 20] Figure 20 is a vector map of p-AAV-TetO-OSK-WPRE3-SV50LpA (TRE2-OSK, pAAV-TRE2-OSK-SV40LpA, or TRE2-OSK) (SEQ ID NO: 33). This vector is a non-limiting example of an AAV vector that contains more than 4.7 kb of nucleic acid (e.g., engineered nucleic acid) sequence between the two ITRs on the vector.

[0165] [Figure 21] FIG. 21 is a series of images showing successful chemical reprogramming of mouse embryonic fibroblasts.

[0166] [Figure 22] FIG. 22 includes a schematic diagram showing a non-limiting example of a Tet-Off system for expressing OCT4, SOX2, and KLF4 in the absence of tetracycline (upper panel), and a schematic diagram showing a non-limiting example of a Tet-ON system for expressing OCT4, SOX2, and KLF4 (OSK) in the presence of tetracycline (lower panel).

[0167] [Figure 23] Figures 23A-23C contain data showing that administration of AAV2 viruses encoding OCT4, SOX2, and KLF4 improved axon regeneration and RGC survival in adult and aged mice 2 weeks after optic nerve crush. Figure 23A is a series of images showing CTB-labeled axons from mice at the indicated ages (by month) and comparing the effects of AAV2 viruses encoding TRE-OSK-SV40 with those encoding GFP. Experiments were performed in the absence of DOX using the Tet-Off system illustrated in the upper panel of Figure 22. Figure 23B quantifies the estimated number of axons per nerve as a function of distance (μm) from the injury site for mice of the indicated ages and treatments. Figure 23C is a chart showing that OSK increased RGC survival after optic nerve injury in adult (3-month-old) and aged (12-month-old) mice compared to control GFP. Survival of RGCs (RBPMS+) is shown for mice of the indicated ages that received viruses encoding d2EGFP or OSK.

[0168] [Figure 24]Figures 24A-24B contain data showing that increasing the reprogramming time from 2 weeks to 5 weeks improved regeneration in aged mice. Figure 24A is a series of photographs showing CTB-labeled axons from a 12-month-old mouse 5 weeks after optic nerve crush injury. Mice were administered a virus encoding GFP or a virus encoding TRE-SV40-OSK and a virus encoding tTA prior to nerve crush injury. Figure 24B is a graph quantifying the estimated number of axons per nerve from Figure 24A as a function of distance (μm) from the injury site.

[0169] [Figure 25]Figures 25A-25C contain data showing that induction of OSK expression using the Tet-On and Tet-Off systems improved regeneration and RGC cell survival in mice, even after optic nerve crush injury. Figure 25A contains a schematic diagram showing a treatment timeline for determining the effects of OSK expression before or after optic nerve crush injury. For the Tet-On system, induction of OSK expression before optic nerve crush injury (pre-injury induction) and after optic nerve crush injury (post-injury induction) are shown (upper panel). OSK expression was induced using doxycycline treatment. For the Tet-Off system, inhibition of OSK induction by doxycycline treatment before optic nerve crush injury (pre-injury inhibition) and after optic nerve crush injury (post-injury inhibition) are shown (lower panel). The shaded lines on the timeline indicate the length of doxycycline (DOX) treatment. Cholera toxin β subunit (CTB) injection for axonal imaging is also shown. Figure 25B is a chart quantifying the estimated number of axons per nerve as a function of distance (μm) from the injury site in 4-week-old (young) mice with no OSK induction (n = 4), OSK induction only before injury (n = 5), OSK expression suppressed from injury (n = 5), and OSK induction after injury (n = 5). The protocol for pre- and post-injury induction used was as shown in Figure 25A. Figure 25C is a chart quantifying the number of RBPMS+ cells from 4-week-old (young) mice with no OSK induction, OSK induction only before injury, OSK suppressed from injury, and OSK induction after injury.

[0170] [Figure 26]Figures 26A-26E contain data showing that expression of OSK from a single transcript improved axon regeneration and retinal ganglion cell (RGC) survival 2 weeks after optic nerve crush injury compared to expression of OCT4, SOX2, and KLF4 from separate transcripts. Figure 26A is a schematic diagram showing the AAV combinations and non-limiting exemplary expression cassettes of the Tet-Off system encoding OCT4, SOX2, and / or KLF4 injected in each group 2 weeks before crush injury. Figure 26B is a chart showing that expression of OSK from a single transcript improved axon regeneration compared to expression of OCT4, SOX2, and KLF4 from separate transcripts. The estimated number of axons per nerve after optic nerve crush injury was quantified as a function of distance (μm) from the injury site for mice receiving tTA virus and one of the following: (1) OCT4 virus, (2) SOX2 virus, (3) KLF4 virus, (4) a virus with a vector encoding OCT4 and SOX2 under a single promoter (OCT4-SOX2), (5) separate OCT4, SOX2, and KLF4 viruses (OCT4, SOX2, KLF4, or O, S, K), or (6) a virus with a vector encoding OCT4, KLF4, and SOX2 under a single promoter (Oct4-Sox2-KLF4 or OSK). The various vectors used are illustrated in Figure 26A. Figure 26C is a chart showing that expression of OSK from a single transcript improved RGC survival relative to expression of OCT4, SOX2, and KLF4 from separate transcripts. Figure 26D contains whole-mount staining of mouse retina and shows that when separate viral vectors encoding OCT4, SOX2, and KLF4 were delivered to mouse eyes by separate viruses, a heterogeneous population of cells was detected, with a small number of RBPMS+ cells. Arrows point to seven different types of cells expressing OCT4, SOX2, KLF4, and / or RBPMS in the upper left image below a schematic diagram of the vectors. Figure 26E contains data showing that when a virus containing a viral vector encoding OSK under a single promoter was delivered to mouse eyes, a more homogeneous population of cells was detected compared to Figure 26D.More OSK-expressing cells were detected that were also RBPMS+ compared to Figure 26D. In the top left image below a schematic of the vectors used, long white arrows point to RBPMS+ cells expressing OCT4, SOX2, and KLF4, while shorter arrows indicate that some cells that do not express RBPMS also expressed OSK.

[0171] [Figure 27] Figure 27 is a chart showing that Tet1 and Tet2 DNA demethylases play a role in OSK-induced regeneration. The estimated number of axons per nerve after optic nerve crush was quantified in mice that received (1) OSK virus and a short hairpin control, (2) OSK virus and a short hairpin against Tet1, or (3) OSK virus and a short hairpin against Tet2.

[0172] [Figure 28] Figure 28 contains data showing that expression of OSK using the Tet-Off system reversed age-related visual loss in aged mice one month after injection of AAV viruses encoding TRE-OSK and tTA. Figure 28 is a chart showing that intravitreal injection of mice with viruses encoding tTA and TRE-OSK reversed the age-related decline in spatial frequency threshold (cycles / degree, visual acuity test) observed in aged mice (12-month-old (12m) and 18-month-old (18m) mice) in the absence of doxycycline (OSK-inducing condition). A visual acuity test based on the optokinetic response (OMR) was used. As a control, age-matched mice received viruses encoding rtTA and viruses encoding TRE-OSK in the absence of doxycycline (uninduced control). Adult mice (3-month-old (3m)) were also used as controls.

[0173] [Figure 29]Figure 29 contains data showing that expression of OSK reversed the age-related decline in retinal ganglion cell (RGC) function in aging mice. Figure 29 is a chart showing measurements of electrical waves generated by RGCs from adult (3-month-old (3m)) and aged (12-month-old (12m) and 18-month-old (18m)) mice. Pattern electroretinograms (pattern ERGs) were used. Mice were injected with rtTA virus and TRE-OSK virus without doxycycline (uninduced control (ctl)) or tTA virus and TRE-OSK virus (OSK induction) without doxycycline. Results were obtained one month after virus injection.

[0174] [Figure 30]Figures 30A-30E contain data showing that expression of OSK improved glaucoma-induced decline in visual acuity and RGC function in 1-month-old mice. Figure 30A is a chart showing that polystyrene microbeads induced glaucoma in adult C57BL / 6J mice compared to saline treatment, as measured by increased intraocular pressure (IOP). IOP measurements are shown for the first 4 weeks of microbead injection. Figures 30B-30C show that 4 weeks after microbead injection into the anterior chamber, there was a significant loss of axon density and RGC density. AAV was injected intravitreally 3 weeks after microbead injection, and it took another week for OSK expression to be observed. Figure 30B contains a chart quantifying axon density using p-phenylenediamine (PPD) staining (e.g., shown on the right) (left panel). Figure 30C contains a chart quantifying RGC cell density using Brn3a staining (e.g., shown on the right) (left panel). Figure 30D is a chart showing the improvement in vision with OSK AAV treatment in mice with induced glaucoma. Mice were intravitreally injected with microbeads to induce glaucoma or saline without microbeads (no glaucoma control; saline). Three weeks after microbead injection, the mice were then treated with (1) a virus encoding rtTA and the virus TRE-OSK in the absence of doxycycline (Beads(OSK AAV Off)); or (2) a virus encoding tTA and the virus TRE-OSK in the absence of doxycycline (Beads(OSK AAV On)). Results are shown 3 weeks after saline or microbead injection (before AAV injection) and 4 weeks after AAV injection (7 weeks after microbeads). Figure 30E is a chart showing the results of RGC function by pattern electroretinogram in mice treated as in Figure 30B.

[0175] [Figure 31]Figures 31A-31C contain data showing that OSK expression promoted neuronal survival and axonal regeneration in human SH-SY5Y neurons after vincristine (VCS)-induced damage. Figure 31A contains a series of images showing the effect of inducing OSK expression (OSK On) compared with not inducing OSK expression (OSK Off) on neuronal structure. Images were taken on days 3 and 9 after 24 hours of VCS treatment. Neuronal cell area is outlined on day 9. Figure 31B is a chart quantifying neuronal cell area (μm2) for cells with induced OSK expression (OSK On) and cells without induced OSK expression (OSK Off) at the indicated days after 24 hours of VCS treatment. Figure 31C is a chart quantifying neuronal cell area (μm2) for cells with induced OSK expression (OSK On) and cells without induced OSK expression (OSK Off) at the indicated days after 48 hours of VCS treatment.

[0176] [Figure 32]Figures 32A-32G show that partial reprogramming by AAV-delivered polycistronic OSK is nontoxic and induces CNS axon regeneration. Figure 32A is a schematic diagram of the Tet-On and Tet-Off AAV vectors used in studies to control OSK expression. Figure 32B shows the body weights of WT mice, OSK transgenic mice, and mice expressing AAV-mediated OSK (1.0 x 10 gene copies) with or without doxycycline induction for the first 4 weeks (n = 5, 3, 6, 4, 6, and 3, respectively). Figure 32C is a schematic diagram showing intravitreal AAV injection to target retinal ganglion cells. Retinal whole-mount presentations and immunofluorescence of cross sections show the infection rate and targeted retinal layers. Scale bars represent 1 mm and 100 μm, respectively. Figure 32D shows the experimental outline of an optic nerve crush study using the Tet-Off system. Figure 32E shows quantification of regenerating fibers with d2EGFP, OCT4, SOX2, KLF4, OS, O+S+K, or OSK AAV at different distances distal to the injury site. Error bars indicate sem (n = 4-7). ****P<0.0001, ANOVA with Bonferroni post-hoc test. Figure 32F shows survival of RBPMS-positive cells in the RGC layer transduced with different AAV vectors 14 days after crush injury (n = 4-8). ***P<0.001, ****P<0.0001, one-way ANOVA with Bonferroni post-hoc test, relative to d2EGFP. Figure 32G shows representative images of optic nerve sections showing CTB-labeled axons in wild-type mice with intravitreal injection of AAV2-tTA and TRE-OSK in the presence and absence of DOX 2 weeks after optic nerve injury. The crush site is indicated by an asterisk. The scale bar represents 200 μm.

[0177] [Figure 33]Figures 33A-33K show that OSK expression promotes axonal regeneration and neuronal survival through a Tet-dependent mechanism. Figure 33A shows the experimental strategy for pre- and post-injury induction of OSK expression. Figure 33B shows retinal RGC survival with pre- and post-injury OSK expression. Figure 33C shows quantification of regenerating fibers from the OSK expression model before and after injury. Figure 33D shows representative images of optic nerves showing regenerating axons 4 weeks after injury, with or without post-injury OSK expression. The crush site is indicated by an asterisk. The scale bar represents 200 μm. Figures 33E-33F show quantification of regenerating fibers and RGC survival in retinas co-transduced with an AAV2 vector encoding polycistronic OSK, tTA, and an shRNA vector carrying a scrambled sequence (Scr), Tet1, or Tet2 sequence to knockdown Tet DNA dioxygenase / demethylase. Figure 33G shows an outline of an experiment to examine axon regeneration in human neurons after vincristine (VCS) damage. Figure 33H shows that OSK rejuvenates human neurons according to the skin and blood clocks. In the upper panel of Figure 33H, P values ​​were calculated using a linear regression model to determine whether DNA methylation age decreased over time. The lower panel of Figure 33H shows the DNA methylation age of human neurons according to OSK expression before (day -) or after (days 1 and 9) VCS damage, as estimated by the skin and blood cell clocks. Figure 33I shows the neurite area of ​​each AAV treatment group. *p<0.05, **p<0.01, ****p<0.0001, one-way ANOVA with Tukey's multiple comparison test. Figure 33J shows representative images and neurite area of ​​human neurons after 9 days of recovery from VCS damage. Figure 33K shows the rDNA methylation age of 1-month-old RGCs. Axons infected with or without GFP were isolated from intact retinas, or axons infected with GFP-AAV or OSK-AAV were isolated from injured retinas 4 days after nerve crush.

[0178] [Figure 34]Figures 34A-34H show the reversal of glaucoma with OSK AAV treatment. Figure 34A is a schematic diagram outlining the experiment. Figure 34B shows intraocular pressure measured weekly by rebound tonometry over the first 4 weeks after microbead injection. Figure 34C shows representative microscopic images of PPD-stained optic nerve cross sections 4 weeks after AAV2 or PBS injection. Scale bar: 50 μm. OSK Off (rtTA+TRE-OSK); OSK On (tTA+TRE-OSK). Figure 34D shows quantification of healthy axons in the optic nerve 4 weeks after PBS or AAV injection. Figure 34E is a schematic diagram of a high-contrast visual stimulation assay for measuring optomotor responses. Vision was assessed using reflexive head movements in response to rotating moving stripe patterns of increasing spatial frequency. Figure 34F shows the spatial frequency threshold response of each mouse measured before treatment and 4 weeks after intravitreal injection of AAV vectors. Figure 34G shows representative pERG waveforms recorded from the same eye at baseline before treatment and 4 weeks after treatment with OSK-OFF AAV (upper graph) or OSK-ON AAV (lower graph). Figure 34H shows the average pERG amplitude of recordings measured from each mouse at baseline before treatment and 4 weeks after intravitreal injection of AAV. *P<0.05; **P<0.01; ***P<0.001, ****P<0.0001. Two-way ANOVA with Tukey's post-hoc test between groups was used for the overall effects of time and treatment. Paired t-tests were used to compare pre- and post-treatment.

[0179] [Figure 35]Figures 35A-35I show that OSK AAV induces axonal regeneration and restores visual function in aged mice. Figure 35A outlines an experiment to test the effect of OSK AAV treatment in aged mice on axonal regeneration after optic nerve crush injury and on the restoration of physiological aging-associated blindness. Figure 35B shows axonal regeneration in 12-month-old mice treated with OSK AAV or control AAV (d2EGFP) 2 or 5 weeks after optic nerve crush injury. Figure 35C is a representative confocal image of a longitudinal section of the optic nerve showing CTB-labeled axons after 5 weeks of OSK treatment. The scale bar represents 200 μm. Figure 35D shows the spatial frequency threshold of young (4 months) and old (12 months) mice treated with OSK-Off or OSK-On AAV. Figures 35E-35F show spatial frequency thresholds and pERG amplitudes in aged mice (12 months): (i) OSK-Off, (ii) OSK-On, or (iii) OSK-On plus: treated with either sh-Scr, sh-Tet1, or sh-Tet2-mediated knockdown of DNA demethylases. OSK-Off (rtTA + TRE-OSK); OSK-On (tTA + OSK). Figure 35G is a hierarchical clustering heatmap showing RNA-Seq expression of 464 differentially expressed genes in cell-sorted purified RGCs from intact young mice (5 months) or intact old mice (12 months), or from old mice treated with either control AAV (TRE-OSK) or OSK-On AAV. Figure 35H is a scatter plot of OSK-induced changes in RNA levels versus age-related changes in mRNA levels. Dots represent differentially expressed genes in RGCs. Figure 35I shows rDNA methylation ages of FACS-isolated 12-month-old RGCs from retinas infected for 4 weeks with -OSK or +OSK AAV together with short hairpin DNA with a scrambled sequence (sh-Scr) or targeted to Tet1 or Tet2 (sh-Tet1 / sh-Tet2).Gene exclusion criteria for Figure 35G and Figure 35H: genes with low overall expression (log2(CPM)<2), genes that did not change significantly with age (absolute log2 fold change<1), or genes that were virally altered (differentially expressed between intact old and TRE-OSK AAV-treated old). *P<0.05; **P<0.01; ***P<0.001, ****P<0.0001. Two-way ANOVA for Figure 35D; one-way ANOVA for Figures 35B, 35E, and 35F.

[0180] [Figure 36]Figures 36A-36H show the effects of OSK (without Myc) on aging and the safety of OSK AAV. Figure 36A is a schematic diagram of the experimental profile testing the reprogramming effect in young and old transgenic mouse fibroblasts. Figure 36B shows that OSKM expression rescues age-related transcriptional changes without inducing pluripotency. For example, Nanog expression is not induced. Figure 36C shows that OSK expression rescues age-related transcriptional changes without inducing pluripotency. For example, Nanog expression is not induced. Figure 36D shows OSK AAV9 expression in the liver compared to transgenic mice. Figure 36E shows the body weights of WT mice and mice expressing AAV-mediated OSK (total 1.0 x 10 gene copies) with or without doxycycline after the first 4 weeks and for the next 9 months (n = 5, 3, 6, 4, respectively). Figure 36F shows the AAV-UBC-rtTA and AAV-TRE-Luc vectors used to measure tissue distribution. Figure 36G shows luciferase imaging of WT mice 2 months after retro-orbital injection of AAV9-UBC-rtTA and AAV9-TRE-Luc (total of 1.0 x 10 gene copies). Doxycycline was delivered via drinking water (1 mg / mL) to the mice shown on the right for 7 days. Figure 36H shows luciferase imaging of the eye (Ey), brain (Br), pituitary gland (Pi), heart (He), thymus (Th), lung (Lu), liver (Li), kidney (Ki), spleen (Sp), pancreas (Pa), testis (Te), fat (Ad), muscle (Mu), spinal cord (SC), stomach (St), small intestine (In), and cecum (Ce) 2 months after retro-orbital injection of AAV9-UBC-rtTA and AAV9-TRE-Luc, followed by 7 days of doxycycline treatment. Luciferase signal is primarily located in the liver. Imaging the same tissues with longer exposure times (Figure 36H, lower panel) revealed lower levels of luciferase signal in the pancreas (the liver was removed).

[0181] [Figure 37]Figures 37A-37D show characterization of the inducible polycistronic AAV system. Figure 37A shows immunofluorescence analysis of whole-mount retinas transduced with polycistronic AAV vectors expressing OCT4, SOX2, and KLF4 in the same cells. Arrows point to triple-positive cells. Figure 37B shows immunofluorescence analysis of whole-mount retinas transduced with AAVs separately encoding OCT4, SOX2, and KLF4. Dotted arrows point to double-positive cells. Solid arrows point to single-positive cells, with the exception of the arrow in the lower right corner of each image, which points to triple-positive cells. Figures 37C-37D are images showing whole-mount retinal presentations of RBPMS and Klf4 immunofluorescence. Figure 37C shows that expression from the AAV2 Tet-Off system can be turned off by Dox in the drinking water (2 mg / mL, 3 days). Figure 37D shows that expression from the AAV2 Tet-On system can be turned on by Dox in the drinking water (2 mg / mL, 2 days). The scale bar represents 1 mm.

[0182] [Figure 38] Figures 38A-38C show that OSK induces long-term axon regeneration after injury without RGC proliferation. Figure 38A shows retinal whole-mount staining, demonstrating that OSK-infected RGCs lack the proliferation marker Ki67 (left), whereas proliferating 293T cells have Ki67 signals (right). The scale bar represents 100 μm. Figure 38B shows whole-nerve imaging of the optic nerve, demonstrating regenerated axons from control (no AAV) or OSK AAV treatment 3 months after injury. The scale bar represents 200 μm. Figure 38C shows whole-nerve imaging, demonstrating CTB-labeled regenerated axons 16 weeks after injury (wpc) in wild-type mice with intravitreal injection of AAV2-tTA and TRE-OSK. The scale bar represents 200 μm.

[0183] [Figure 39]Figures 39A-39D show that the Tet-On system has a better turn-on rate and higher survival rates of OSK-transduced RGCs. Figure 39A shows representative images showing d2EGFP expression in retinas from the Tet-Off AAV system with different Dox treatments. When pretreated with DOX to suppress expression (with DOX), GFP expression only faintly appeared after 8 days of DOX withdrawal and was much weaker than the peak expression (always without DOX). Figure 39B shows representative images showing d2EGFP in retinas from the Tet-On AAV system. GFP expression was not observed in the absence of DOX, and GFP expression peaked at 2 days after Dox induction and did not become stronger with 5 days of DOX induction. Figure 39C shows representative immunofluorescence images of GFP-positive or KLF4-positive RGCs in intact and crushed samples. Figure 39D shows quantification of GFP or KLF4 positive cells, indicating higher survival of OSK-expressing RGCs after crush injury. Scale bars represent 200 μm in Figures 39A, 39B, and 39C.

[0184] [Figure 40]Figures 40A-40F show the identification of the epigenetic mechanism behind the OSK effect. Figure 40A shows representative images of retinal whole mounts transduced with AAV2 encoding d2EGFP or OSK in the presence or absence of crush injury. Retinal whole mounts were immunostained for the RGC marker RBPMS and the mTOR activation marker pS6. Figure 40B shows quantification of the % pS6-positive RGCs in intact and crush samples. Figure 40C shows quantification of the transduction rate of shRNA-YFP AAV in RGCs that expressed OSK. Figure 40D shows representative images of retinal whole mounts transduced with AAV2 encoding OSK in combination with sh-Scr, sh-Tet1, or sh-Tet2 YFP AAV. Retinal whole mounts were immunostained for Klf4. Scale bars represent 100 μm in Figures 40A and 40D. Figure 40E shows Tet1 vs. GAPDH mRNA levels in mouse RGCs with sh-Scr or sh-Tet1 treatment in the presence of OSK expression. Figure 40F shows Tet2 vs. GAPDH mRNA levels in mouse RGCs with sh-Scr or sh-Tet2 AAV treatment in the presence of OSK expression.

[0185] [Figure 41]Figures 41A-41K show that OSK robustly induces human neuronal axon regeneration independently of the mTOR pathway. Figure 41A shows immunofluorescence of differentiated human neurons transduced with AAV-DJ vectors encoding TRE-OSK and tTA (OSK On) or TRE-OSK alone (OSK Off). Figure 41B shows mRNA levels of Oct4, Sox2, and Klf4 in human neurons transduced with AAV-DJ vectors as in Figure 41A. Figure 41C shows FACS profiles of G1, S, and G2 phases in undifferentiated and differentiated cells with OSK On or Off. Figure 41D shows quantification of the proliferating S-phase cell population. Figure 41E shows representative images and neurite area of ​​human neurons after vincristine damage with or without OSK expression. Figure 41F shows quantification of neurite area at different time points after vincristine damage. Figure 41G shows Tet2 mRNA levels in human neurons treated with sh-Scr and sh-Tet2 AAVs. Figure 41H shows S6 phosphorylation levels in human neurons treated with rapamycin (10 nM) for 5 days. Figure 41I shows the effect of mTOR inhibition on axon regeneration in differentiated neurons with OSK Off or OSK On. Figure 41J shows DNA methylation age in human neurons before (day -) or 1 and 9 days after vincristine (VCS) damage in the absence of OSK expression. Estimated using skin or blood cell clocks. Figure 41K shows mouse Oct4 mRNA levels in human neurons treated with sh-Scr or sh-Tet2 AAVs in the absence or presence of OSK expression.

[0186] [Figure 42]Figures 42A-42C show the effects of OSK in a mouse model induced by microbeads. Figure 42A shows quantification and representative confocal microscopy images of RGCs from retinal flat mounts stained with the RGC-specific marker anti-Brn3a and the nuclear stain DAPI 4 weeks after microbead or saline injection. The scale bar represents 75 mm. Figure 42B shows quantification and representative photomicrographs of healthy axons in the optic nerve from PPD-stained optic nerve cross sections 4 weeks after microbead or saline injection. The scale bar represents 10 μm. Figure 42C shows quantification and representative confocal microscopy images of RGCs 4 weeks after AAV injection and 8 weeks after microbead or saline injection.

[0187] [Figure 43] Figures 43A-43G show the effects of OSK in aging mice. Figure 43A shows the effect of OSK expression on RGC survival in young, adult, and aging mice after optic nerve crush injury. Figure 43B shows axon regeneration promoted by OSK expression compared to d2EGFP controls in young (1-month-old), adult (3-month-old), and aging (12-month-old) mice 2 weeks after injury. Figure 43C shows a comparison of pERG measurements at different ages after 1 month of OSK Off or OSK On treatment. OSK Off, rtTA + TRE = OSK AAV; OSK On, tTA + OSK AAV. Figure 43D shows a comparison of RGC cell density in 4- and 12-month-old mice after 1 month of OSK Off or OSK On treatment. Figure 43E shows a comparison of axon density in 4- and 12-month-old mice after 1 month of OSK Off or OSK On treatment. Figure 43F shows a comparison of pERG measurements at different ages one month after -OSK or +OSK treatment. -OSK: AAV-rtTA + AAV-TRE-OSK; +OSK: AAVtTA + AAV-TRE-OSK. Figure 43G shows spatial frequency thresholds in 18-month-old mice treated with -OSK or +OSK AAV for 4 weeks.

[0188] [Figure 44]Figures 44A-44D show RNA-seq analysis of genes whose expression was reset by REVIVER treatment. Figure 44A is a scatter plot of OSK-induced changes in RNA levels versus age-related changes in mRNA levels. Dots represent differentially expressed genes in RGCs and are shown. Gene exclusion criteria: genes with low overall expression (log2(CPM)<2), genes that did not change significantly with age (absolute log2 fold change<1), or virally altered genes (differentially expressed between intact old and TRE-OSK AAV-treated old mice). Figure 44B is a hierarchical clustering heatmap showing RNA-seq expression of sensory genes in cell-sorted purified RGCs from intact young mice (5 months) or intact old mice (12 months), or old mice treated with either control AAV (TRE-OSK) or OSK-On AAV. Figure 44C shows the top 10 biological processes that were lower in the old compared to the young and restored by OSK, and Figure 44D shows the top 10 biological processes that were higher in the old compared to the young and reduced by OSK.

[0189] [Figure 45] Figures 45A-45C show methylation clock analysis of mouse RGCs and human neurons. Figure 45A shows the correlation between rDNA methylation age and chronological age of sorted mouse RGCs. Figure 45B shows the average DNA methylation levels of RGCs from different ages and treatments. Figure 45C shows the average DNA methylation levels of human neurons treated with OSK before (-) treatment with vincristine (VCS) or ~ days (1 and 9) after VCS damage.

[0190] [Figure 46]Figures 46A-46B show that OSK mediates axon regeneration in a Tet2-dependent manner. Tet2 conditional knockout mice were used. Mouse eyes were injected with (1) AAV-CRE (Tet2 cKO); (2) AAV-tTA + AAV-TRE-OSK:OSK (Tet2 WT); or (3) AAV-tTA + AAV-TRE-OSK + AAV-CRE:OSK (Tet2 cKO). Axon regeneration was assayed after optic nerve crush injury. Figure 46A shows a representative optic nerve image. Figure 46B shows a graph quantifying axon number. DETAILED DESCRIPTION OF THE INVENTION

[0191] The present disclosure is based, at least in part, on unexpected results demonstrating that expression of OCT4, SOX2, and KLF4 in the absence of exogenous c-Myc expression can be used to promote in vivo partial reprogramming and tissue regeneration. Surprisingly, using the eye as a model tissue as described herein, it has been determined that, in some embodiments, a combination of OCT4, SOX2, and KLF4 (OSK) can be used to reset the youthful gene expression pattern and epigenetic age of retinal ganglion cells to promote optic nerve regrowth and vision restoration in rodent models of glaucoma and in aged animals. In some embodiments, the DNA demethylases Tet1 and Tet2 are required for these restorative activities. This suggests, without being bound by any particular theory, that the DNA methylation clock is not only a correlate of age but also a regulator of it.

[0192] In certain embodiments, provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors) encoding OCT4, SOX2, and KLF4, each alone or in combination, recombinant viruses (e.g., lentivirus, alphavirus, vaccinia virus, retrovirus, adenovirus, herpes virus, or AAV) comprising the same, pharmaceutical compositions comprising the engineered nucleic acids and / or recombinant viruses, kits comprising the engineered nucleic acids and / or recombinant viruses, and methods for controlling (e.g., inducing, inducing and then arresting, etc.) cell reprogramming, reversing aging, tissue repair, organ regeneration, and tissue regeneration.

[0193] In certain embodiments, expression of one or more of the genes is transient (e.g., using an inducible promoter to control gene expression). Expression of one or more of the genes (e.g., OCT4, SOX2, KLF4, or a combination thereof) can be regulated by altering the activity of the inducer. As a non-limiting example, tetracycline transactivator (tTA) can induce expression from a tetracycline-responsive promoter in the absence of tetracycline. When tetracycline is added, tTA can no longer bind to the promoter and induce expression. As another non-limiting example, reverse tetracycline transactivator (rtTA) can induce expression from a tetracycline-responsive promoter in the presence of tetracycline. When tetracycline is removed, rtTA can no longer bind to the promoter and induce expression. As described herein, an inducible AAV vector (OSK) encoding OCT4, SOX2, and KLF4 promoted in vivo optic nervous system regeneration after damage. Thus, expression of these three genes may be useful for tissue and organ regeneration, tissue and organ repair, reversing aging, treating neurodegenerative diseases and conditions, and cell reprogramming. As described below, in some cases, the vectors described herein may be used in a concentration of 2 x 10 per preparation. 12It can be packaged into viruses at higher titers than particles, allowing precise control of OSK expression in mammalian cells in vitro and in vivo.

[0194] Cellular reprogramming allows the generation of multiple cell types from existing somatic cells. Yamanaka factors (OCT4, SOX2, KLF4, and c-Myc, collectively also known as OSKM) have been shown to induce pluripotency in differentiated cells, but administration of these factors can induce teratomas or other cancers in vivo (Takahashi et al., Cell. 2006 Aug 25;126(4):663-76; (Abad et al., Nature. 2013 Oct 17;502(7471):340-5). As a result of these safety concerns, the use of Yamanaka factors has largely been limited to in vitro applications. Furthermore, existing methods of gene therapy suffer from inefficient and inconsistent gene transduction of target cells. The engineered nucleic acids, recombinant viruses containing the same, pharmaceutical compositions thereof, and kits provided herein overcome many of these limitations. Engineered Nucleic Acids

[0195] The engineered nucleic acids of the present disclosure may encode OCT4, SOX2, KLF4, and their homologs or variants (e.g., functional variants), either alone or in combination. In certain embodiments, the engineered nucleic acid (e.g., the engineered nucleic acid) does not encode c-Myc. In certain embodiments, the engineered nucleic acid (e.g., the engineered nucleic acid) does not encode functional c-Myc because it lacks the c-Myc sequence. Assays for determining transcription factor (e.g., OCT4, SOX2, KLF4, or any combination thereof) activity are known in the art and include cell-based and in vitro transcription assays. Transcription factor expression can also be determined using other methods, including enzyme-linked immunosorbent assay (ELISA), Western blot, and RNA quantification (e.g., using reverse transcription polymerase chain reaction).

[0196] A transcription factor (e.g., OCT4, SOX2, KLF4, or a homolog or variant thereof, including mammalian OCT4, mammalian SOX2, and mammalian KLF4) can be encoded by a single nucleic acid, or a single nucleic acid (e.g., an engineered nucleic acid) can encode two or more transcription factors (e.g., each operably linked to a different promoter, or both operably linked to the same promoter). For example, in certain embodiments, a nucleic acid (e.g., an engineered nucleic acid) can encode OCT4; SOX2; KLF4; OCT4 and SOX2; OCT4 and KLF4; SOX2 and KLF4; or OCT4, SOX2, and KLF4, in any order.

[0197] In certain embodiments, the engineered nucleic acid (e.g., the engineered nucleic acid) encodes an inducer (e.g., tTA or rtTA). In certain embodiments, the nucleic acid (e.g., the engineered nucleic acid) can encode one or more transcription factors (e.g., one, two, or three transcription factors) and an inducer. In certain embodiments, the inducer is encoded by a separate nucleic acid (e.g., the engineered nucleic acid) that does not also encode a transcription factor (e.g., OCT4, SOX2, or KLF4). In certain embodiments, the inducer is encoded by a nucleic acid (e.g., the engineered nucleic acid) that also encodes a transcription factor (e.g., OCT4, SOX2, and / or KLF4). In certain embodiments, the inducer is encoded by a nucleic acid (e.g., an engineered nucleic acid) that also encodes one or more transcription factors selected from the group consisting of OCT4; SOX2; KLF4; and any combination thereof (e.g., OCT4; SOX2; KLF4; OCT4 and SOX2; OCT4 and KLF4; SOX2 and KLF4; or OCT4, SOX2, and KLF4).

[0198] The transcription factors (e.g., OCT4, SOX2, KLF4, or any combination thereof) or inducers described herein can contain one or more amino acid substitutions. Variants can be prepared according to methods for altering polypeptide sequences known to those skilled in the art, such as those found in references summarizing such methods, such as those found in Molecular Cloning: A Laboratory Manual, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or Current Protocols in Molecular Biology, F. M. Ausubel et al., eds., John Wiley & Sons, Inc., New York. Conservative amino acid substitutions include substitutions made between amino acids in the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

[0199] In certain embodiments, engineered nucleic acids of the present disclosure include RNA (e.g., mRNA) and / or DNA. In some embodiments, the RNA and / or DNA is further modified. By way of non-limiting example, a nucleic acid (e.g., an engineered nucleic acid) of the present disclosure can be a modified RNA (e.g., mRNA) encoding OCT4, KLF4, SOX2, an inducing factor, or any combination thereof. See, e.g., Warren et al., Cell Stem Cell. 2010 Nov 5;7(5):618-30. By way of non-limiting example, engineered nucleic acids (e.g., RNA, including mRNA, or DNA) of the present disclosure can be formulated as nanoparticles for delivery. See, e.g., Dong et al., Nano Lett. 2016 Feb 10;16(2):842-8. In some embodiments, the nanoparticles comprise acetylated galactose. See, e.g., Lozano-Torres et al., J Am Chem Soc. 2017 Jul 5;139(26):8808-8811. In some embodiments, the engineered nucleic acid (e.g., RNA, including mRNA, or DNA) is electroporated or transfected into cells. In certain embodiments, the engineered nucleic acid is delivered as naked nucleic acid (e.g., naked DNA or naked RNA).

[0200] In some embodiments, the engineered nucleic acid formulated as a nanoparticle for delivery is not an AAV vector. Suitable vector backbones for nanoparticle formulation include, but are not limited to, NANOPLASMID™ vectors and NTC "8" series mammalian expression vectors. Non-limiting examples of vector backbones for nanoparticle formulation include NTC9385R and NTC8685. Without being bound by any particular theory, NTC "8" series mammalian expression vectors may be useful because they can generally be cleared by cells within a few weeks. NTC "8" series mammalian expression vectors contain a CMV promoter, which can be operably linked to sequences encoding OCT4, KLF4, SOX2, or a combination thereof. Without being bound by any particular theory, NANOPLASMID™ vectors are less immunogenic than other vectors and can be expressed at higher levels and for longer periods of time. This may be useful for long-term expression of operably linked nucleic acids. In some embodiments, NANOPLASMID™ vectors may be useful for long-term expression of OCT4, KLF4, SOX2, or combinations thereof.

[0201] In some embodiments, engineered nucleic acids encoding OSK may be useful for generating induced pluripotent stem cells. Without being bound by any particular theory, modified RNA (e.g., mRNA) may have the advantages of minimal activation of the innate immune response and limited cytotoxicity, thereby allowing robust and sustained protein expression. In some embodiments, the RNA (e.g., mRNA) contains modifications that include full substitution of either cytidine with 5-methylcytidine (5mC) or uridine with pseudouridine (psi).

[0202] In some embodiments, OCT4, KLF4, and / or SOX2 expression can be activated using a CRISPR activation system. In some embodiments, the expression of one or more transcription factors selected from the group consisting of OCT4, KLF4, SOX2, and combinations thereof can be activated using a CRISPR activation system. See, for example, Liao et al., Cell. 2017 Dec 14;171(7):1495-1507.e15; Liu et al., 2018, Cell Stem Cell 22, 1-10, February 1, 2018. Generally, the CRISPR activation system includes an enzymatically dead Cas9 nuclease (or nuclease-deficient Cas9 (dCas9)) fused to a transcription activation complex (e.g., including VP64, P65, Rta, and / or MPH). Non-limiting examples of sequences encoding VP64, P65, Rta, and / or MPH are provided below. VP64, P65, Rta, or MPH can be encoded by a sequence containing a sequence at least 70% (e.g., 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to any of the VP64, P65, Rta, and / or MPH sequences described herein. This Cas9 fusion protein can be referred to as a CRISPR activator. A guide RNA targeting the promoter and / or enhancer region of a gene of interest is used in the CRISPR activation system to target the dCas9-transcriptional activation complex and drive expression of the endogenous gene.

[0203] In some embodiments, expression of OCT4; KLF4; SOX2; or any combination thereof can be activated using a transcription activator-like effector nuclease (TALEN) or zinc finger nuclease (ZFN) system.

[0204] The engineered nucleic acids of the present disclosure may encode sgRNAs for targeting the promoter and / or enhancer regions of the endogenous loci of OCT4, SOX2, and / or KLF4 in a cell. The engineered nucleic acids of the present disclosure may encode sgRNAs for targeting the promoter and / or enhancer regions of the endogenous loci of one or more transcription factors selected from OCT4; SOX2; KLF4; and any combination thereof in a cell. In some embodiments, the engineered nucleic acid (e.g., an expression vector) further encodes dCas9 (dead Cas9) and a transcription activation complex (e.g., VP64, P65, Rta, MPH). In some embodiments, dCas9 (dead Cas9) and a transcription activation complex (e.g., VP64, P65, Rta, MPH) are administered to a cell on an engineered nucleic acid (e.g., an expression vector). In some embodiments, the vector encoding the sgRNA and / or dCas9 (dead Cas9) and transcription activation complex (e.g., VP64, P65, Rta, MPH) is a viral vector (e.g., an AAV vector). In some embodiments, the dCas9 (dead Cas9) and transcription activation complex (e.g., VP64, P65, Rta, MPH) are introduced into cells as proteins.

[0205] In some embodiments, guide RNAs targeting the enhancer and / or promoter regions of OCT4, SOX2, and / or KLF4 are formulated as nanoparticles and co-injected with dCas9-VP64 protein. In some embodiments, guide RNAs targeting the enhancer and / or promoter regions of OCT4, SOX2, KLF4, or any combination thereof are formulated as nanoparticles and co-injected with dCas9-VP64 protein. In some embodiments, guide RNAs and / or nucleic acids encoding dCas9 (dead Cas9) and transcriptional activation complexes (e.g., VP64, P65, Rta, MPH) are administered as naked nucleic acids (e.g., naked DNA formulated in nanoparticles). In some embodiments, the guide RNA and / or nucleic acid encoding dCas9 (dead Cas9) and a transcription activation complex (e.g., VP64, P65, Rta, MPH) is delivered by a recombinant virus (e.g., a lentivirus, adenovirus, retrovirus, herpesvirus, alphavirus, vaccinia virus, or adeno-associated virus (AAV)).

[0206] Non-limiting example sequences of guide RNAs targeting the endogenous OCT4 or SOX2 locus are provided by Liu et al., Cell Stem Cell. 2018 Feb 1;22(2):252-261.e4. Non-limiting examples of guide RNAs targeting OCT4, SOX2, and / or KLF4 are also provided by Weltner et al., Nat Commun. 2018 Jul 6;9(1):2643.

[0207] Without being bound by any particular theory, the use of the CRISPR-CAS9 system to activate endogenous expression of OCT4, KLF4, and / or SOX2 in the absence of c-Myc expression may eliminate potential toxicity associated with exogenous and / or supraphysiological gene expression.

[0208] Nucleic acids (e.g., engineered nucleic acids) encoding transcription factors (OCT4, SOX2, KLF4, or any combination thereof) or encoding inducers can be introduced onto expression vectors using conventional cloning techniques. Suitable expression vectors include vectors having a promoter (e.g., a constitutive or inducible promoter, including a TRE promoter) and a terminator sequence (e.g., an SV40 sequence described herein) operably linked to a nucleic acid (e.g., an engineered nucleic acid) encoding OCT4, SOX2, KLF4, or any combination thereof. In some embodiments, the nucleic acid (e.g., an engineered nucleic acid) encodes a promoter operably linked to a nucleic acid encoding an inducer. In some embodiments, the vector comprises a WPRE sequence. Expression vectors containing the necessary elements for expression are commercially available and known to those of skill in the art (see, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, Fourth Edition, Cold Spring Harbor Laboratory Press, 2012).

[0209] The vectors of the present invention may further contain marker sequences for use in identifying cells that have or have not been transformed or transfected with the vector, or that have been reprogrammed. Markers include, for example, genes encoding proteins that increase or decrease either resistance or sensitivity to antibiotics or other compounds (e.g., ampicillin resistance genes, kanamycin resistance genes, neomycin resistance genes, tetracycline resistance genes, and chloramphenicol resistance genes), genes encoding enzymes having activities detectable by standard assays known in the art (e.g., β-galactosidase, senescence-associated β-galactosidase, luciferase, or alkaline phosphatase), and genes that visibly affect the phenotype of transformed or transfected cells, hosts, colonies, or plaques (e.g., green fluorescent protein). In some embodiments, the vectors used herein are capable of autonomous replication and expression of structural gene products present on the DNA segments to which they are operably linked.

[0210] In certain embodiments, the expression vector comprises an inducible promoter (e.g., a tetracycline-responsive promoter) operably linked to a sequence encoding a transcription factor (e.g., OCT4, SOX2, KLF4, or any combination thereof). In certain embodiments, the promoter operably linked to a sequence encoding a transcription factor (e.g., OCT4, SOX2, KLF4, or any combination thereof) is a tissue- or cell-type-specific promoter (e.g., a brain-specific, liver-specific, muscle-specific, neuronal-cell-specific, glial-cell-specific, endothelial-cell-specific, lung-specific, heart-specific, bone-specific, gut-specific, skin-specific promoter, or eye-specific promoter). By way of example, a muscle-specific promoter can be the desmin promoter (e.g., a sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO:29). In some embodiments, the eye-specific promoter can be a promoter that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to a sequence selected from SEQ ID NOs: 101-104.

[0211] In certain embodiments, the promoter operably linked to a sequence encoding a transcription factor (e.g., OCT4, SOX2, KLF4, or any combination thereof) is age- or senescence-specific (e.g., the age- or senescence-specific promoter can be the p16 promoter or a Cas9-directed transcription factor that binds to methylated DNA, which is known to accumulate with age).

[0212] In certain embodiments, the expression vector comprises a constitutive promoter operably linked to a nucleic acid (e.g., an engineered nucleic acid) encoding OCT4, SOX2, KLF4, or any combination thereof. In some embodiments, such vectors can be inactivated using a clustered regularly interspaced short palindromic repeats (CRISPR) / guide RNA system. For example, the guide RNA can be complementary to the vector and can target Cas9 nuclease to the vector. In some embodiments, the guide RNA is complementary to a transgene (e.g., a transgene encoding OCT4, KLF4, SOX2, or a combination thereof) in any of the expression vectors described herein. Cas9 can then create a double-strand break in the vector and / or mutate the vector, rendering it inactive.

[0213] In certain embodiments, the promoter operably linked to the inducer-encoding sequence is a constitutive promoter (e.g., CMV, EF1 alpha, SV40 promoter, PGK1, UBC, CAG, human beta-actin gene promoter, or UAS). In certain embodiments, the promoter operably linked to the inducer-encoding sequence is a tissue-specific promoter (e.g., a brain-specific, liver-specific, muscle-specific, neuron-specific, lung-specific, heart-specific, bone-specific, gut-specific, skin-specific promoter, or eye-specific promoter). By way of example, a muscle-specific promoter can be the desmin promoter (e.g., a sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO:29).

[0214] The nucleic acid (e.g., an engineered nucleic acid) (e.g., an expression vector) may further comprise a separator sequence (e.g., an IRES or polypeptide cleavage signal). Exemplary polypeptide cleavage signals include 2A peptides (e.g., T2A, P2A, E2A, and F2A). The 2A peptide may comprise a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO:9. In a nucleic acid (e.g., an engineered nucleic acid) (e.g., an expression vector) encoding more than one transcription factor (e.g., OCT4, SOX2, KLF4, or any combination thereof), each transcription factor may be operably linked to a different promoter or to the same promoter. The transcription factors may be separated on the nucleic acid (e.g., by a peptide separator sequence). Expression of the nucleic acid (e.g., an engineered nucleic acid) results in distinct amino acid sequences encoding each transcription factor.

[0215] In certain embodiments, expression vectors of the present disclosure (e.g., expression vectors encoding OCT4, KLF4, SOX2, or combinations thereof) may further comprise a selection agent (e.g., an antibiotic, including blasticidin, geneticin, hygromycin B, mycophenolic acid, puromycin, zeocin, actinomycin D, ampicillin, carbenicillin, kanamycin, and neomycin) and / or a detectable marker (e.g., GFP, RFP, luciferase, CFP, mCherry, DsRed2FP, mKate, biotin, FLAG tag, HA tag, His tag, Myc tag, V5 tag, etc.).

[0216] In certain embodiments, expression vectors encoding inducers of the present disclosure may further comprise a selection agent (e.g., an antibiotic, including blasticidin, geneticin, hygromycin B, mycophenolic acid, puromycin, zeocin, actinomycin D, ampicillin, carbenicillin, kanamycin, and neomycin) and / or a detectable marker (e.g., GFP, RFP, luciferase, CFP, mCherry, DsRed2FP, mKate, biotin, FLAG tag, HA tag, His tag, Myc tag, V5 tag, etc.).

[0217] In certain embodiments, the expression vector (e.g., encoding OCT4, SOX2, KFF4, or any combination thereof) is present on a viral vector (e.g., an AAV vector). In certain embodiments, the expression vector encoding the inducer is present on a viral vector (e.g., an AAV vector). AAV vectors used herein generally include ITRs flanking an expression cassette (e.g., a nucleic acid (e.g., an engineered nucleic acid) comprising a promoter sequence and a terminator sequence operably linked to a sequence encoding OCT4, SOX2, KFF4, or any combination thereof, a nucleic acid (e.g., an engineered nucleic acid) comprising a promoter sequence operably linked to a sequence encoding an inducer, or a combination thereof).

[0218] In certain embodiments, the number of base pairs between two ITRs on an AAV vector of the present disclosure is less than 5 kilobases (kb) (e.g., less than 4.9 kb, less than 4.8 kb, less than 4.7 kb, less than 4.6 kb, less than 4.5 kb, less than 4.4 kb, less than 4.3 kb, less than 4.2 kb, less than 4.1 kb, less than 4 kb, less than 3.5 kb, less than 3 kb, less than 2.5 kb, less than 2 kb, less than 1.5 kb, less than 1 kb, or less than 0.5 kb). In certain embodiments, an AAV vector having a distance of less than 4.7 kb between two ITRs has a minimum of 0.5 x 10 10 particle-forming units per ml (pfu / ml), at least 1 × 10 10 pfu / ml, at least 5 × 10 10pfu / ml, at least 1 × 10 11 pfu / ml, at least 5 × 10 11 pfu / ml, at least 1 × 10 12 pfu / ml, at least 2 × 10 12 pfu / ml, at least 3 × 10 12 pfu / ml, at least 4 × 10 12 pfu / ml, at least 5 × 10 12 pfu / ml, at least 6 × 10 12 pfu / ml, at least 7 × 10 12 pfu / ml, at least 8 × 10 12 pfu / ml, at least 9 × 10 12 pfu / ml, or at least 1 × 10 13 It can be packaged into virus at titers of pfu / ml.

[0219] In certain embodiments, expression vectors of the disclosure are at least 1 kilobase (kb) (e.g., at least 1 kb, 2 kb, 3 kb, 4 kb, 5 kb, 6 kb, 7 kb, 8 kb, 9 kb, 10 kb, 50 kb, or 100 kb). In certain embodiments, expression vectors of the disclosure are less than 10 kb (e.g., less than 9 kb, less than 8 kb, less than 7 kb, less than 6 kb, less than 5 kb, less than 4 kb, less than 3 kb, less than 2 kb, or less than 1 kb).

[0220] Without being bound by any particular theory, compared with separate nucleic acids (e.g., engineered nucleic acids) encoding one or two of the transcription factors, an expression vector (e.g., an AAV vector) encoding OCT4, SOX2, and KLF4 under a single promoter results in more efficient transduction of all three transcription factors in vivo. In certain embodiments, the infection efficiency of a recombinant virus (e.g., lentivirus, alphavirus, vaccinia virus, retrovirus, adenovirus, herpesvirus, or AAV) carrying a vector of the present disclosure in a cell (e.g., an animal cell, including a mammalian cell) is at least 20% (e.g., at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, or 100%). Recombinant viruses

[0221] Aspects of the present disclosure provide recombinant viruses (e.g., lentivirus, alphavirus, vaccinia virus, adenovirus, herpesvirus, retrovirus, or AAV). The recombinant viruses (e.g., lentivirus, alphavirus, vaccinia virus, adenovirus, herpesvirus, retrovirus, or AAV) can carry nucleic acids (e.g., engineered nucleic acids) (e.g., expression vectors) encoding transcription factors (e.g., OCT4, SOX2, KLF4, or any combination thereof), or combinations thereof. In some embodiments, the recombinant viruses carry nucleic acids encoding at least two transcription factors selected from OCT4, SOX2, and KLF4 (e.g., OCT4 and SOX2; KLF4 and SOX2; OCT4, KLF4, and SOX2; or OCT4 and KLF4). In some embodiments, the recombinant viruses carry nucleic acids encoding at least three transcription factors selected from OCT4, SOX2, and KLF4 (e.g., OCT4, SOX2, and KLF4). In some cases, the recombinant viruses of the present disclosure include a nucleic acid encoding an inducer.

[0222] In certain embodiments, the recombinant virus is a recombinant AAV. In some embodiments, the recombinant AAV has tissue-specific targeting capability, such that the AAV transgene will be specifically delivered to one or more predetermined tissue(s). Generally, the AAV capsid is the relevant factor in determining the tissue-specific targeting capability of AAV. The AAV capsid may comprise an amino acid sequence derived from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, and variants thereof. Non-limiting examples of the tissue specificity of AAV serotypes are provided in Table 1. An "x" indicates that the indicated AAV serotype can deliver a transgene to a specific tissue. Table 1. Non-limiting examples of AAV serotypes and their utility in specific tissues [Table 1]

[0223] Recombinant AAV containing specific capsid proteins can be generated using any suitable method. See, for example, U.S. Patent Application Publication US2003 / 0138772, incorporated herein by reference. AAV capsid protein sequences are also known in the art. See, for example, published PCT application WO2010 / 138263, incorporated herein by reference. Generally, recombinant AAV is generated by a host cell from the following components: (1) a nucleic acid (e.g., an engineered nucleic acid) sequence encoding an AAV capsid protein or a fragment thereof, (2) a nucleic acid (e.g., an engineered nucleic acid) encoding a functional rep gene, (3) a recombinant AAV vector containing AAV terminal inverted repeats flanking a transgene (e.g., a nucleic acid (e.g., an engineered nucleic acid) encoding OCT4, KLF4, SOX2, or a combination thereof), and (4) helper functions that allow packaging of the recombinant AAV vector by the AAV capsid protein. In some cases, the recombinant AAV vector comprises a nucleic acid encoding an inducer. In certain embodiments, helper functions are introduced by helper vectors known in the art.

[0224] In some cases, a suitable host cell line (e.g., HEK293T cells) can be routinely used to produce the recombinant AAV disclosed herein. One or more expression vectors encoding one or more of the above-described components can be introduced into the host cell by exogenous nucleic acid (e.g., engineered nucleic acid), which can be cultured under suitable conditions that allow the production of AAV particles. When needed, a helper vector can be used to facilitate replication, assembly of AAV particles, or any combination thereof. In certain embodiments, the recombinant AAV vector is present on a nucleic acid (e.g., engineered nucleic acid) that is separate from other components (e.g., a nucleic acid (e.g., engineered nucleic acid) sequence encoding an AAV capsid protein or fragment thereof, a nucleic acid (e.g., engineered nucleic acid) encoding a functional rep gene, and helper functions that allow packaging of the recombinant AAV vector by the AAV capsid protein). In certain embodiments, the host cell can stably express one or more components required to produce an AAV virus. In that case, the remaining components can be introduced into host cells, the cell culture supernatant can be collected, and the viral particles contained therein can be harvested by conventional methodologies. Methods for activating OCT4, SOX2, and KLF4, alone or in combination, and their substitutes

[0225] Aspects of the present disclosure, in some embodiments, relate to activating OCT4, SOX2, and KLF4, either alone or in combination, in cells, tissues, and / or organs. In some embodiments, OCT4, SOX2, and KLF4, either alone or in combination, are activated in the absence of c-Myc activation. Cells, tissues, and / or organs can be in vivo (e.g., within a subject) or ex vivo. As used herein, activation encompasses any nucleic acid (e.g., nucleic acid including RNA, including DNA, or any combination thereof), protein, antibody, chemical agent, or any combination thereof, that can increase the biological activity of a protein of interest (e.g., OCT4, SOX2, and / or KLF4). Biological activity (e.g., gene expression, reprogramming ability, transcription factor activity, etc.) can be measured using any conventional method known in the art. In some embodiments, any nucleic acid (e.g., RNA-containing, DNA-containing, or any combination thereof), protein, antibody, chemical agent, or any combination thereof described herein replaces OCT4, SOX2, and / or KLF4. In some embodiments, any nucleic acid (e.g., RNA-containing, DNA-containing, or any combination thereof), protein, antibody, chemical agent, or any combination thereof described herein replaces OCT4, SOX2, KLF4, or any combination thereof. In some embodiments, any of the nucleic acids (e.g., engineered nucleic acids) encoding inducers, engineered proteins encoding inducers, chemical agents that can modulate (e.g., activate or inhibit) the activity of inducers, and / or recombinant viruses encoding inducers described herein are used to activate inducers.

[0226] Activation of OCT4, SOX2, and KLF4, each alone or in combination, includes increasing the expression (eg, RNA and / or protein expression) of OCT4, SOX2, and KLF4, each alone or in combination. In some embodiments, following administration to a cell, tissue, organ, and / or subject of a nucleic acid (e.g., a nucleic acid including RNA, including DNA, or any combination thereof) encoding OCT4, SOX2, and / or KLF4, a protein encoding OCT4, SOX2, and / or KLF4, an antibody capable of activating the encoding of OCT4, SOX2, and / or KLF4, a chemical agent capable of activating the encoding of OCT4, SOX2, and / or KLF4, or any combination thereof, expression of OCT4, SOX2, and KLF4, each alone or in combination, is increased by at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or 1000% compared to before administration. In some embodiments, following administration to a cell, tissue, organ, and / or subject of a nucleic acid (e.g., a nucleic acid including RNA, including DNA, or any combination thereof) encoding OCT4, SOX2, KLF4, or any combination thereof, a protein encoding OCT4, SOX2, KLF4, or any combination thereof, an antibody capable of activating the encoding of OCT4, SOX2, KLF4, or any combination thereof, a chemical agent capable of activating the encoding of OCT4, SOX2, KLF4, or any combination thereof, or any combination thereof, the expression of OCT4, SOX2, and KLF4, each alone or in combination, is increased by at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or 1000%, compared to before administration.

[0227] Activation of an inducer includes increasing expression (e.g., RNA and / or protein expression) of the inducer. In some embodiments, after administration of a nucleic acid (e.g., a nucleic acid including RNA, including DNA, or any combination thereof) encoding the inducer, a protein encoding the inducer, a chemical agent capable of modulating the activity of the inducer, or any combination thereof to a cell, tissue, organ, and / or subject, expression of the inducer is increased by at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or 1000% compared to before administration.

[0228] Expression can be measured by any conventional method known in the art, including quantifying the levels of the protein of interest (e.g., using ELISA and / or Western blot analysis with an antibody that recognizes the protein of interest) or quantifying the RNA (e.g., mRNA) levels of the gene of interest (e.g., using reverse transcription polymerase chain reaction).

[0229] In addition to the engineered nucleic acids discussed herein, OCT4, SOX2, and KLF4, alone or in combination, can be activated in cells, tissues, organs, and / or subjects by the use of engineered proteins. For example, proteins encoding OCT4, SOX2, and / or KLF4 can be produced (e.g., recombinantly or synthetically) and administered to cells, tissues, organs, and / or subjects by any suitable route. For example, proteins encoding one or more transcription factors selected from the group consisting of OCT4; SOX2; KLF4; and any combination thereof can be produced (e.g., recombinantly or synthetically) and administered to cells, tissues, organs, and / or subjects by any suitable route.

[0230] In some embodiments, activating the expression of OCT4; SOX2; KLF4; their substitutes; or any combination thereof from a tetracycline-inducible expression vector comprises administering tetracycline (e.g., doxycycline) to a cell, organ, tissue, or subject. As one skilled in the art would understand, the route of tetracycline administration can depend on the type of cell, organ, tissue, and / or the nature of the subject. In some embodiments, tetracycline is administered directly to a cell, organ, and / or tissue. By way of non-limiting example, tetracycline can be administered to the subject's eye by any suitable method, including tetracycline-containing eye drops, sustained-release devices (e.g., micropumps, particles, and / or depots), and tetracycline-containing therapeutic contact lenses. In some embodiments, tetracycline is administered systemically to a subject (e.g., via drinking water or intravenous injection). Tetracycline can be administered topically (e.g., via a cream) or via a subcutaneous pump (e.g., to deliver tetracycline to specific tissues). Tetracyclines can be administered intravenously, intradermally, intra-arterially, intralesionally, intratumorally, intracranially, intra-articularly, intraprostatically, intrapleurally, intranasally, intravitreally, intravaginally, intrarectally, topically, intratumorally, intramuscularly, intraperitoneally, subcutaneously, subconjunctivally, intravesicularly, mucosally, intrapericardially, intraumbilically, intraocularly, orally, topically, locally, systemically, by injection, infusion, continuous infusion, localized irrigation bathing directly in target cells, by catheter, by cream, by particles (e.g., nanoparticles, microparticles), by lipid compositions (e.g., liposomes), or by other methods known to those skilled in the art or by any combination of the foregoing (see, e.g., Remington's Pharmaceutical Sciences (1990), incorporated herein by reference).

[0231] By way of non-limiting example, engineered proteins can be further modified or formulated for delivery to cells, tissues, organs, and / or subjects. For example, a protein transduction domain (i.e., a PTD or cell-penetrating peptide) can be attached to an engineered protein (e.g., OCT4, SOX2, and / or KLF4). By way of non-limiting example, a protein transduction domain (i.e., a PTD or cell-penetrating peptide) can be attached to an engineered protein encoding an inducer. Without being bound by any particular theory, protein transduction domains facilitate the delivery of cargo (e.g., proteins, nucleic acids, nanoparticles, viral particles, etc.) across cell membranes. Protein transduction domains include cationic peptides, hydrophobic peptides, and / or cell-specific peptides. See, e.g., Zhou et al., Cell Stem Cell. 2009 May 8;4(5):381-4; Zahid et al., Curr Gene Ther. 2012 Oct;12(5):374-80.

[0232] In some embodiments, proteins encoding OCT4, SOX2, and / or KLF4 and / or inducers are formulated in nanoparticles (e.g., for nuclear delivery). In some embodiments, proteins encoding OCT4, SOX2, KLF4, or any combination thereof (e.g., OCT4 and SOX2; KLF4 and SOX2; OCT4 and KLF4; or KLF4, SOX2, and OCT4) are formulated in nanoparticles (e.g., for nuclear delivery). In certain embodiments, the nanoparticles further comprise proteins encoding inducers. For example, chitosan [poly(N-acetylglucosamine)] is a biodegradable polysaccharide that can be used to formulate nanoparticles by several methods. In some embodiments, chitosan polymer nanoparticles are loaded with proteins encoding OCT4, SOX2, and / or KLF4 and / or inducers and delivered to the nucleus of a cell. See, e.g., Tammam et al., Oncotarget. 2016 Jun 21;7(25):37728-37739.

[0233] In some embodiments, the chemical agent, antibody, and / or protein displaces OCT4, SOX2, and / or KLF4. In some embodiments, the chemical agent, antibody, protein, or any combination thereof displaces OCT4, SOX2, KLF4, or any combination thereof (e.g., OCT4 and SOX2; OCT4 and KLF4; KLF4 and SOX2; or KLF4, SOX2, and OCT4). For example, the chemical agent, antibody, and / or protein may promote expression of OCT4, SOX2, and / or KLF4. In certain cases, the chemical agent, antibody, and / or protein may promote expression of one or more transcription factors selected from OCT4; SOX2; KLF4; and any combination thereof. In some embodiments, the chemical agent, antibody, and / or protein may activate downstream target genes of OCT4, SOX2, and / or KLF4. In some embodiments, a chemical factor, antibody, protein, or any combination thereof can activate downstream target genes of one or more transcription factors selected from the group consisting of OCT4; SOX2; KLF4; and any combination thereof. In some embodiments, a chemical factor, antibody, and / or protein is said to substitute for OCT4, SOX2, and / or KLF4 when used together with two other transcription factors and can promote cellular reprogramming. In some embodiments, a chemical factor, antibody, protein, or any combination thereof is said to substitute for OCT4, SOX2, KLF4, or any combination thereof when used together with two other transcription factors and can promote cellular reprogramming. For example, cellular reprogramming can be determined by measuring gene expression (e.g., expression of embryonic markers and / or pluripotency markers). In some embodiments, pluripotency markers include AP, SSEA1, and / or Nanog.

[0234] In some embodiments, the antibody is used to activate OCT4, SOX2, and / or KLF4. In some embodiments, the antibody is used to activate one or more transcription factors selected from OCT4, SOX2, KLF4, or any combination thereof. In some embodiments, the antibody does not target OCT4, SOX2, and / or KLF4. In some embodiments, the antibody does not target OCT4, SOX2, KLF4, or any combination thereof. In some embodiments, the antibody increases expression of OCT4, SOX2, and / or KLF4. In some embodiments, the antibody increases expression of OCT4, SOX2, KLF4, or any combination thereof. In some embodiments, the antibody does not increase expression of OCT4, SOX2, and / or KLF4. In some embodiments, the antibody displaces OCT4, SOX2, and / or KLF4. In some embodiments, the antibody does not increase expression of OCT4, SOX2, KLF4, or any combination thereof. In some embodiments, the antibody substitutes for OCT4, SOX2, KLF4, or any combination thereof. Any suitable method for identifying an antibody that can substitute for a transcription factor (e.g., OCT4, SOX2, and / or KLF4) can be used. Any suitable method for identifying an antibody that can substitute for a transcription factor (e.g., OCT4, SOX2, KLF4, or any combination thereof) can be used. See, e.g., Blanchard et al., Nat Biotechnol. 2017 Oct;35(10):960-968.

[0235] In some embodiments, another protein (e.g., a nucleic acid encoding the protein or a polypeptide encoding the protein) can be used to replace OCT4, SOX2, and / or KLF4. In some embodiments, another protein (e.g., a nucleic acid encoding the protein or a polypeptide encoding the protein) can be used to replace OCT4, SOX2, KLF4, or a combination thereof. For example, OCT4 can be replaced by Tet1, NR5A-2, Sall4, E-cadherin, NKX3-1, or any combination thereof. In some embodiments, OCT4, SOX2, and / or KLF4 can be replaced by NANOG and / or TET2. In some embodiments, OCT4, SOX2, KLF4, or any combination thereof can be replaced by NANOG and / or TET2. See, e.g., Nat Cell Biol. 2018 Aug;20(8):900-908; Gao et al., Cell Stem Cell. 2013 Apr 4;12(4):453-69. Nanog and Lin28 can replace Klf4. See, e.g., Yu et al., Science. 318, 1917-1920, 2007). In some embodiments, OCT4, SOX2, and / or KLF4 are replaced by Tet3 (Tet methylcytosine dioxygenase 3). In some embodiments, OCT4, SOX2, KLF4, or any combination thereof are replaced by Tet3 (Tet methylcytosine dioxygenase 3). In some embodiments, the nucleic acid encoding the Tet1 DNA demethylase comprises a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to NM_030625.3 or NM_001253857.2. In some embodiments, the amino acid encoding the Tet1 DNA demethylase comprises a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to NP_085128.2 or NP_001240786.1.In some embodiments, the nucleic acid encoding the Tet2 DNA demethylase comprises a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to NM_001127208.2, NM_001040400.2, NM_001346736.1, or NM_017628.4. In some embodiments, the amino acid encoding the Tet2 DNA demethylase comprises a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to NP_060098.3, NP_001035490.2, NP_001333665.1, or NP_001120680.1. In some embodiments, the nucleic acid encoding the Tet3 DNA demethylase comprises a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to NM_001287491.2, NM_001347313.1, NM_183138.2, or NM_001366022.1. In some embodiments, the amino acid encoding the Tet3 DNA demethylase comprises a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to NP_001274420.1, NP_001334242.1, NP_898961.2, or NP_001352951.1. Tet1, Tet2, and / or Tet3 can be derived from any species. In some embodiments, Tet1, Tet2, and / or Tet3 are truncated forms of their wild-type counterparts. As a non-limiting example, Tet1, Tet2, and / or Tet3 are N-terminally truncated and catalytically active compared to their wild-type Tet1, Tet2, and / or Tet3 counterparts. In some embodiments, Tet1, Tet2, and / or Tet3 comprise only the catalytic domain of Tet1, Tet2, and / or Tet3. In some embodiments, Tet1, Tet2, and / or Tet3 comprise the catalytic domain of Tet1, Tet2, Tet3, or any combination thereof.Non-limiting examples of functional truncated Tet1 can be found in Hrit et al., Elife. 2018 Oct 16;7. pii: e34870.

[0236] Additional methods for substituting OCT4, SOX2, and / or KLF4 to promote cellular reprogramming are known in the art. For example, Heng et al., Cell Stem Cell 6, 167-174 (2010);Eguchi et al., Proc. Natl Acad. Sci. USA 113, E8257-E8266 (2016);Gao et al., Cell Stem Cell 12, 453-469 (2013);Long et al., Cell Res. 25, 1171-1174 (2015);Hou et al., Science 341, 651-654 (2013);Redmer et al., EMBO Rep. 12, 720-726 (2011);Tan et al., J. Biol. Chem. 290, 4500-4511 (2014);Anokye-Danso et al. al., Cell Stem Cell 8, 376-388 (2011); Miyoshi et al., Cell Stem Cell 8, 633-638 (2011); Shu et al., Cell 153, 963-975 (2013); Yu, J. et al., Science 318, 1917-1920 (2007).

[0237] In some embodiments, chemical factors replace OCT4, SOX2, and / or KLF4 (e.g., can be used in place of OCT4, SOX2, and / or KLF4 in conjunction with two other transcription factors to promote cell reprogramming). In some embodiments, chemical factors replace OCT4, SOX2, KLF4, or any combination thereof (e.g., can be used in place of OCT4, SOX2, KLF4, or any combination thereof in conjunction with two other transcription factors to promote cell reprogramming). For example, SOX2 can be replaced by CHIR, FSK, or 616452. OCT4 can be replaced by DZNep. Since Sall4 can be used to replace OCT4 as mentioned above, any compound that replaces Sall4 can also be used to replace OCT4. For example, CHIR, FSK, and 616452 can be used to replace Sall4. Nanog can be replaced by 2i medium. See, e.g., Hou et al., Science. 2013 Aug 9;341(6146):651-4. See also, e.g., Zhao et al., Cell. 2015 Dec 17;163(7):1678-91.

[0238] In some embodiments, chemical reprogramming comprises using chemical substances that reduce the toxicity of the chemical factor that induces reprogramming.Non-limiting examples of chemical substances that reduce the toxicity of chemical reprogramming include ROCK inhibitors (for example, Y27632 and Fasudil) and P38 MAPK inhibitors (for example, SB203580 and BIRB796).See, for example, Li et al., Cell Stem Cell.2015 Aug 6;17(2):195-203.

[0239] OCT4, KLF4, SOX2, alternatives, or any combination thereof can be activated (e.g., expression can be induced) in combination with activating a reprogramming enhancer and / or inhibiting a reprogramming barrier. Reprogramming enhancers can be activated using any suitable method known in the art, including overexpressing the enhancer, increasing the expression of endogenous genes encoding the enhancer (e.g., using CRISPR technology), using chemical agents and / or antibodies to increase the biological activity of the enhancer, and using chemical agents and / or antibodies to promote the expression of the enhancer. Reprogramming barriers can be inhibited using any suitable method known in the art, including knocking down the expression of inhibitors (e.g., by siRNA, miRNA, shRNA), knocking out endogenous copies of the inhibitor (e.g., using CRISPR technology, TALEN, zinc finger nucleases, etc.), using chemical agents and / or antibodies to reduce the biological activity of the inhibitor, and using chemical agents and / or antibodies to reduce the expression of the inhibitor.

[0240] Non-limiting examples of enhancers and barriers to reprogramming are provided by Table 2. See also, e.g., Ebrahimi, Cell Regen (Lond). 2015 Nov 11;4: 10, which is incorporated by reference in its entirety for this purpose. Table 2. Non-limiting examples of strategies to enhance reprogramming [Table 2]

[0241] Additional reprogramming enhancing factors that can be activated in combination with OCT4, KLF4, SOX2, their substitutes, or any combination thereof include histone lysine demethylases (e.g., KDM2, KDM3, and KDM4). Histone lysine demethylases can be activated by being overexpressed in cells, tissues, organs, and / or subjects. Chemical activators of histone lysine demethylases are also encompassed by the present disclosure. For example, vitamin C can be used to activate KDM3 and / or KDM4.

[0242] In some embodiments, OCT4, SOX2, KLF4, their surrogates, or any combination thereof are activated in conjunction with the activation of C / EBRα and Tfcp2l 1. Without being bound by any particular theory, C / EBRα and Tfcp2l 1, together with Klf4, may drive enhancer demethylation and activation mediated by Tet2 during reprogramming.

[0243] In some embodiments, OCT4, SOX2, KLF4, their substitutes, or any combination thereof are activated in cells, tissues, organs, and / or subjects in combination with cytokines that facilitate reprogramming. IL6 is a non-limiting example of a cytokine. See, e.g., Mosteiro et al., Science. 2016 Nov 25;354(6315), which is incorporated herein by reference in its entirety for this purpose.

[0244] In some embodiments, OCT4, SOX2, KLF4, their substitutes, or any combination thereof are activated in cells, tissues, organs, and / or subjects in combination with miRNA activation (e.g., miRNA administration and / or miRNA expression). For example, miRNAs that promote cell cycle progression can be introduced into cells, tissues, organs, and / or subjects. Non-limiting examples of miRNAs that promote cell cycle progression include miR302-367, miR371-373, miR-200b, miR-200c, miR-205, miR290-295, miR-93, miR-106, and miR135b.

[0245] By way of non-limiting example, neural regeneration can be enhanced by combining activation of OCT4, SOX2, KLF4, their surrogates, or any combination thereof with activation of enhancers, including overexpression of KLF family members (e.g., KLF7), overexpression of c-Myc, STAT3 activation, overexpression of SOX11, overexpression of Lin28, overexpression or delivery of soluble proteins encoding insulin-like growth factor 1 (IGF1) and osteopontin (OPN), and activation of B-RAF (e.g., introduction of a gain-of-function mutation). For example, Blackmore et al., Proc Natl Acad Sci US A. 2012 May 8;109(19):7517-22;Belin et al., Neuron. 2015 May 20;86(4): 1000-1014;Bareyre et al., Proc Natl Acad Sci USA. 2011 Apr 12;108(15):6282-7;Norsworthy et al., Neuron. 2017 Jun 21;94(6):1112-1120.e4;Wang et al., Cell Rep. 2018 Sep 4;24(10):2540-2552.e6;Liu et al., Neuron. 2017 Aug 16;95(4):817-833;O'Donovan et al., J Exp Med, 2014. 211(5): pp. 801-14, each of which is incorporated herein by reference in its entirety for this purpose.

[0246] In some embodiments, OCT4, SOX2, KLF4, their substitutes, or any combination thereof are activated in cells, tissues, organs, and / or subjects in combination with the suppression or knockdown of reprogramming barriers. Non-limiting examples of reprogramming barriers include Chaf1a, Chaf1b, Ube2i, sumo2, and / or Nudt21. See, e.g., Brumbaugh et al., Cell. 2018 Jan 11;172(1-2):106-120.e21; Cheloufii et al., Nature. 2015 Dec 10;528(7581):218-24; and Borkent et al., Stem Cell Reports, 2016.6(5):p.704-716, each of which is incorporated herein by reference in its entirety for this purpose.

[0247] As a non-limiting example, the reprogramming barrier may be a DNA methyltransferase (DNMT), and inhibiting the DNMT may promote tissue, cell, and / or organ reprogramming. Most DNA methyltransferases use S-adenosyl-L-methionine as the methyl donor. The DNMT may be from any species. There are at least three different types of methyltransferases: m6A methyltransferase can methylate the amino group at the c-6 position of adenine on DNA (e.g., Enzyme Commission (EC) No. 2.1.1.72); m4C methyltransferase can generate N4-methylcytosine (e.g., Enzyme Commission (EC) No. 2.1.1.113); and M5C methyltransferase can generate C5-methylcytosine (e.g., Enzyme Commission (EC) No. 2.1.1.37).

[0248] Non-limiting examples of mammalian DNA methyltransferases (DNMTs) include DNMT1 and its isoforms DNMT1b and DNMT1o (egg-specific), DNMT3a, DNMT3b, and DNMT3L. GenBank Accession Nos. NM_001130823.3 (isoform a), NM_001318730.1 (isoform c), NM_001318731.1 (isoform d), and NM_001379.3 (isoform b) are non-limiting examples of nucleotide sequences encoding human DNMT1. Nucleic acids encoding DNMT1 can include sequences that are at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to the sequences submitted by GenBank Accession Nos. NM_001130823.3 (isoform a), NM_001318730.1 (isoform c), NM_001318731.1 (isoform d), and / or NM_001379.3 (isoform b). GenBank Accession Nos. NP_001124295.1 (isoform a), NP_001305659.1 (isoform c), NP_001305660.1 (isoform d), and NP_001370.1 (isoform b) are non-limiting examples of amino acid sequences encoding human DNMT1. The amino acid sequence encoding DNMT1 can include a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to the sequence submitted by GenBank Accession Nos. NP_001124295.1 (isoform a), NP_001305659.1 (isoform c), NP_001305660.1 (isoform d), and / or NP_001370.1 (isoform b). Nucleic acids encoding human DNMT3A include GenBank Accession Nos. NM_001320892.1, NM_001320893.1, NM_022552.4, NM_153759.3, NM_175629.2, and NM_175630.1.Nucleic acids encoding DNMT3A can be at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to the sequences submitted by GenBank Accession Nos. NM_001320892.1, NM_001320893.1, NM_022552.4, NM_153759.3, NM_175629.2, and / or NM_175630.1. Amino acid sequences encoding human DNMT3A include GenBank Accession Nos. NP_001307821.1, NP_001307822.1, NP_072046.2, NP_715640.2, NP_783328.1, and NP_783329.1. The amino acid sequence encoding DNMT3A can be at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to the sequence submitted by GenBank Accession Nos. NP_001307821.1, NP_001307822.1, NP_072046.2, NP_715640.2, NP_783328.1, and / or NP_783329.1. Nucleic acids encoding human DNMT3B include GenBank Accession Nos. NM_001207055.1, NM_001207056.1, NM_006892.3, NM_175848.1, NM_175849.1, and NM_175850.2. Nucleic acids encoding DNMT3B can be at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to the sequences submitted by GenBank Accession Nos. NM_001207055.1, NM_001207056.1, NM_006892.3, NM_175848.1, NM_175849.1, and / or NM_175850.2. Amino acid sequences encoding human DNMT3B include GenBank Accession Nos. NP_001193984.1, NP_001193985.1, NP_008823.1, NP_787044.1, NP_787045.1, and NP_787046.1.The amino acid sequence encoding DNMT3B can be at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to the sequence submitted by GenBank Accession Nos. NP_001193984.1, NP_001193985.1, NP_008823.1, NP_787044.1, NP_787045.1, and / or NP_787046.1. Nucleic acids encoding human DNMT3L include GenBank Accession Nos. NM_013369.3 and NM_175867.2. Nucleic acids encoding DNMT3L can be at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to the sequences submitted under GenBank Accession Nos. NM_013369.3 and / or NM_175867.2. Amino acid sequences encoding human DNMT3L include GenBank Accession Nos. NP_037501.2 and NP_787063.1. Amino acid sequences encoding DNMT3L can be at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to the sequences submitted under GenBank Accession Nos. NP_037501.2 and / or NP_787063.1.

[0249] DNMTs can be inhibited using any suitable method known in the art. Suitable methods include knocking down DNMT mRNA, genetically knocking out DNMTs, and using DNMT inhibitors (e.g., chemical inhibitors). DNMT inhibitors are being investigated through clinical trials (e.g., Phase III clinical trials) in the United States and elsewhere. Non-limiting examples of DNMT inhibitors include VIDAZA™ (azacitidine) (e.g., for the treatment of myelodysplastic syndrome and acute myeloid leukemia (AML)), DACOGEN™ (decitabine) (e.g., for the treatment of AML and chronic myeloid leukemia (CML)), and guadecitabine (SGI-110) (e.g., for the treatment of AML). In 2012, the European Union approved DACOGEN™ (decitabine) for use in patients with AML.

[0250] DNMTs can be inhibited by inhibiting DNMT stabilizers. Suitable methods for inhibiting DNMT stabilizers include knocking down the mRNA encoding the stabilizer, gene knockout of the gene encoding the stabilizer, and using inhibitors (e.g., chemical inhibitors). As a non-limiting example, KDM1a, also known as Lsd1 or Aof2, is a stabilizer of DNMT1. See, for example, Wang et al., Nat Genet. 2009 Jan;41(1):125-9. In some embodiments, KDM1a expression is knocked down using shRNA disclosed herein or known in the art. In some embodiments, KDM1a is inhibited to prevent damage induced by hypermethylation from DNMTs. This can be useful for promoting reprogramming.

[0251] In some embodiments, histone methyltransferase is a reprogramming barrier and is inhibited to facilitate cell, tissue, and / or organ reprogramming. Histone methyltransferase can be inhibited by any suitable method, including the use of chemical inhibitors. For example, 3-deazaneplanocin A (Dznep), epz004777, and BIX-01294 are examples of histone methyltransferase inhibitors.

[0252] In some embodiments, the reprogramming barrier is histone deacetylase (HDAC), and the HDAC is inhibited to facilitate cell, tissue, and / or organ reprogramming. Non-limiting examples of HDAC inhibitors include valproic acid (VPA), trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), sodium butyrate (SB), belinostat (PXD101), panobinostat (LBH589), quisinostat (JNJ-26481585), abequidinostat (PCI-24781), divinostat (ITF2357), resminostat (4SC-201), phenylbutyric acid (PBA), depsipeptide (romidepsin), entinostat (MS-275), mocetinostat (MGCD0103), and tubastatin A (TBA).

[0253] In some embodiments, the reprogramming barrier is NF-κB, which is inhibited to facilitate cell, tissue, and / or organ reprogramming. Non-limiting examples of NF-κB inhibitors include BAY11-7082, TPCA1, and p65 siRNA. See, for example, the NF-κB small molecule guide compiled by Abcam, which is available on the Abcam website (http: / / www.abcam.com / ). www.abcam.com / reagents / nf-kb-small-molecule-guide ).

[0254] In some embodiments, the reprogramming barrier is a cytokine secreted by senescent cells, where the cytokine is inhibited to facilitate cell, tissue, and / or organ reprogramming. Non-limiting examples of cytokine inhibitors include drugs that kill senescent cells, including anti-TNFα (Mahmoudi et al., Biorxiv, 2018) and Navitoclax.

[0255] In some embodiments, the reprogramming barrier is microRNA (miRNA), and the microRNA is inhibited to facilitate the reprogramming of cells, tissues, and / or organs.Non-limiting examples of the microRNA that is the reprogramming barrier include miR Let-7 and miR-34.Without being bound by any particular theory, miR Let-7 inhibits cell cycle, so the inhibition of miR Let-7 can increase the efficiency of reprogramming, and miR-34 inhibits the translation of p53, so the inhibition of miR-34 can facilitate reprogramming.

[0256] In some embodiments, OCT4, SOX2, KLF4, their substitutes, or any combination thereof are activated in combination with inhibition of PTEN, SOCS3, RhoA, and / or ROCK in cells, tissues, organs, and / or subjects to enhance nerve regeneration. In some embodiments, PTEN is deleted, SOCS3 is deleted, RhoA is knocked down, and / or ROCK is knocked down in cells, tissues, organs, and / or subjects. For a description of inhibition of PTEN, SOCS3, RhoA, and / or ROCK, see, e.g., Park et al., Science. 2008 Nov 7;322(5903):963-6; Smith et al., Neuron. 2009 Dec 10;64(5):617-23; Koch et al., Front Cell Neurosci. 2014 Sep 5;8:273; Koch et al., Cell Death Dis. 2014 May 15;5:e1225, each of which is incorporated herein by reference in its entirety for this purpose.

[0257] In some embodiments, OCT4, SOX2, KLF4, their substitutes, or any combination thereof are activated in cells, tissues, organs, and / or subjects in combination with neural electrical stimulation (e.g., high-contrast visual stimulation) to promote neural regeneration. For a description of high-contrast visual stimulation, see, e.g., Lim et al., Nat Neurosci. 2016 Aug; 19(8): 1073-84, which is incorporated herein by reference in its entirety for this purpose.

[0258] In some embodiments, OCT4, SOX2, KLF4, their surrogates, or any combination thereof are activated in cells, tissues, organs, and / or subjects in combination with gamma-band light stimulation to promote neural regeneration. For a description of gamma-band light stimulation, see, e.g., McDermott et al., J Alzheimers Dis. 2018; 65(2): 363-392, which is incorporated herein by reference in its entirety for this purpose. Engineered cells

[0259] Engineered cells and methods for producing engineered cells are also encompassed by the present disclosure. Engineered cells may be useful, for example, in cell-based therapies (e.g., stem cell therapy). Stem cell therapy is currently undergoing clinical trials (see, e.g., David Cyranoski, Nature 557, 619-620 (2018)), but toxicity (e.g., off-target toxicity) is a concern. Without being bound by any particular theory, engineered cells of the present disclosure (e.g., cells engineered using AAV vectors encoding OCT4, KLF4, and / or SOX2 and / or inducers) may have lower toxicity because AAV does not integrate into the host cell genome, and the use of the inducible system described herein to control expression of OCT4, KLF4, and / or SOX2 may allow for precise control of gene expression (e.g., amount and timing).

[0260] Any of the nucleic acids (e.g., engineered nucleic acids) (e.g., expression vectors) capable of inducing OCT4, KLF4, and / or SOX2 expression, the engineered proteins described herein, chemical agents that activate (e.g., induce expression of) OCT4, KLF4, and / or SOX2, antibodies that activate (e.g., induce expression of) OCT4, KLF4, and / or SOX2, and / or recombinant viruses (e.g., lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpes virus, or AAV) described herein, alone or in combination, can be introduced into a host cell, host tissue, or organ to produce an engineered cell, engineered tissue, or engineered organ. Nucleic acids (e.g., engineered nucleic acids) (e.g., expression vectors) capable of inducing expression of OCT4; KLF4; SOX2; or any combination thereof, engineered proteins described herein, chemical agents that activate (e.g., induce expression of) OCT4; KLF4; SOX2; or any combination thereof, antibodies that activate (e.g., induce expression of) OCT4; KLF4; SOX2; or any combination thereof, and / or any of the recombinant viruses described herein (e.g., lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpes virus, or AAV), alone or in combination, can be introduced into host cells, host tissues, or organs to produce engineered cells, engineered tissues, or engineered organs. In some embodiments, a nucleic acid (e.g., an engineered nucleic acid) encoding an inducer, an engineered protein encoding an inducer, a chemical agent that can modulate (e.g., activate or inhibit) the activity of the inducer, and / or a recombinant virus encoding an inducer is also introduced into a host cell, host tissue, or organ to produce an engineered cell, engineered tissue, or engineered organ.

[0261] In some embodiments, the engineered cells are induced pluripotent stem cells (iPSCs).

[0262] In some embodiments, viral vectors (e.g., AAV vectors, including vectors having a TRE promoter operably linked to nucleic acids encoding OCT4, KLF4, and SOX2) are packaged into viruses with AAV-DJ capsids. In some embodiments, the AAV-DJ capsids increase the transduction efficiency of cultured cells compared to cells without the AAV-DJ capsid. In some embodiments, an AAV virus encoding OSK is administered to cells. In some embodiments, an AAV virus encoding an inducer (e.g., AAV-DJ virus) or a protein encoding the inducer is administered to the same cells. In some embodiments, the system generates engineered cells (e.g., induced pluripotent stem cells). In some embodiments, the engineered cells are further differentiated (e.g., into eye, ear, nose, mouth including gums and tooth roots, bone, lung, milk, breast, pancreas, stomach, esophagus, muscle including cardiac muscle, liver, blood vessels, skin including hair, heart, brain, nervous tissue, kidney, testes, prostate, penis, cloaca, fin, ovary, or intestinal cells). In some embodiments, the differentiated cells are used for transplantation purposes. In some embodiments, the engineered cells are cultured to create engineered tissues. In some embodiments, the engineered cells are cultured to create engineered organs. In some embodiments, the engineered cells are retinal pigment epithelial cells, neuronal cells, pancreatic beta cells, or cardiac cells. composition

[0263] The compositions of the present disclosure may include at least one of any of the following, alone or in combination: a nucleic acid (e.g., an engineered nucleic acid) (e.g., an expression vector) capable of inducing OCT4, KLF4, and / or SOX2 expression described herein; an engineered protein; an engineered cell; a chemical agent that activates (e.g., induces expression of) OCT4, KLF4, and / or SOX2; an antibody that activates (e.g., induces expression of) OCT4, KLF4, and / or SOX2; and / or a recombinant virus (e.g., a lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpes virus, or AAV). In certain embodiments, the compositions of the present disclosure comprise at least one of any of the following, alone or in combination: a nucleic acid (e.g., an engineered nucleic acid) (e.g., an expression vector) capable of inducing expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein, an engineered cell, a chemical agent that activates (e.g., induces expression of) OCT4; KLF4; SOX2; or any combination thereof, an antibody that activates (e.g., induces expression of) OCT4; KLF4; SOX2; or any combination thereof, and / or a recombinant virus (e.g., lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpes virus, or AAV) described herein. In some embodiments, the composition comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more different nucleic acids (e.g., engineered nucleic acids) (e.g., expression vectors encoding OCT4, KLF4, and / or SOX2) that can induce OCT4, KLF4, and / or SOX2 expression. In some embodiments, the composition comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more different nucleic acids (e.g., engineered nucleic acids) (e.g., expression vectors encoding OCT4; KLF4; SOX2; or any combination thereof) that can induce expression of OCT4; KLF4; SOX2; or any combination thereof.In some embodiments, the composition comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more different viruses (e.g., lentivirus, alphavirus, vaccinia virus, adenovirus, retrovirus, herpesvirus, or AAV), each carrying one or more different transgenes. In some embodiments, the composition comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more different chemical agents that activate (e.g., induce expression of) OCT4, KLF4, and / or SOX2. In some embodiments, the composition comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more different chemical agents that activate (e.g., induce expression of) OCT4; KLF4; SOX2; or any combination thereof. In some embodiments, the composition further comprises one or more nucleic acids (e.g., engineered nucleic acids) encoding the inducer, one or more engineered proteins encoding the inducer, one or more chemical agents that can modulate (e.g., activate or inhibit) the activity of the inducer, and / or one or more recombinant viruses encoding the inducer. In some embodiments, the composition comprises engineered cells (e.g., induced pluripotent stem cells and / or differentiated cells). In some embodiments, the composition comprises engineered proteins encoding OCT4, SOX2, and / or KLF4. In some embodiments, the composition comprises engineered proteins encoding OCT4, SOX2, KLF4, or any combination thereof. In some embodiments, the composition further comprises an engineered protein encoding the inducer.

[0264] In some embodiments, the composition further comprises a pharmaceutically acceptable carrier. A suitable carrier can be readily selected by one skilled in the art depending on the indication for which the nucleic acid (e.g., engineered nucleic acid) (e.g., expression vector) capable of inducing OCT4, KLF4, and / or SOX2 expression, chemical agent (e.g., that induces the expression of) OCT4, KLF4, and / or SOX2, antibody (e.g., that activates the expression of) OCT4, KLF4, and / or SOX2, engineered protein, engineered cell, and / or recombinant virus (e.g., lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpes virus, or AAV) is intended. A suitable carrier can be readily selected by one skilled in the art depending on the indication for which the nucleic acid (e.g., an engineered nucleic acid) (e.g., an expression vector) capable of inducing expression of OCT4; KLF4; SOX2; or any combination thereof, a chemical agent that activates (e.g., induces expression of) OCT4; KLF4; SOX2; or any combination thereof, an antibody that activates (e.g., induces expression of) OCT4; KLF4; SOX2; or any combination thereof, an engineered protein, an engineered cell, and / or a recombinant virus (e.g., lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpes virus, or AAV) is being used. A suitable carrier can be readily selected by one of skill in the art, taking into account the indication for which the nucleic acid (e.g., an engineered nucleic acid) encoding the inducer, the engineered protein encoding the inducer, the chemical agent capable of modulating (e.g., activating or inhibiting) the activity of the inducer, and / or the recombinant virus (e.g., lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpesvirus, or AAV) containing the inducer, etc. For example, one suitable carrier includes saline, which can be formulated with various buffer solutions (e.g., phosphate-buffered saline).Other exemplary carriers include sterile saline, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, and water. The choice of carrier is not a limitation of the disclosure.

[0265] Optionally, the compositions of the present disclosure may include other pharmaceutical ingredients, such as preservatives or chemical stabilizers, in addition to a nucleic acid (e.g., an engineered nucleic acid) (e.g., an expression vector) capable of inducing OCT4, KLF4, and / or SOX2 expression, engineered cells containing OCT4, KLF4, and / or SOX2, engineered proteins, chemical agents that activate (e.g., induce expression of) OCT4, KLF4, and / or SOX2, antibodies that activate (e.g., induce expression of) OCT4, KLF4, and / or SOX2, and / or recombinant viruses (e.g., lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpes virus, or AAV), etc., and carrier(s). Optionally, the compositions of the present disclosure may include other pharmaceutical ingredients, such as preservatives or chemical stabilizers, in addition to a nucleic acid (e.g., an engineered nucleic acid) (e.g., an expression vector) capable of inducing expression of OCT4, KLF4, SOX2, or any combination thereof, engineered cells containing OCT4, KLF4, SOX2, or any combination thereof, engineered proteins, chemical agents that activate (e.g., induce expression of) OCT4, KLF4, SOX2, or any combination thereof, antibodies that activate (e.g., induce expression of) OCT4, KLF4, SOX2, or any combination thereof, and / or recombinant viruses (e.g., lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpesvirus, or AAV), etc., and carrier(s). Suitable exemplary preservatives include chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, parabens, ethyl vanillin, glycerin, phenol, and parachlorophenol. Suitable chemical stabilizers include gelatin and albumin. The compositions of the present disclosure may further include a nucleic acid (e.g., an engineered nucleic acid) encoding the inducer, an engineered protein encoding the inducer, a chemical agent capable of modulating (e.g., activating or inhibiting) the activity of the inducer, and / or a recombinant virus encoding the inducer.

[0266] Nucleic acids (e.g., engineered nucleic acids) (e.g., expression vectors) capable of inducing expression of OCT4; KLF4; SOX2; or any combination thereof, engineered cells, chemical agents that activate (e.g., induce expression of) OCT4; KLF4; SOX2; or any combination thereof, engineered proteins encoding OCT4; KLF4; SOX2; or any combination thereof, antibodies that activate (e.g., induce expression of) OCT4; KLF4; SOX2; or any combination thereof, and / or The encoding recombinant virus (e.g., lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpes virus, or AAV) is administered in an amount sufficient to transfect cells of the desired tissue (e.g., eye, ear, nose, mouth including gums and tooth roots, bone, lung, breast, pancreas, stomach, esophagus, muscle including cardiac muscle, liver, blood vessels, skin including hair, heart, brain, nervous tissue, kidney, testis, prostate, penis, cloaca, fin, ovary, or intestinal tissue) and to provide sufficient levels of gene transfer and expression without undue adverse effects. Either the nucleic acid (e.g., engineered nucleic acid) encoding the inducer, the engineered protein encoding the inducer, the chemical agent capable of modulating (e.g., activating or inhibiting) the activity of the inducer, and / or the recombinant virus encoding the inducer is administered in an amount sufficient to transfect cells of the desired tissue (e.g., eye, ear, nose, mouth including gums and tooth roots, bone, lung, breast, pancreas, stomach, esophagus, muscle including cardiac muscle, liver, blood vessels, skin including hair, heart, brain, nervous tissue, kidney, testis, prostate, penis, cloaca, fin, ovary, or intestinal tissue) and to provide sufficient levels of gene transfer and expression without undue adverse effects. Examples of pharmaceutically acceptable routes of administration include, but are not limited to, direct delivery to a selected organ (e.g., direct delivery to the eye, ear, nose, mouth including gums and tooth roots, bone, lung, milk, breast, pancreas, stomach, esophagus, muscle including cardiac muscle, liver, blood vessels, skin including hair, heart, brain, nervous tissue, kidney, testicle, prostate, penis, cloaca, fin, ovary, or intestine).Any of the nucleic acids (e.g., engineered nucleic acids) (e.g., expression vectors) capable of inducing OCT4, KLF4, and / or SOX2 expression described herein, engineered cells, chemical agents that activate (e.g., induce expression of) OCT4, KLF4, and / or SOX2, engineered proteins, antibodies that activate (e.g., induce expression of) OCT4, KLF4, and / or SOX2, and / or recombinant viruses (e.g., lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpes virus, or AAV) can be administered intravenously, intradermally, intravenously, intravenously, intravenously, intravenously, intramuscularly, or intravenously. The compound may be delivered intravenously, intralesionally, intratumorally, intracranially, intraarticularly, intraprostatically, intrapleurally, intranasally, intravitreally, intravaginally, intrarectally, topically, intratumorally, intramuscularly, intraperitoneally, subcutaneously, subconjunctivally, intravesicularly, mucosally, intrapericardially, intraumbilically, intraocularly, orally, topically, locally, systemically, by injection, infusion, continuous infusion, localized perfusion bathing the target cells directly, by catheter, by cream, by lipid compositions (e.g., liposomes), or by other methods or combinations of any of the foregoing that would be known to one of skill in the art.Nucleic acids (e.g., engineered nucleic acids) (e.g., expression vectors) capable of inducing expression of OCT4; KLF4; SOX2; or any combination thereof, as described herein, engineered cells, chemical agents that activate (e.g., induce expression of) OCT4; KLF4; SOX2; or any combination thereof, engineered proteins, antibodies that activate (e.g., induce expression of) OCT4; KLF4; SOX2; or any combination thereof, and / or recombinant viruses (e.g., lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpes virus, or AAV), Any may be delivered intravenously, intradermally, intra-arterially, intralesionally, intratumorally, intracranially, intra-articularly, intraprostatically, intrapleurally, intranasally, intravitreally, intravaginally, intrarectally, topically, intratumorally, intramuscularly, intraperitoneally, subcutaneously, subconjunctivally, intravesicularly, mucosally, intrapericardially, intraumbilically, intraocularly, orally, topically, locally, systemically, by injection, infusion, continuous infusion, localized perfusion bathing the target cells directly, by catheter, by cream, by lipid compositions (e.g., liposomes), or by other methods or combinations of any of the foregoing that would be known to one of skill in the art. Any of the nucleic acids encoding the inducers, chemical agents capable of modulating the activity of the inducers, engineered proteins encoding the inducers, and / or recombinant viruses encoding the inducers can be delivered intravenously, intradermally, intra-arterially, intralesionally, intratumorally, intracranially, intra-articularly, intraprostatically, intrapleurally, intranasally, intravitreally, intravaginally, intrarectally, topically, intratumorally, intramuscularly, intraperitoneally, subcutaneously, subconjunctivally, intravesicularly, mucosally, intrapericardially, intraumbilically, intraocularly, orally, topically, locally, systemically, by injection, infusion, continuous infusion, localized perfusion bathing directly in target cells, by catheter, by cream, by lipid compositions (e.g., liposomes), or by other methods known to those skilled in the art or by any combination of the foregoing. Routes of administration can be combined if desired.

[0267] In some embodiments, the nucleic acid is delivered non-virally (e.g., not on a viral vector and / or not by a virus). In some embodiments, the nucleic acid (e.g., RNA or DNA) encoding OCT4, SOX2, and / or KLF4, and / or the inducer is administered by a liposome. In some embodiments, the nucleic acid (e.g., RNA or DNA) encoding OCT4, SOX2, KLF4, or any combination thereof, and / or the inducer is administered by a liposome. In some embodiments, the nucleic acid (e.g., RNA or DNA) encoding OCT4, SOX2, and / or KLF4, and / or the inducer is administered by a particle. In some embodiments, the nucleic acid (e.g., RNA or DNA) encoding OCT4, SOX2, KLF4, or any combination thereof, and / or the inducer is administered by a particle. In some embodiments, the nucleic acid is RNA (e.g., mRNA).

[0268] In some embodiments, a pharmaceutical composition comprising an expression vector encoding OCT4, KLF4, and / or SOX2 or a pharmaceutical composition comprising a virus carrying an expression vector is administered to a cell, tissue, organ, or subject. In some embodiments, a pharmaceutical composition comprising an expression vector encoding an inducer or a pharmaceutical composition comprising a virus carrying an expression vector is administered to a cell, tissue, organ, or subject. In some embodiments, the virus and / or expression vector encoding OCT4, KLF4, and / or SOX2 is administered systemically. In some embodiments, the virus and / or expression vector encoding an inducer is administered systemically. In some embodiments, the virus and / or expression vector encoding OCT4, KLF4, and / or SOX2 is administered locally (e.g., directly to the tissue or organ of interest, including the eye, ear, nose, mouth, including gums and tooth roots, bone, lung, breast, pancreas, stomach, esophagus, muscle, including cardiac muscle, liver, blood vessels, skin, including hair, heart, brain, nervous tissue, kidney, testis, prostate, penis, cloaca, fin, ovary, or intestine). In some embodiments, the inducer-encoding virus and / or expression vector is administered locally (e.g., directly to the tissue or organ of interest, including the eye, ear, nose, mouth, including gums and tooth roots, bone, lung, breast, pancreas, stomach, esophagus, muscle, including cardiac muscle, liver, blood vessels, skin, including hair, heart, brain, nervous tissue, kidney, testes, prostate, penis, cloaca, fin, ovary, or intestine). In some embodiments, the inducer (e.g., a nucleic acid encoding the inducer, a protein encoding the inducer, or a virus encoding the inducer) and / or a chemical agent capable of modulating (e.g., activating or inhibiting) the activity of the inducer is administered using the same route of administration as OCT4, KLF4, and / or SOX2 (e.g., a nucleic acid encoding OCT4, KLF4, and / or SOX2).In some embodiments, the inducer (e.g., a nucleic acid encoding the inducer, a protein encoding the inducer, or a virus encoding the inducer) and / or a chemical agent capable of modulating (e.g., activating or inhibiting) the activity of the inducer is administered by a different route of administration, such as OCT4, KLF4, and / or SOX2 (e.g., a nucleic acid encoding OCT4, KLF4, and / or SOX2).

[0269] In some embodiments, a pharmaceutical composition comprising an expression vector encoding OCT4; KLF4; SOX2; or any combination thereof, or a pharmaceutical composition comprising a virus carrying the expression vector, is administered to a cell, tissue, organ, or subject. In some embodiments, a pharmaceutical composition comprising an expression vector encoding an inducer, or a pharmaceutical composition comprising a virus carrying the expression vector, is administered to a cell, tissue, organ, or subject. In some embodiments, the virus and / or expression vector encoding OCT4; KLF4; SOX2; or any combination thereof is administered systemically. In some embodiments, the virus and / or expression vector encoding the inducer is administered systemically. In some embodiments, viruses and / or expression vectors encoding OCT4; KLF4; SOX2; or any combination thereof are administered locally (e.g., directly to a tissue or organ of interest, including the eye, ear, nose, mouth including gums and tooth roots, bone, lung, breast, breast, pancreas, stomach, esophagus, muscle including cardiac muscle, liver, blood vessels, skin including hair, heart, brain, nervous tissue, kidney, testes, prostate, penis, cloaca, fin, ovary, or intestine). In some embodiments, viruses and / or expression vectors encoding inducers are administered locally (e.g., directly to a tissue or organ of interest, including the eye, ear, nose, mouth including gums and tooth roots, bone, lung, breast, breast, pancreas, stomach, esophagus, muscle including cardiac muscle, liver, blood vessels, skin including hair, heart, brain, nervous tissue, kidney, testes, prostate, penis, cloaca, fin, ovary, or intestine). In some embodiments, the inducer (e.g., a nucleic acid encoding the inducer, a protein encoding the inducer, or a virus encoding the inducer) and / or a chemical agent capable of modulating (e.g., activating or inhibiting) the activity of the inducer is administered using the same route of administration as OCT4; KLF4; SOX2; or any combination thereof (e.g., OCT4; KLF4; SOX2; OCT4 and SOX2; OCT4 and KLF4; KLF4 and SOX2; or a nucleic acid encoding KLF4, OCT4, and SOX2).In some embodiments, the inducer (e.g., a nucleic acid encoding the inducer, a protein encoding the inducer, or a virus encoding the inducer) and / or a chemical agent capable of modulating (e.g., activating or inhibiting) the activity of the inducer is administered by a different route of administration, such as OCT4; KLF4; SOX2; or any combination thereof (e.g., a nucleic acid encoding OCT4; KLF4; SOX2; OCT4 and SOX2; OCT4 and KLF4; KLF4 and SOX2; or a nucleic acid encoding KLF4, OCT4, and SOX2).

[0270] In some embodiments, the expression vector is an inducible vector, on which a nucleic acid encoding OCT4, KLF4, and / or SOX2, and / or an inducer, is expressed in an inducible TRE promoter (e.g., TRE3G, TRE2, or P tight In some embodiments, the expression vector is an inducible vector, on which a nucleic acid encoding OCT4; KLF4; SOX2; or any combination thereof, and / or an inducer is operably linked to an inducible TRE promoter (e.g., TRE3G, TRE2, or P tight) operably linked to a TRE promoter-containing gene. In some embodiments, the virus and / or inducible vector is administered in conjunction with tetracycline (e.g., doxycycline). In some embodiments, the virus and / or expression vector comprising a TRE promoter is administered separately from the tetracycline (e.g., doxycycline). For example, any of the TRE promoter-containing viruses and / or expression vectors described herein can be administered systemically, and the tetracycline can be administered locally (e.g., to the organ or tissue of interest). In some embodiments, any of the TRE promoter-containing viruses and / or expression vectors described herein can be administered locally (e.g., directly to the tissue or organ of interest, including the eye, ear, nose, mouth, including gums and tooth roots, bone, lung, breast, udder, pancreas, stomach, esophagus, muscle, including cardiac muscle, liver, blood vessels, skin, including hair, heart, brain, nervous tissue, kidney, testis, prostate, penis, cloaca, fin, ovary, or intestine), and the tetracycline can be administered systemically. As a non-limiting example, a virus and / or expression vector containing a TRE promoter is administered directly to the subject's eye (e.g., injected), and tetracycline (e.g., doxycycline) is administered systemically (e.g., orally as a pill).

[0271] In some embodiments, tetracycline is administered intravenously, intradermally, intraarterially, intralesionally, intratumorally, intracranially, intraarticularly, intraprostatically, intrapleurally, intranasally, intravitreally, intravaginally, intrarectally, topically, intratumorally, intramuscularly, intraperitoneally, subcutaneously, subconjunctivally, intravesicularly, mucosally, intrapericardially, intraumbilically, intraocularly, orally, topically, locally, systemically, by injection, infusion, continuous infusion, localized irrigation directly bathing target cells, by catheter, by cream, or by lipid composition. In some embodiments, tetracycline is administered directly to cells, organs, and / or tissues. By way of non-limiting example, tetracycline can be administered to a subject's eye by any suitable method, including tetracycline-containing eye drops, sustained-release devices (e.g., micropumps, particles, and / or depots), and tetracycline-containing therapeutic contact lenses. In some embodiments, the tetracycline is administered to the subject systemically (e.g., in the drinking water or via intravenous injection). The tetracycline can also be administered topically (e.g., via a cream) or via a subcutaneous pump (e.g., to deliver the tetracycline to specific tissues).

[0272] By way of example, the dose of recombinant virus (e.g., lentivirus, alphavirus, vaccinia virus, adenovirus, retrovirus, herpesvirus, or AAV) virion, e.g., dose of genome copies per kilogram of body weight (GC / kg), required to achieve a particular therapeutic effect will vary based on several factors, including, but not limited to, the route of recombinant virus (e.g., lentivirus, alphavirus, vaccinia virus, adenovirus, retrovirus, herpesvirus, or AAV) virion administration, the level of gene or RNA expression required to achieve the therapeutic effect, the particular disease or disorder being treated, and the stability of the gene or RNA product. One of skill in the art can readily determine a recombinant virus (e.g., lentivirus, alphavirus, vaccinia virus, adenovirus, retrovirus, herpesvirus, or AAV virion) dose range for treating a patient with a particular disease or disorder based on the above and other factors.

[0273] An effective amount of a recombinant virus (e.g., lentivirus, alphavirus, vaccinia virus, adenovirus, retrovirus, herpesvirus, or AAV) is an amount sufficient to target and infect an animal and target the desired tissue. In some embodiments, an effective amount of a recombinant virus (e.g., lentivirus, alphavirus, vaccinia virus, adenovirus, retrovirus, herpesvirus, or AAV) is an amount sufficient to generate a stable somatic transgenic animal model. The effective amount will depend primarily on factors such as the species, age, weight, and health of the subject, and the tissue to be targeted. Therefore, it may vary between animals and tissues. For example, an effective amount of a recombinant virus (e.g., lentivirus, alphavirus, vaccinia virus, adenovirus, retrovirus, herpesvirus, or AAV) is generally about 10 9 From 10 16 The volume of solution containing the genome copies ranges from about 1 ml to about 100 ml. In some cases, about 10 11From 10 13 Doses between 10 and 20 recombinant virus (e.g., lentivirus, adenovirus, retrovirus, alphavirus, vaccinia virus, herpesvirus, or AAV) genome copies are appropriate. 10 or 10 11 Recombinant viral (e.g., lentivirus, adenovirus, retrovirus, alphavirus, vaccinia virus, herpesvirus, or AAV) genome copies are effective for targeting ocular tissue (e.g., retinal tissue). In some cases, stable transgenic animals are generated by multiple doses of recombinant viruses (e.g., lentivirus, adenovirus, retrovirus, herpesvirus, alphavirus, vaccinia virus, or AAV).

[0274] In some embodiments, a dose of recombinant virus (e.g., lentivirus, adenovirus, retrovirus, herpesvirus, alphavirus, vaccinia virus, or AAV) is administered to a subject no more than once per calendar day (e.g., a 24-hour period). In some embodiments, a dose of recombinant virus (e.g., lentivirus, alphavirus, vaccinia virus, adenovirus, retrovirus, herpesvirus, or AAV) is administered to a subject no more than once per 2, 3, 4, 5, 6, or 7 calendar days. In some embodiments, a dose of recombinant virus (e.g., lentivirus, alphavirus, vaccinia virus, adenovirus, retrovirus, herpesvirus, or AAV) is administered to a subject no more than once per calendar week (e.g., 7 calendar days). In some embodiments, one dose of recombinant virus (e.g., lentivirus, alphavirus, vaccinia virus, adenovirus, retrovirus, herpesvirus, or AAV) is administered to a subject no more than every two weeks (e.g., once every two calendar weeks). In some embodiments, one dose of recombinant virus (e.g., lentivirus, alphavirus, vaccinia virus, adenovirus, retrovirus, herpesvirus, or AAV) is administered to a subject no more than once per calendar month (e.g., once every 30 calendar days). In some embodiments, one dose of recombinant virus (e.g., lentivirus, alphavirus, vaccinia virus, adenovirus, retrovirus, herpesvirus, or AAV) is administered to a subject no more than once per six calendar months. In some embodiments, one dose of recombinant virus (e.g., lentivirus, alphavirus, vaccinia virus, adenovirus, retrovirus, herpesvirus, or AAV) is administered to a subject no more than once per calendar year (e.g., 365 days, or 366 days in a leap year).

[0275] In some embodiments, particularly high recombinant virus (e.g., lentivirus, alphavirus, vaccinia virus, adenovirus, retrovirus, herpesvirus, or AAV) concentrations are present (e.g., ∼10 13Where the total volume of a recombinant virus (e.g., lentivirus, alphavirus, vaccinia virus, adenovirus, retrovirus, herpesvirus, or AAV) is greater than 1000 GC / ml, the recombinant virus (e.g., lentivirus, alphavirus, vaccinia virus, adenovirus, retrovirus, herpesvirus, or AAV) composition is formulated to reduce aggregation of AAV particles in the composition. Suitable methods for reducing aggregation can be used, including, for example, adding detergents, adjusting pH, adjusting salt concentrations, etc. (See, e.g., Wright FR, et al., Molecular Therapy (2005) 12, 171-178, the contents of which are incorporated herein by reference).

[0276] By way of non-limiting example, transgene delivery by AAV has been shown to be promising and non-toxic in humans. For example, AAV can be delivered to the eye. See, e.g., Smalley Nat Biotechnol. 2017 Nov 9;35(11):998-999.

[0277] The formulation of pharmaceutically acceptable excipients and carrier solutions is well known to those skilled in the art, as is the development of suitable dosages and treatment regimens for using the specific compositions described herein in various treatment regimens. Typically, these formulations will contain at least about 0.1% or more of the active compound, but the percentage of the active ingredient(s) can of course vary, conveniently being between about 1 or 2% and about 70% or 80% or more of the total weight or volume of the formulation. Naturally, the amount of active compound in each therapeutically useful composition can be prepared in such a way that a suitable dosage is obtained by any given unit dose of the compound. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, and other pharmaceutical considerations will be considered by those skilled in the art of preparing such pharmaceutical formulations. Therefore, different dosages and treatment regimens may be desirable.

[0278] In some embodiments, the method includes the use of a nucleic acid (e.g., an engineered nucleic acid) capable of inducing OCT4, KLF4, and / or SOX2 expression (e.g., an expression vector), an engineered cell comprising OCT4, KLF4, and / or SOX2, an engineered protein encoding OCT4, KLF4, and / or SOX2, a chemical agent that activates (e.g., induces expression of) OCT4, KLF4, and / or SOX2, an antibody that activates (e.g., induces expression of) OCT4, KLF4, and / or SOX2, and / or The recombinant virus (e.g., lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpes virus, or AAV) can be delivered directly to a target tissue, e.g., directly to the tissue of interest (e.g., eye, ear, nose, mouth, including gums and roots of teeth, bone, lung, breast, pancreas, stomach, esophagus, muscle, including cardiac muscle, liver, blood vessels, skin, including hair, heart, brain, nervous tissue, kidney, testicle, prostate, penis, cloaca, fin, ovary, or intestine), e.g., by a suitably formulated pharmaceutical composition disclosed herein.

[0279] In some embodiments, nucleic acids (e.g., engineered nucleic acids) (e.g., expression vectors) that can induce expression of OCT4; KLF4; SOX2; or any combination thereof, engineered cells comprising OCT4; KLF4; SOX2; or any combination thereof, engineered proteins encoding Oct4, KLF4, SOX2, or a combination thereof, chemical agents that activate (e.g., induce expression of) OCT4, KLF4, SOX2, or a combination thereof, or agents that activate (e.g., induce expression of) OCT4, KLF4, SOX2, or a combination thereof. The antibody, which induces expression of a recombinant virus (e.g., a lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpes virus, or AAV), can be delivered directly to the target tissue, e.g., directly to the tissue of interest (e.g., eye, ear, nose, mouth, including gums and roots of teeth, bone, lung, breast, pancreas, stomach, esophagus, muscle, including cardiac muscle, liver, blood vessels, skin, including hair, heart, brain, nervous tissue, kidney, testis, prostate, penis, cloaca, fin, ovary, or intestine), for example, by a suitably formulated pharmaceutical composition as disclosed herein.

[0280] In some embodiments, a nucleic acid (e.g., an engineered nucleic acid) (e.g., an expression vector) encoding an inducer, an engineered cell containing the inducer, an engineered protein encoding the inducer, a chemical agent capable of modulating the activity of the inducer, and / or a recombinant virus (e.g., a lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpesvirus, or AAV) encoding the inducer is delivered directly to a target tissue, e.g., directly to the tissue of interest (e.g., eye, ear, nose, mouth, including gums and tooth roots, bone, lung, breast, pancreas, stomach, esophagus, muscle, including cardiac muscle, liver, blood vessels, skin, including hair, heart, brain, nervous tissue, kidney, testis, prostate, penis, cloaca, fin, ovary, or intestine), e.g., by a suitably formulated pharmaceutical composition as disclosed herein.

[0281] However, in certain circumstances, separately or in addition, nucleic acids (e.g., engineered nucleic acids) capable of inducing OCT4, KLF4, and / or SOX2 expression (e.g., expression vectors), and / or nucleic acids encoding inducers, nucleic acids (e.g., engineered nucleic acids) capable of inducing expression of a combination of transcription factors selected from OCT4, KLF4, and / or nucleic acids encoding inducers, engineered cells, engineered proteins, chemical factors that activate (e.g., induce expression of) OCT4, KLF4, and / or SOX2, chemical factors that activate (e.g., induce expression of) a combination of transcription factors selected from OCT4, KLF4, and SOX2, or factors that modulate the activity of the inducers (e.g., expression vectors). It may be d...

Claims

1. a) a recombinant nucleic acid encoding OCT4; b) a recombinant nucleic acid encoding SOX2; and c) a recombinant nucleic acid encoding KLF4; 1. A pharmaceutical composition for use in rejuvenating at least one cell, tissue, or organ in a subject in need thereof comprising: Where: The pharmaceutical composition does not comprise a recombinant nucleic acid encoding c-MYC; The pharmaceutical composition does not induce Nanog expression; and rejuvenating at least one cell, tissue, or organ does not include reprogramming the at least one cell, tissue, or organ to a pluripotent state; The pharmaceutical composition.

2. The pharmaceutical composition of claim 1 , wherein at least one recombinant nucleic acid is encapsulated in a nanoparticle.

3. The pharmaceutical composition of claim 1 or 2, wherein the recombinant nucleic acid is DNA.

4. The pharmaceutical composition of claim 1 or 2, wherein the recombinant nucleic acid is RNA.

5. The pharmaceutical composition described in claim 4, wherein the RNA is mRNA.

6. A pharmaceutical composition described in any one of claims 1 to 5, wherein the recombinant nucleic acid is present on one or more expression vectors.

7. At least one expression vector comprises: (i) an inducible promoter operably linked to any one or combination of the recombinant nucleic acids; (ii) P2A self-cleaving peptide; (iii) T2A self-cleaving peptide; (iv) a terminator sequence derived from SV-40; or (v) inverted terminal repeats (ITRs) flanking a recombinant nucleic acid encoding OCT4, a recombinant nucleic acid encoding SOX2, a recombinant nucleic acid encoding KLF4, or a combination thereof; The pharmaceutical composition of claim 6, comprising:

8. (a) the recombinant nucleic acid encoding OCT4 encodes an amino acid sequence that is at least 90% identical to SEQ ID NO: 2 or 41; (b) the recombinant nucleic acid encoding SOX2 encodes an amino acid sequence that is at least 90% identical to SEQ ID NO: 4 or 43; and / or (c) the recombinant nucleic acid encoding KLF4 encodes an amino acid sequence that is at least 90% identical to SEQ ID NO: 6 or 45; The pharmaceutical composition according to any one of claims 1 to 7.

9. (i) the recombinant nucleic acid encoding OCT4 comprises a sequence that is at least 90% identical to SEQ ID NO:40; (ii) the recombinant nucleic acid encoding SOX2 comprises a sequence that is at least 90% identical to SEQ ID NO: 42; and / or (iii) the recombinant nucleic acid encoding KLF4 comprises a sequence that is at least 90% identical to SEQ ID NO: 44; The pharmaceutical composition according to any one of claims 1 to 8.

10. (a) the P2A self-cleaving peptide is a polypeptide having a sequence at least 90% identical to GSGATNFSLLKQAGDVEENPGP (SEQ ID NO: 118); (b) the T2A self-cleaving peptide is a polypeptide having a sequence at least 90% identical to SEQ ID NO:9; (c) the inducible promoter comprises a sequence that is at least 90% identical to SEQ ID NO:7; (d) the terminator sequence derived from SV-40 is at least 90% identical to SEQ ID NO:8; or (e) at least one ITR sequence is at least 90% identical to SEQ ID NO:22; The pharmaceutical composition according to any one of claims 7 to 9.

11. The pharmaceutical composition according to any one of claims 1 to 10, wherein the pharmaceutical composition further comprises an inducer.

12. The pharmaceutical composition of claim 11, wherein the inducer is tetracycline.

13. The pharmaceutical composition according to any one of claims 1 to 12, wherein the pharmaceutical composition comprises a recombinant nucleic acid encoding a reverse tetracycline-controlled transactivator (rtTA).

14. The pharmaceutical composition according to any one of claims 6 to 13, wherein the one or more expression vectors are viral vectors.

15. The pharmaceutical composition described in claim 14, wherein the viral vector is an adeno-associated viral (AAV) vector.

16. The pharmaceutical composition described in claim 15, wherein the AAV vector is an AAV2 or AAV9 vector.

17. The pharmaceutical composition according to any one of claims 1 to 16, comprising the following order: a. the first inverted terminal repeat (ITR) sequence; b. TRE3G promoter sequence; c. OCT4 sequence; d. P2A cleavage sequence; e. SOX2 sequence; f. T2A cleavage sequence; g. KLF4 sequence; h. a terminator sequence derived from SV-40; and i. a second inverted terminal repeat (ITR) sequence; an expression vector comprising a nucleic acid element comprising The pharmaceutical composition.

18. The pharmaceutical composition according to any one of claims 1 to 17, comprising the following order: a. a first inverted terminal repeat (ITR) sequence, where the first ITR sequence is at least 90% identical to SEQ ID NO:22; b. a TRE3G promoter sequence, wherein the TRE3G promoter sequence comprises at least a minimal CMV promoter sequence; c. an OCT4 sequence, wherein the OCT4 sequence encodes an amino acid sequence that is at least 90% identical to SEQ ID NO: 2 or 41; d. a P2A cleavage sequence, wherein the P2A cleavage sequence encodes a polypeptide that is at least 90% identical to SEQ ID NO:118; e. a SOX2 sequence, wherein the SOX2 sequence encodes an amino acid sequence that is at least 90% identical to SEQ ID NO: 4 or 43; f. a T2A cleavage sequence, wherein the T2A cleavage sequence encodes a polypeptide that is at least 90% identical to SEQ ID NO:9; g. a KLF4 sequence, wherein the KLF4 sequence encodes an amino acid sequence that is at least 90% identical to SEQ ID NO: 6 or 45; h. a terminator sequence derived from SV-40, wherein the terminator sequence derived from SV-40 is at least 90% identical to SEQ ID NO:8; and i. a second inverted terminal repeat (ITR) sequence; an expression vector comprising a nucleic acid element comprising The pharmaceutical composition.

19. A pharmaceutical composition described in any one of claims 6 to 16, wherein at least one of the one or more expression vectors contains a sequence that is at least 90% identical to SEQ ID NO: 38 or SEQ ID NO:

121.

20. 20. The pharmaceutical composition of any one of claims 1 to 19, wherein the pharmaceutical composition induces OCT4 expression, SOX2 expression, and / or KLF4 expression for a period of time sufficient to rejuvenate at least one cell, tissue, or organ and insufficient to reprogram the cell to a pluripotent state.

21. The pharmaceutical composition of any one of claims 1 to 20, wherein after administration of the composition to a subject, at least one rejuvenated cell, tissue or organ does not express at least one stem cell marker.

22. The pharmaceutical composition of claim 21, wherein the stem cell marker is Esrrb, Lin28, TRA-1-60 / TRA-1-81 / TRA-2-54, SSEA1, SSEA4, or any combination thereof.

23. 23. The pharmaceutical composition of any one of claims 1 to 22, wherein rejuvenating at least one cell, tissue, or organ comprises restoring epigenetic information of at least one cell, tissue, or organ.

24. A pharmaceutical composition described in any one of claims 1 to 23, wherein rejuvenating at least one cell, tissue, or organ comprises re-establishing the epigenetic status of the cell, tissue, or organ to an epigenetic status that is similar to the status formed shortly after fertilization or terminal differentiation.

25. The pharmaceutical composition of claim 23 or 24, wherein the epigenetic information comprises epigenetic information lost due to aging, injury, disease, or any combination thereof in at least one cell, tissue, or organ.

26. 26. The pharmaceutical composition of any one of claims 1 to 25, wherein the subject has, is suspected of having, or is at risk of having, an eye disease, aging, cancer, a musculoskeletal disease, an age-related disease, or a neurodegenerative disease.

27. The pharmaceutical composition according to any one of claims 1 to 26, wherein the subject is a human or non-human mammal.

28. 28. The pharmaceutical composition of any one of claims 1 to 27, wherein the cell, tissue, or organ is from the eye, ear, nose, mouth, bone, lung, breast, pancreas, stomach, esophagus, muscle, liver, blood vessel, skin, heart, brain, nervous tissue, kidney, testis, prostate, penis, cloaca, fin, ovary, intestine, or hair.

29. A cell comprising the pharmaceutical composition according to any one of claims 1 to 28.

30. A tissue comprising a pharmaceutical composition according to any one of claims 1 to 28.

31. An organ comprising a pharmaceutical composition described in any one of claims 1 to 28.

32. A kit comprising a pharmaceutical composition according to any one of claims 1 to 28 and instructions for using the pharmaceutical composition.

Citation Information

Patent Citations

  • Methods of Rejuvenating Cells In Vitro and In Vivo

    US20100190250A1

  • Method for preparing induced pluripotent stem cells and its applications

    US20140093486A1